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ABSTRAC T OF DISSERTATION

SYNTHESIS AND EVALUATION OF PYRIDINIUM DERIVATIVES AS
CENTRAL NERVOUS SYSTEM NICOTINIC ACETYLCHOLINE RECEPTOR
LIGANDS

This project utilized synthesis and in vitro assays to generate antagonist SARs at
various nAChR subtypes. Alkylation of the pyridino nitrogen of the nicotine
molecule afforded subtype specific antagonists at a4ß2* nAChR subtypes and
nAChR subtypes that mediate nicotine-evoked dopamine release. Using this data, a
series of mono-azaaromatic quaternary salts were produced and evaluated in binding
and functional assays for a4ß2* and a7* nAChR subtypes and nAChR subtypes that
mediate nicotine-evoked dopamine release. Additionally, bis-azaaromatic quaternary
salts were synthesized and evaluated in the same assays. Two potent lead compounds
were identified. N-n-dodecylnicotinium iodide (NDDNI) was found to be very potent
at both a4ß2* nAChR subtypes and nAChR subtypes that mediate nicotine-evoked
dopamine release.
And the most promising candidate was N-N’-bisdodecylpicolinium dibromide (bDDPiB), which was selective for the nAChR
subtypes that mediate nicotine-evoked dopamine release (IC 50 = 9 nM).
Additionally, using the data from the SARs, predictive computer models were
generated to assist in future compound assessment without in vitro assays. Three
self-organizing map (SOMs) models were generated from three different sets of
compounds. The groups consisted of the mono-substituted compounds, the bissubstituted compounds, and both sets combined. The models were able to
successfully "bin" the test set of compounds after developing a model from a similar
set of training compounds. Additionally, using genetic functional activity (GFA)
algorithms an evolutionary approach to generating predictive model equations was

applied to the compounds. Three separate equations were generated in order to form
a predictive method for evaluating affinities at the α4β2* receptor subtype.
In addition to the modeling and SAR work of the quaternary ammonium compounds,
novel synthetic methods were also employed to develop enantiomerically pure
nicotine analogs. Efficient enantioselective syntheses of (S)- and R-(+)-nornicotine,
(S)-and R-(+)-anabasine, and (S)-and R-(+)-anatabine have been developed, affording
isomers in high enantiomeric excess.
KEYWORDS: Nicotinic receptors, Antagonists, Nicotine, Enantiomeric synthesis,
Self-organizing maps
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Chapter 1: Overview and Research Plan
1.1.

Overview

In order to bring a drug to market, it first must go through two major areas of research:
drug discovery and drug development. Drug discovery incorporates both chemical and
biological methodologies in order to identify a compound or a group of compounds,
which exhibit favorable in vitro activity in specific pharmacological assays. After the
initial identification of a lead compound, the development process then incorporates
formulation studies and human clinical trials to assess the bioavailability, stability, and
safety of the drug candidate (Figure 1.1).

Within the discovery process, there are several important issues to assess. The first is the
determination of an active compound. Once a structure is determined to be bioactive in
in vitro screens, a series of structurally similar compounds are synthesized and evaluated
and structure-activity relationships (SAR) are defined in an attempt to optimize biological
activity, since the initial compound “hit” is rarely the most efficacious. The synthetic
compounds are prioritized according to their bioactivity, and a lead candidate is then
identified. The data obtained can be compiled to form a library of information or an SAR
database relating the structure of the compounds to their bioactivities.

From this

information, computer-assisted models of the compound’s interaction with the receptor
may be developed.

Depending on the system being evaluated, a variety of techniques may be used to
generate computer models for assessing biological activity.
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Those compounds that

interact with a biological target that previously has been crystallized, e.g. an enzyme or
protein molecule, can be modeled in the active site using in silico methods involving
molecular modeling and docking to the crystallized target. For those biological targets
that have not been identified crystallographically, e.g. receptors, several methodologies
can be utilized in order to achieve a three-dimensional model of the molecular
recognition site from SAR data.

Pharmacophore models (three-dimensional

approximation of the active binding site) can be generated from large numbers of
compounds and their activities predicted using comparative molecular field analysis
(CoMFA).

Additionally, mathematical models, genetic functional approximation

algorithms (GFAs), and self-organizing maps (SOMs) can be used as methodologies to
predict activities or trends at a given receptor or enzyme active site.

Further drug development includes the pre-clinical processes associated with toxicity
screening, formulation, and characterization of the absorption, distribution, metabolism,
and elimination (ADME) properties of the potential drug molecule.

After full

characterization of the compound, as well as determination of dosing parameters, drug
candidates enter human clinical studies. In order to obtain approval for clinical studies,
an Investigational New Drug application (IND) must be filed. This document contains all
pertinent data to the drug’s safety and efficacy as determined in the studies mentioned
above. If accepted, trials in healthy human volunteers (Phase I) may begin followed by
patient volunteers (Phase II-IV). After all information on safety, efficacy, and dosage
regimes is collected, drug approval is sought from the Food and Drug Administration
(FDA) through a New Drug Application (NDA).

2

In addition to their therapeutic uses, the development of compounds may also be useful
as diagnostic and pharmacological tools in the analysis of perspective drug candidates. In
in vitro binding assays, a test ligand that interacts with the receptor binding site is used as
a measurement tool in order to assess the relative affinities of the drug candidates for the
target binding site. These ligands must be selective and potent at their site of action in
order to be used as diagnostic tools.

An objective of this research is to involve aspects of the drug discovery process to aid in
identifying potential drug candidates for therapeutic use or as analytical tools to help
determine biological functions.

3

Figure 1.1 Components of the Drug Discovery and Drug Development Process
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1.2.

Molecular Target and Lead Identification

Nicotinic acetylcholine receptors (nAChRs) belong to a ligand- gated ion channel
superfamily of receptors located in both the peripheral and central nervous systems.
Neuronal nAChRs are composed of five subunits that assemble in both heterologous
(α- and β-subunits) and homologous forms (α -subunits).

Several different nAChR

combinations, or subtypes, have been identified, with the α4β2* being the most studied
heterologous subtype and the α7* being the most studied homologous subtype. Since
definitive subunit combinations have yet to be determined, an asterisk (*) is used
following subtype nomenclature to indicate the reported subunit make-up. In addition to
the above receptor subtypes, which are thought to produce a pharmacological effect
without other nAChR subtypes, there are other receptor populations where multiple
subtypes contribute to one pharmacological response. While these heterologous subunit
combinations have not yet been fully assigned, they are referred to by their biological
function that they initiate (e.g. the nicotinic receptor that facilitates dopamine (DA)
release.

These subtypes, which have recently begun to be identified as the α4β2*,

α4α5β2*, α6β2β3*, and α6α4β2β3*, all contributing to nicotine-evoked DA release.
Research in the field of nAChRs has focused mainly on the development of receptor
agonists, and to a lesser extent antagonists, that act at specific nicotinic receptor subtypes
in order to elucidate function, as well as to serve as potential drug therapies in disease
states such as Alzheimer's and Parkinson's disease, schizophrenia, pain management, and
nicotine addiction.
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Previous research in the Crooks and Dwoskin laboratories has focused on the
development of ligands, specifically antagonists that may be more efficacious and
specific than the more established “classical” antagonists (e.g. DHßE). In this respect,
alkylation of the pyridyl nitrogen of the nicotine (NIC) molecule afforded two lead
compounds, N-octylnicotinium iodide (NONI), an antagonist at the nAChR subtypes that
facilitate DA release, and N-decylnicotinium iodide (NDNI), an antagonist at the α4β2*
receptor subtype (Crooks et al. 1995; Dwoskin et al. 1999). Thus, quaternary ammonium
compounds of this type were considered as useful lead candidates for exploring the
complex biological activities at the molecular level through SAR studies at individual
nAChR receptor subtypes.

1.3.

Hypothesis and Specific Aims of Research

The nicotinic receptor has been implicated in many disease states, including Alzheimer’s
and Parkinson’s disease and schizophrenia. With the diverse subtype architecture of the
nicotinic receptor, novel selective ligands are needed for both furthering research and use
as treatments for diseases. Current research has focused in the development of agonists
for these purposes. However, the development of novel antagonists at various nAChR
subtypes should also give insight into the pharmacology of these receptors. This research
will utilize synthesis and in vitro assays to generate antagonist SARs at various nAChR
subtypes.

These SARs will be used to develop potent and selective antagonists at

individual nicotinic receptor subtypes.

Additionally, using the data from the SARs,

predictive computer models will be generated to assist in future compound assessment
without in vitro assays.

6

Specific Aim 1
SARs directed at alteration of the nicotine molecule will result in optimization of the
potency, activity, and nicotinic receptor subtype selectivity of these novel classes of
nicotinic receptor ligands. Alterations will include changing the pyridino head group,
e.g. pyridinium and picolinium groups, increasing the carbon chain length, and creating
both mono- and bis-substituted molecules.

Specific Aim 2
Utilizing the SARs developed in specific aim 1, computer generated models can be
developed for screening of compounds at α4β2* receptor subtypes. Modeling techniques
will include GFA and SOM model generation.

Specific Aim 3
The synthesis of quaternary ammonium salts outlined in specific aim 1, which utilize
commercially available pyridine moieties, e.g. pyridine and S-(-)-nicotine, are useful for
discovering new nAChR antagonists. In addition to those commercially available
compounds, new potential nicotinic receptor ligands head groups will be developed.
Novel enantioselective synthetic procedures of nornicotine, anabasine, and anatabine will
be developed and optimized.

Copyright © Joshua Thomas Longen Ayers 2006
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Chapter 2: Background

2.1.

Molecular Pharmacology

Nicotinic acetylcholine receptors (nAChRs) are members of the ligand-gated ion channel
superfamily of receptors, activated by endogeno us acetylcholine (ACh), and are widely
distributed throughout the body. Other members of this superfamily include, gammaaminobutyric acid (GABAA), serotonin (5-HT), glycine, and several glutamate
receptors

(e.g.

N- methyl-D-aspartate

(NMDA),

α-amino-3-hydroxy-5- methyl-4-

isoxazolepropionate (AMPA), and kinate). Members of this family of receptors all share
a pair of disulphide-bonded cystines in their N-terminus extracellular halves that are
separated by 13 residues (Kao and Karlin 1986; Karlin and Akabas 1995; Ortells and
Lunt 1995). Nicotinic receptors modulate a wide range of physiological areas, including
the central and peripheral nervous systems and the function of the cardiovascular,
immune, and neuromuscular systems and are located at the neuromuscular junction in
autonomic ganglia, and in the central nervous system (CNS) (Sargent 1993; Lloyd and
Williams 2000). nAChRs are preferentially located presynaptically, where they play a
role in neurotransmitter release (McGehee and Role 1995; Wonnacott 1997).
Postsynaptic nAChRs, however, have also been identified in brain regions, although their
function and importance is still being investigated (Colquhoun and Patrick 1997).

2.2.

Structure of the nAChR

It is generally accepted that nAChRs are membrane-bound pentameric complexes
composed of individual protein subunits.

When activated by interaction with

acetylcholine or other appropriate agonists, the receptor allows passage of cations, e.g.
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Na+, Ca2+, and K+, through the central pore. These complexes have an approximate
molecular weight of 300 kDa. The protein subunits assemble with a 5- fold axis of
symmetry and form the ion conduction pathway of the receptor (Karlin and Akabas 1995;
Schmitt 2000) (Figure 2.1A). Each subunit is composed of a large N-terminus loop
followed by four transmembrane spanning hydrophobic regions, M1-M4 (Claudio et al.
1983; Leonard et al. 1988). The portions of the M1 and the complete segments of the M3
and M4 transmembrane regions interact with the lipid bilayer, separating the pore from
the hydrophobic membrane (Karlin 2002; Miyazawa et al. 2003). M2 has a high degree
of segregated hydrophilic and hydrophobic portions of the amino acid helical cylinder
and forms the inner portion of the ion channel with some sections of the M1 (Leonard et
al. 1988; Changeux et al. 1998; Grutter and Changeux 2001; Karlin 2002; Miyazawa et
al. 2003). Additionally, alterations to the amino acid sequence of the M2 portion affect
the ion selectivity of the channel (Imoto et al. 1988; Adcock et al. 1998) (Figure 2.1B).

Smit et al. (2001) provided the high-resolution structure of the Acetylcholine Binding
Protein (AChBP), which provided a number of insights into the structure and function of
nAChRs.

AChBP is a soluble protein synthesized in snail neuronal glial cells and

modulates synaptic transmissions (Brejc et al. 2001; Smit et al. 2001). This protein binds
many of the same ligands as the peripheral and neuronal nAChRs, including nicotine,
epibatidine, (+)-tubocurarine, and α-bungarotoxin.

The affinities for these ligands

closely resemble those found in the α7* subtype, though with higher overall affinities.
This similarity can be attributed in part to the AChBP’s similar amino acid residues and a

9

significant sequence alignment (20 - 24%, α7 ~ 24%) with the extracellular portions of
the α subunits (Grutter and Changeux 2001; Karlin 2002; Smit et al. 2003).

As stated above, several of the nAChR subtypes have a conserved 13 residue Cys-loop at
the N-terminus. This loop is present in the AChBP; it is only 12 amino acid residues and
is not conserved. The nAChR subunits are typically hydrophobic residues that make up
the loop, while the AChBP’s subunits are mostly hydrophilic (Karlin 2002; Smit et al.
2003). It has been proposed that differences in the 13 amino acid sequence of the Cysloop are because nAChR subtypes are membrane bound and interacting with the
transmembrane domain of the receptor. The AChBP is not membrane bound, therefore, it
would not need to have the conserved residues in order to function (Karlin 2002; Smit et
al. 2003).

The AChBP also provided insight into the binding site of the nAChR.

Examination of the peripheral nAChR ACh-binding site by mutagenesis and
photoaffinity labeling studies identified the residues involved in ACh-binding (Corringer
et al. 2000). When compared to the peripheral nAChR subtype, the AChBP has high
conservation of residues that line the ACh-binding site (Smit et al. 2001; Karlin 2002). It
was originally thought that the position of the binding site was contained within the αsubunit within the ion channel (Miyazawa et al. 1999). The binding site of the AChBP,
however, was found to be at the outside of the complex approximately midway in
between the top and bottom of the receptor. Additionally, access to receptor binding site
was found to be from the outside not through the ion channel (Changeux and Edelstein
2001; Karlin 2002). Studies of the AChBP binding site also demonstrated that the site
was located at the interface of two subunits.

10

The same binding phenomenon was

determined for peripheral and neuronal nAChR subtypes (Corringer et al. 2000). Luetje
and Patrick (1991) demonstrated that both the α- and β-subunits are important in agonist,
as well as antagonist, sensitivity to nAChRs. The heteropentamer’s interfacial binding
site was split into two components, the principal (α-subunit) and the complementary (the
neighboring subunit, e.g. β-subunits in the CNS and γ/δ in the periphery).
Homopentamer’s binding sites are also split into the principle and complementary
components but both are contributed by the α-subunits. The principal component is
composed of three loops, A (Tyr93, α1-numbering), B (Trp149), and C (Tyr190, Cys
192, Cys 193, and Tyr 198). The complementary component is also composed of three
loops, D (Trp55 and Glu57, γ-numbering), E (Leu109, Tyr111, Tyr117, and Leu119), and
F (Asp 174 and Glu176) (Smit et al. 2003; Grutter et al. 2004). Tyr93 (methyl groups),
Trp149 (ammonium ion), and Loop C (ester moiety) all interact with the binding of ACh
(Cohen et al. 1991; Zhong et al. 1998; Grutter et al. 2000). Additionally, Sine et al.
(2002) have reported that the AChBP binding of HEPES has been crystallized and the
charged ammonium group was found to interact with the Trp143 (Trp149 in the
peripheral nAChR) residue, confirming the calculations of Zhong et al. (1998). Docking
experiments using models of the extracellular domains of nAChR subtypes based on the
AChBP structure have been performed with success (Zhong et al. 1998; FruchartGaillard et al. 2002; Le Novere et al. 2002; Schapira et al. 2002). The use of such
experiments may lead to increased understanding of the nAChR; however, without
crystallized structures of each individual subtype, data collected will not be definitive.
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2.3.

NAChR Subunit Nomenclature and Composition

Nicotinic receptors have been characterized into two different classes, peripheral and
neuronal.

The peripheral muscle-type nicotinic receptor has been extensively

characterized due to the abundance and reproducibility of the receptor. When various
toxins were found to bind to the acetylcholine binding site of the muscle nicotinic
receptor, radiolabeled forms of these toxins were utilized to identify, quantitate, and
purify these receptors. From these studies, the major binding subunit of the nicotinic
receptor has become known as the α subunit. This subunit is identified by two adjacent
cysteine residues (residues 192 and 193) (Figure 2.1A), as well as a highly conserved
binding domain possessing aromatic amino acids involved in π-interactions (Grutter and
Changeux 2001; Sharpless and Wonnacott 2001). From the information gathered using
these criteria, ten such subunits have been identified, α1-α10, in various peripheral and
central nervous systems (Sargent 1993; Elgoyhen et al. 2001).
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Figure 2.1 Subunit designation and composition

Reprinted from Brain Res Bull, 57(2), Tassonyi E. et al., The role of nicotinic acetylcholine receptors
in the mechanisms of anesthesia, 133-150, Copyright (2002), with permission from Elsevier
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The α subunit has been found in combination with other subunits, β, γ, ε, and δ, in the
periphery. These other subunits were initially identified as structural subunits. Similarly,
α subunits in the central nervous system were found with subunits that lacked the
disulfide bridge.

These non-alpha or β subunits have been identified as β1-β4 for

heterologolously

expressed

neuronal

receptors (Sargent 1993).

Additionally,

homologolously expressed neuronal receptors that only contain the α subunit have also
been discovered.

The various subunits found have been further organized into four

subfamilies, I-IV. Subfamilies I and II contain the homologously expressed subunits, α9
and α10 (subfamily I) and α7 and α8 (subfamily II).

The peripheral muscle-type

receptor subunits (α1, β1, γ, ε, and δ) compose subfamily IV. Finally the largest of the
subfamilies, subfamily III (α2-α6 and β2-β4), has been further subdivided into three
tribes. Tribe 1 contains the binding subunits, α2, α3, α4, and α6. The β subunits, β2 and
β4, make up tribe 2. Tribe 3 is composed of α5 and β3 (Corringer et al. 2000).

Skeletal muscle nicotinic receptors were found to have a subunit composition of
(α1)2 :β1:γ:δ or (α1)2 :β1:ε:δ depending on the age of the receptor subtype (Karlin and
Akabas 1995).

The ε subunit replaces the γ subunit in adult mammalian muscle

receptors. The pentameric structure of this subtype is α1:γ:α1:δ :β1 or α1:ε:α1:δ:β1.
Additionally, contrary to the initial findings of the ACh binding site, the α1, γ or ε, and δ
all contributing to the binding of acetylcholine, with the majority of the binding sites
located in the α1 subunit (Adcock et al. 1998) (Figure 2.1C).
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As stated above, CNS nicotinic receptor subunits tend to associate in two modes, e.g.
heterologously and homologously. However, in contrast to the significant amount of
information on the muscle-type receptors, the subunit make-up and stoichiometries of the
neuronal nAChRs are not as well characterized. Members of subfamilies I and IV and
the α8 subunit (subfamily II) are not expressed in the mammalian brain (Corringer et al.
2000; Elgoyhen et al. 2001). A number of researchers have isolated cDNA or gene
clones of several α subunits, α2, α3, α4, α5, α6, and α7, as well as three β subunits, β2,
β3, and β4 (Boulter et al. 1987; Goldman et al. 1987; Deneris et al. 1988; Wada et al.
1988; Deneris et al. 1989; Boulter et al. 1990; Seguela et al. 1993). Subunit mRNA for
different α and β subunits have been identified in various overlapping brain regions,
suggesting subunit complexity (Wilkens 2001). The binding site of the heterologously
expressed nAChR subtypes is formed from both tribe 1 (α2, α3, α4, and α6) and tribe 2
(β2 and β4). Additionally, the function of the receptors requires that at least one subunit
of α and one of β be present. Tribe 3 subunits (α5 and β3) have also been proposed to
exist in such multi α or β complexes as modulators of the other paired subunits (Lin and
Meyer 1998; Girod et al. 1999) (Figure 2.1C). Therefore, the subunit composition of the
pentameric system is two binding site pairs and a fifth subunit from tribes 2 or 3 (Luetje
2004).

Homologously expressed receptor subtypes demonstrated a five α subunit binding site
structure (suggesting a pentameric structure), each of which may exhibit different
affinities for nicotinic ligands (Palma et al. 1996; Orr-Urtreger et al. 1997; Rakhilin et al.
1999).

Only the α7 subunit from the homomeric subfamily II exists in the CNS.
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Therefore, the only homologously expressed subtype is often referred to as the α7*
nAChR subtype.

2.4.

nAChR Subtype Formation

It should be noted that before there is any discussion about subunit assembly, there is still
much to be learned about the composition of naturally expressed nAChR subtypes.
Although many researchers have presented compelling evidence towards a particular
subtype combination, other more complex assemblies may exist in vivo, and therefore an
asterisk (*) follows native subtypes that are putatively assigned, after the convention
adopted by Lukas et al. (Lukas et al. 1999).

Heterologously expressed nAChR Subtypes
Affinity labeling, immunoprecipitation, [3 H]-nicotine binding, in situ hybridization, and
constitutive gene knockout studies all demonstrate that the α4β2* receptor subtype is the
predominant neuronal nicotinic receptor for which nicotine has high affinity (Clarke et al.
1985; Marks et al. 1986; Whiting et al. 1987; Wada et al. 1989; Flores et al. 1992;
Picciotto et al. 1998; Zoli et al. 1998). Xenopus oocytes express α4β2 receptors with a
stoichiometry of (α4)2 (β2)3 , with the presumed order being α4:β2:α4:β2:β2 (Anand et al.
1991; Cooper et al. 1991). Two identical agonist binding sites exist at the α4 and β2
subunit interfaces. It has also been proposed that an α5 subunit may be associated with
some populations of α4β2* receptors (Conroy et al. 1992; Sharpless and Wonnacott
2001). α4β2* nAChR have been associated with anxiety, depression, pain, cognition,
and neurodegeneration (Lloyd and Williams 2000).

16

Another form of heterologously expressed nAChR subtype is the nicotinic receptors that
mediate NIC-evoked DA release. Although not as prevalent in brain tissue as α4β2*
subtypes (Schulz et al. 1991), these subunit assemblies are very important in regulation
of dopamine release, as determined from antagonist studies involving several known
compounds that interact at the nAChR subtype (Schulz and Zigmond 1989; Grady et al.
1992; Crooks et al. 1995; Cartier et al. 1996). The existence of DA release facilitating
nAChR subtypes is further supported by autoradiography studies, where a potent, nonspecific agonist, [3 H](+)-epibatidine, is proposed to bind to areas of the brain containing
α4β2* nAChR subtypes as well as a second receptor class that were also marked by
[125 I]neuronal bungarotoxin, a sensitive ligand to the nAChR subtype facilitating DA
release (Holladay et al. 1997). Although, initially defined as one subtype, α3β2*, the
exact assignment of the subunit composition of these DA releasing nAChR subtypes was
uncertain for many years. mRNA of several nAChR subunits were shown to be present
in areas of the brain associated with dopamine release, including α4, α5, α6, α7, β3, and
β4 subunits located in the substantia nigra, which projects to the striatum, a known area
involved in dopamine release (Deneris et al. 1989; Wada et al. 1989; Wonnacott 1997;
Charpantier et al. 1998). Additionally, mRNA of the modulatory subunits α6 and β3 had
high expression levels in the substantia nigra (Deneris et al. 1989; Goldner et al. 1997;
Charpantier et al. 1998). Studies involving α5 subunits (closely related structurally to β
subunits) revealed that the replacement of the non-binding β4 subunit with an α5 subunit
leads to a change in the pore Ca2+ permeabilities and desensitization rates (Wang et al.
1996; Gerzanich et al. 1998) (Figure 2.1C). Moreover, increased agonist potencies were
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observed when incorporating α5 into the oocyte α3β2 subunit assembly to yield a subunit
composition of α3:β2:α5:β2:α3 (Gerzanich et al. 1998).

These findings generated

considerable debate as to the exact subunit composition of nAChR subtypes mediating
NIC-evoked DA release (Klink et al. 2001; Azam et al. 2002; Champtiaux et al. 2002;
Whiteaker et al. 2002; Zoli et al. 2002), and there remained a large focus on elucidating
the specific nAChR subtypes responsible for DA release. The discovery and use of the
α-conotoxins (α-ctx), particularly α-ctx MII, has greatly increased understanding of this
receptor class. Two receptor classes, α-ctx MII sensitive and α-ctx MII resistant, have
been determined using α-ctx MII. The α-ctx MII sensitive receptors were identified as
an α3β2* subtype due to α-ctx MII sensitivity for oocytes expressing the α3β2 subtype.
However, α3 knockout mice studies did not eliminate [125 I]α-ctx MII binding in the brain
(Whiteaker et al. 2002). Further studies found that deletion of α6 and β3 subunits led to
a loss of [125 I]α-ctx MII binding (Champtiaux et al. 2003; Cui et al. 2003).

α6

containing receptors were found to be sensitive to α-ctx MII, neuronal bungarotoxin, and
α-ctx PnIa, all reported α3β2* subtype antagonists (Kuryatov et al. 2000; Dowell et al.
2003; Everhart et al. 2003). In addition to the α6 subunit investigations, knockout mice
have been used to determine which individual subunits are responsible for functional
receptor subtypes. Loss of function was demonstrated for α4-, α5-, α6-, β2-, and β3-null
mutant mice, implicating their role modulating NIC-evoked DA release (Grady et al.
2001; Champtiaux et al. 2003; Cui et al. 2003; Salminen et al. 2004). Salminen et al.
(2004) also determined that β4- and α7-null mutant mice have no loss of receptor
function. By coupling the knockout mice data with the α-ctx MII data, Luetje (2004) has
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identified four distinct DA releasing subtypes: α-ctx MII sensitive subtypes, α6β2β3 and
α6α4β2β3, where α6 and α4 form with the β2 subunit to form the binding sites and αctx MII resistant subtypes consisting of α4β2 and α4α5β2 with the α4 and β2 subunits
forming the agonist binding sites (Luetje 2004). For purposes of this publication, this
family of receptors will be referred to by its functional designation, e.g. the receptors that
mediate NIC-evoked DA release.

Homologously expressed nAChR Subtypes
In addition to heterologously expressed nAChR subtypes, there exists a second class of
homologously expressed receptor subtypes. Originally, these homomers were identified
using the same methods utilized in identifying muscle-type nAChRs. Using radiolabeled
α-bungarotoxin, a known α1β1γδ ligand (Lee 1972), researchers found a receptor
population which demonstrated a high affinity for the compound (Marks et al. 1986).
Using α7 mRNA brain distributions as well as the autoradiographic binding data, this
receptor subtype was identified as an α7 homomer (Clarke et al. 1985; Wada et al. 1989;
Seguela et al. 1993; Chen and Patrick 1997). This class of homomeric receptor subtype
is almost as prevalent as the α4β2* population of nAChRs in the brain. However, these
receptors are expressed differently in different brain regions (Holladay et al. 1997). The
α7* receptor subtypes are highly permeable to Ca2+ ions (Seguela et al. 1993; de Fiebre
et al. 1995), and rapidly desensitize in the presence of agonists (Castro and Albuquerque
1993). Synapse formation, mediation of nicotine-induced seizures, and modulation of
neurotransmitter release are some functions potentially regulated by the α7* nAChR
(Orr-Urtreger et al. 1997).
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2.5.

Pharmacology of Nicotine at the nAChR

As stated above, nicotinic receptors mediate a wide variety of effects on many systems in
the body. Nicotine, the principal alkaloid and active compound in tobacco, has been
found to interact with the acetylcholine binding site on nicotinic receptor subtypes.
Nicotine exposure has been shown to enhance memory and attention, increase arousal,
decrease anxiety, and cause weight loss (Arneric and Brioni 1999).

Additionally,

nicotine has been shown to be highly addictive due to its ability to affect the modulation
of dopamine release. Like acetylcholine and other agonists, nicotine has been shown to
first activate the opening of the receptor ion channel. After activation, nicotine exposure
causes a second conformational change in which the receptor becomes refractory or
desensitized (Corringer et al. 1998). In its desensitized state, the ion channel is closed,
and the receptor is in a resting state. Before activation by an agonist, the receptor has a
high affinity for binding nicotine or other agonist molecules. Interestingly, after binding
of nicotine, the subsequent desensitized state also has an increased affinity for nicotine,
even though it is unable to function (Sharpless and Wonnacott 2001). Additionally, at the
binding site, the ß-subunit may control the extent of desensitization or inactivation of the
receptor after long-term agonist exposure (Fenster et al. 1997; Kuryatov et al. 2000; Kuo
et al. 2005). Concentrations needed to desensitize the receptor are also much less then
those required to activate the receptor (Rowell and Hillebrand 1994; Fenster et al. 1997;
Grady et al. 1997). An increase in receptor number, or up-regulation, also occurs when
a4ß2* receptors are exposed to chronic nicotine treatments (Wonnacott et al. 1990).
However, this upregulation is not due to an increase in receptor mRNA production, and

20

may be due to a recruitment of nicotinic receptors from a reserve pool (Marks et al. 1992;
Bencherif et al. 1995). It should also be noted that different nAChR subtypes respond to
agonists differently, and their desensitization rates and function can vary when exposed
long term to NIC (Nguyen et al. 2004; Grilli et al. 2005). As stated above, α7 receptors
are characterized by their very rapid desensitization, whereas receptors modulating DA
release are more resistant to desensitization (Castro and Albuquerque 1993; Gray et al.
1996; Yu et al. 1996). Interestingly, the opposite is true for regulation of these receptor
subtypes using chronic NIC infusion.

a7* receptor subtypes are more resistant to

regulation by NIC, where as a6* containing receptors (DA mediating nAChR subtypes)
are down-regulated when exposed to chronic NIC (Collins et al. 1994; Lai et al. 2005).
Desensitization, as well as up-regulation, has allowed researchers not only to search for
agonists that are selective for various subtypes, but also to explore subtype-selective
antagonists as therapeutic agents (Arneric and Brioni 1999).

2.6.

Existing Assays for Evaluating Affinity and Functional Responses at
nAChRs

Radioligand Binding Studies
Only a limited number of pharmacological tools are available to evaluate affinity and
function at the various nicotinic receptors. Radioligand binding assays are often used as
the first step in determining ligand affinity for individual nAChRs, due to methodological
ease and the capacity for rapid screening. These assays are carried out using native
tissue, or utilizing receptors expressed in Xenopus oocytes or other stably-transfected cell
lines.
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Ligand binding assays developed for the α4β2* receptor subtype are performed using
several different ligands, including [3 H]S-(-)-nicotine (NIC), [3 H]cytisine, [3 H](+)epibatidine, and [3 H]ACh. Several different brain regions may be used to obtain native
tissue nAChRs, including the thalamus, cortex, and striatum. Cell line K-177, a line of
human embryonic kidney (HEK) 293 cells that stably express the human α4β2 nAChR,
has also been utilized in binding assays (Gopalakrishnan et al. 1996). α7* nAChR
subtypes are also assayed via radioligand binding methods; the most widely used ligands
for these studies have been [3 H]-α-bungarotoxin and [3 H]- methyllycaconitine. Native
tissue receptors, as well as stable cell lines expressing a7 receptors have been used in
these binding assays (Gopalakrishnan et al. 1995; Quik et al. 1996; Whiteaker et al.
1999). A third class of neuronal nAChRs, the subtypes that mediate NIC-evoked DA
release, has primarily utilized [3 H]-(+)-epibatidine as the radioligand in the binding assay.
However, due to its non-specificity (α4β2 activity), this radioligand must be used in
conjunction with unlabeled cytisine to block [3 H](+)-epibatidine binding to the α4β2*
subtype (Marks et al. 1998). Cloned cell lines have revealed several possible candidates
for these studies. α3α5β2, α3β2, and α3β4 nAChR clones have all shown an affinity for
n-bungarotoxin and epibatidine (Lin and Meyer 1998). [125 I]-α-ctx MII has also been
used as a ligand for the nAChR subtype mediating NIC-evoked DA release (Holladay et
al. 1997).

22

Functional Assays
In order to differentiate between agonists and antagonist at nAChR subtypes, functional
studies must be utilized in addition to the binding studies. These functional assays must
also be used to assess what is occurring at the actual receptor site. Binding studies only
represent the affinity of ligands for the desensitized form of the receptor and may not
give an accurate indication of the ligand’s interaction with a functional receptor (e.g. the
non-desensitized form). As in the binding studies, functional assays must be subtype
specific. Current approaches incorporate the use of slices or synaptosomes from various
brain regions, as well as recombinant receptors expressed in Xenopus oocytes, or in
stably-transfected cell lines. α4β2* subtypes have traditionally been assayed using ion
flux assays involving the radioactive ion [86 Rb+].

86

Rb+ is an ion considered to be

equivalent to the endogenous cation K+. Rodent brain synaptosomes or stably transfected
cell lines (K177 cells or IMR-32 cells) are preloaded with

86

Rb+ and superfusion systems

in the presence of agonist are used to efflux the radiolabel through the ion channel.
Functional response is designated once the compound either elicits efflux (agonist), or
inhibits efflux when NIC is introduced into the system as an agonist (antagonist). Data
from 86 Rb+ efflux and [3 H]-nicotine binding assays have shown correlative EC 50 and IC 50
values for agonist- induced efflux, respectively, as well as correlation of similar sites of
action within brain regions. It is important to note that α7 [125 I]-α-bungarotoxin binding
data does not correlate with

86

Rb+ efflux brain regions, offering further proof that

efflux is a functional assay for α4β2* nAChRs (Marks et al. 1998).
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86

Rb+

Generally, ion flux functional assays for α7 subunits have proven to be unsuccessful, due
to rapid α7* receptor desensitization, which has been reported to occur over several
milliseconds (Seguela et al. 1993). Consequently, electrophysiology studies have been
used to characterize these homomeric receptor subtypes.

Whole-cell voltage clamp

experiments using either hippocampal interneurons or Xenopus oocytes expressing α7
subtypes have been shown to be useful in determining functional activity before the
receptor is desensitized (Frazier et al. 1998; Papke and Thinschmidt 1998; Papke et al.
2000).

As mentioned above, the nAChR has been implicated in the mediation of NIC-evoked
dopamine release. Therefore, nAChR subtypes that mediate NIC-evoked DA release
have been assayed utilizing neurotransmitter (NT) release methodologies. These assays,
usually utilize brain slices or synaptosomes, oocytes, or stably-transfected cell lines,
which are preloaded with [3 H]-dopamine and superfused to monitor the efflux of the
radiolabel in the presence of agonist. Drug candidates can be added to the system to
measure their intrinsic (agonist) activity, and compounds can also be tested against a
known agonist (e.g. NIC) to determine the ability of the compound to inhibit agonistevoked dopamine response (antagonist response). Native tissues, such as striatum, as
well as cell lines, including IMR-32 human neuroblastoma cells and rat PC12 cells, both
of which are ganglionic in nature and express an α3-containing subtype (possibly α3β4),
have been employed using this assay method (Lukas 1993; Donnelly- Roberts et al.
1998). Although this assay does not differentiate between the four possible subtypes that
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mediate DA release, it has been invaluable in identifying non-α4β2 and non-α7 selective
ligands.

Researchers may choose to use several types of tissues when conducting any of the
assays outlined above. However, both native tissue and expressed cells have benefits and
limitations. Using neuronal tissue affords a more accurate representation of the native
receptor but limits the effective determination of nAChR subtype compositions, due to
the complexity of the neuronal tissue, as well as the limitations of the pharmacological
assays. Additionally, the rodent brain (e.g. rat or mouse) is small, and large amounts of
tissue may be needed in order to fully assess a series of compounds, adding a high cost to
the process. Expressed cells, in contrast, can be grown in large quantities, are quite easy
to manipulate, and provide an accurate determination of subunit composition. These cells
are also cost-effective, when screening large numbers of compounds.

However,

perceived strengths of homogeneity and basic cell function are also weaknesses for these
tissue preparations. In addition, while the subunit composition of nAChRs is known in
both Xenopus oocytes and transfected cells, they are not necessarily identical to the
corresponding native receptor subtypes, with regard to subunit combination,
stoichiometry, post-translational modification, and placement within the brain regions.
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2.7.

Nicotinic Ligands of the nAChR

2.7.1.

Agonists

Alkaloids
The tobacco plant, Nicotinia tobacum, contains many different naturally occurring
alkaloids.

The most abundant, NIC (1), has a varied pharmacological profile, as

discussed above, throughout the body, both peripherally and centrally. R-(+)-Nicotine
(R-NIC, 2), the enantiomer of NIC, which is formed during pyrolysis of tobacco products
and is present in tobacco smoke, also has activity at nAChRs. In addition to NIC, N.
tobacum contains several other alkaloids, including, S-(-)-nornicotine (3), S-(-)-cotinine
(4), S-(-)-anabasine (5), and S-(-)-anatabine (6). R-NIC has lower affinity for the α4β2*
receptor subtype than that reported for (1 ), as determined by inhibition of [3 H]-NIC
binding (Ki = 46 and 2 nM, respectively) (Crooks et al. 1995). Stimulation of DA release
in striatal tissue with (2) afforded an equivalent efficacy but a lower potency than (1)
(Garvey et al. 1994). Compounds 3 and 4 have been evaluated in the NIC-evoked [3 H]DA release assay and both evoked [3 H]-DA release but neither was as potent as NIC. S(-)-Nornicotine (EC 50 = 1.0 µM) was more potent than S-(-)-cotinine (EC 50 = 30.0 µM)
(Teng et al. 1997; Dwoskin et al. 1999). [3 H]-NIC binding affinities for (3) and (4) were
also determined in comparison to that of NIC and were 259- fold and 3900- fold lower in
affinity, respectively (Garvey et al. 1994; Lin and Meyer 1998). Compound 5 exhibits a
30-fold decrease in affinity when compared to NIC in the [3 H]-NIC binding assay, a 40%
efficacy in the

86

Rb+ efflux assay compared to NIC, and an EC 50 value of 15.4 µM in the

NIC-evoked [3 H]-DA release assay (Marks et al. 1993; Dwoskin et al. 1995).
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Figure 2.2 Structures of Alkaloid Molecules and Pyridine Ring Modified NIC Molecules
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Anabaseine and Anabaseine Analogs
Anabaseine (7) is a 1’, 2’-dehydroanabasine analog. It is found in cured tobacco and in
the marine worm Hoponemetines hydrobiologia. Compound 7 affords about a 20- fold
decrease in rat brain [3 H]-NIC binding affinity when compared to NIC, and has a similar
selectivity for α4β2* nAChR subtypes (Ki = 32 nM) over α7* nAChR subtypes (Ki = 58
nM) (de Fiebre et al. 1995; Kem et al. 1997). However, intrinsic α7 activity is 200%
higher for (7) over NIC in expressed oocytes. A 3’-substituted anabaseine analog, GTS21 (8), exhibits partial agonist activity at rat α7 receptors expressed in Xenopus oocytes
(ca. 28% of the ACh response) and low activities at α4β2 oocyte-expressed receptors. In
contrast, human α7 receptor activity elicited by (8), when compared to that elicited at rat
α7 nAChRs, was less efficacious (Briggs et al. 1997; Meyer et al. 1998). 4-OH-GTS-21
(9), a GTS-21 metabolite, showed a similar increase in affinity for the α7 receptor
subtype when compared to (8) in rat oocyte PC-12 cells utilizing the [125 I]α-Btx binding
assay [e.g. Ki = 45 nM (4-OH-GTS-21) and 31 nM (GTS-21)]. Additionally, the 4-OH
metabolite had more affinity for the binding sites of human SK-N-SH cells when assayed
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in the [125 I]α-Btx binding assay (Ki = 170 nM (9) and 23 µM (8)) (Meyer et al. 1998;
Papke et al. 2000).

Figure 2.3 Structures of Anabaseine and Modified Anabaseine Molecules
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Two series of restricted nicotine analogs (10-12) have affinities for nAChRs. A synrotamers of NIC (10a) elicited antinociceptive effects in the tail flick assay (a purported
α4β2* mediated effect), with the (+)-enantiomer having a 12- fold greater effect over the
(-)-enantiomer (Sabey et al. 1999; Sarkar et al. 2004). Interestingly, affinity values of
these enantiomers in the [3 H]-NIC binding assay were reversed; the (+)- and (-)enantiomers of 10) having Ki values of >10,000 and 605 nM, respectively. The racemic
desmethyl analog (10b) had a higher affinity for α4β2* nAChRs (Ki = 167 nM) when
compared to the N-methyl enantiomers (Chavadarian et al. 1983; Glassco et al. 1993).
Xu et al. (2001) obtained similar values for the syn-rotamer compounds 10a and 10b (Ki
= 400 and 220 nM, respectively) in the [3 H]-NIC binding assay, and these compounds
demonstrated different affinities in the [3 H]-MLA binding assay, Ki = 590 nM (10a) and
20.2 µM (9b). Binding affinities for the anti- rotameric analogs (11a and 11b) of NIC and
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nornicotine indicated no appreciable affinity of these compounds at the α7 receptor
subtype (Ki >100 µM for both compounds) and only weak micromolar affinity in the
[3 H]-NIC binding assay (Ki = 12.2 and 10.5 µM, respectively) (Xu et al. 2001).
Compound 12, a racemic 6-methoxy substituted analog of (10b), had a much lower
affinity (Ki = 1.9 µM) than that of NIC in the [3 H]-NIC binding assay using rat brain
homogenate, but exhibited strong antinociceptive effects in the rat tail flick assay
(McDonald et al. 1996).
Figure 2.4 Structures of Conformationally Restricted NIC Analogs
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Cytisine
Cytisine (Cyt, 13), an alkaloid found in laburnum of the Leguminosae family, has
exhibited selectivity for neuronal nAChR subtypes over those in the periphery (Astles et
al. 2002). Cyt has demonstrated high affinity and activity at α4β2* nAChRs. In [3 H]NIC binding assays, Ki values ranging from 0.14-2.7 nM for Cyt have been reported
(Marks et al. 1993; Court et al. 1994; Whiteaker et al. 1998). Cyt has been shown to
favor α4-containg subtypes over the a7* nAChR subtype (Astles et al. 2002). Functional
studies have revealed that Cyt elicits ion flux in both brain thalamic synaptosomes, as
well as in cells expressing α4β2* nicotinic receptors (EC 50 = 0.019 – 71.4 nM) (Marks et
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al. 1993; Peng et al. 1994; Marks et al. 1996). Cyt has low µM affinity (Ki = 1.6 µM) in
the [125 I]-α-Btx binding assay using rat brain preparations (α7* nAChRs) (Marks et al.
1993). In the [3 H]-DA release assay from rat striatal slices, Cyt was a partial agonist
(Sacaan et al. 1995). However, Grady et al. (1992) reported that Cyt was a full agonist
when evaluating DA release from mouse striatal synaptosomes (Grady et al. 1992). Cyt
is also able to distinguish between the β4 and β2 subunits using oocyte-expressed cells
systems, with the α4β4 nAChR subtype eliciting a much larger agonist response than the
α4β2 subtype (Luetje and Patrick 1991).

Epibatidine
Epibatidine (Epi, 14), an alkaloid originally isolated from Epipedobates tricolour (an
Ecuadorian poisonous frog), was first structurally determined by Daly et al. (1991) to be
an azabicycloheptane (Daly et al. 1991; Spande et al. 1992; Badio and Daly 1994). To
date, Epi is the most potent natural agonist at nAChRs. Epi has demonstrated very little
enantioselectivity at various nAChRs (Badio and Daly 1994; Gerzanich et al. 1995). In
rat homogenate binding assays using various specific radiolabeled ligands, Epi had
picomolar affinities at α4β2* receptor subtypes (Ki = 70 pM), low nanomolar affinities at
α7* (Ki = 21 nM), and low micromolar affinities at α1βγδ receptor subtypes (2.7 µM,
respectively) (Gopalakrishnan et al. 1996; Sullivan and Bannon 1996). Cell expressed
nAChRs demonstrated similar α4β2 affinities (Ki =19 pM) and slightly weaker α7
affinities (Ki = 200 nM). Affinities for α3β2 and α3β4 nAChRs were determined to be
over 10- fold lower than for α4β2 nAChRs (Ki = 230 and 380 pM, respectively)
(Gerzanich et al. 1995; Xiao et al. 1998). In functional assays, Epi has been evaluated in
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the NIC-evoked [86 Rb+] efflux assay using K177 cells expressing the α4β2* nAChR
(EC50 = 17 nM), as well as oocyte-expressed α7 nAChRs (EC 50 = 1.3 µM)
(Gopalakrishnan et al. 1996; Sullivan and Bannon 1996). Epi was also 150- fold more
potent (EC 50 = 0.4 nM) than nicotine (EC 50 = 60 nM) in evoking DA release from rat
striatal slices, and 40% more efficacious (Sullivan et al. 1994).

Figure 2.5 Structures of Cytisine, Epibatidine, Anatoxin-a

H

H
N

H
HN

CH3

N
H

O

HN
N

O

13 Cystine

14 (+)-Epibatidine

Cl
15 (+)-Anatoxin-a

Anatoxin-a
(+)-Anatoxin-a (Atx, 15), isolated from the freshwater blue- green algae Anabaena flosaquae, has an azabicyclononene skeleton and exhibits a wide variety of nAChR activities.
Atx has a similar affinity to NIC (Atx, Ki = 3.5 nM; NIC, Ki = 1-3 nM) in the [3 H]-NIC
binding assay using rat brain homogenate (Wonnacott et al. 1991). Binding studies using
rat α7* native receptors and [125 I]-α-Btx revealed that (+)-Atx had a 60-fold higher
binding affinity than NIC at this receptor subtype. Using mouse thalamic synaptosomes
and M10 cells, 15 has been shown to be more efficacious than NIC in the NIC-evoked
[86 Rb+] efflux assay (EC 50 = 48 - 93 nM and 180 - 2500 nM, respectively) (Thomas et al.
1993; Marks et al. 1996). Using α7 receptors expressed in Xenopus oocyte cells, ion flux
assays demonstrated a 50- fold increase in potency for Atx over NIC (Thomas et al.
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1993).

Additionally, (+)-anatoxin is 10- fold more potent than NIC in PC-12 cells

expressing a ganglionic-type receptor (Daly et al. 1991). The (-)-Atx enantiomer has
1000-fold less affinity for α4β2* receptors and 50- fold less affinity for α7* receptors,
compared to (+)-Atx, when assaying rat brain tissue (Macallan et al. 1988). Reduction of
the olefinic bond in the octene ring of (+)-Atx causes a 20-fold decrease in affinity at
both [3 H]-NIC (α4β2*) and α-Btx (α7*) binding sites in rat brain tissue.

2.7.2.

Antagonists

Competitive Antagonists
d-Tubocurarine (d-TC, 16) is a classical nAChR antagonist isolated from the South
American bush Chondodendron tomentosum. Originally used as a poison on the tips of
arrows, d-TC was found to be a potent antagonist at muscle type nAChR [(α1)2 βγδ or
(α1)2βεδ] (Sharpless and Wonnacott 2001). d-TC binds to many different peripheral and
neuronal nicotinic receptor subtypes with a low micromolar affinity, and is able to
antagonize several different functional responses of nicotinic receptors at micromolar
concentrations in Xenopus oocytes (Chiappinelli et al. 1993; Cachelin and Rust 1995;
Chavez-Noriega et al. 1997). Similar activities were seen in native neuronal receptor
assays for α4β2* nAChR subtypes and receptor subtypes mediating DA release (Grady et
al. 1992), further supporting the observation that d-TC is not a selective ligand at nAChR
subtypes. It should also be noted that, while d-TC does exhibit competitive antagonistic
properties in the systems mentioned above, it also may have a non-competitive
component to its receptor inhibition profile (Cachelin and Rust 1994; Chavez-Noriega et
al. 1997).
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Dihydro-β-erythroidine (DHβE, 17), an alkaloid isolated from Erythrina seeds,
competitively binds to nAChRs, with affinities in the nanomolar range, at both α4β2*
nAChR subtypes and receptor subtypes mediating DA release (Crooks et al. 1995;
Khiroug et al. 2004). Characterization of DHβE in a number of oocyte expression
systems demonstrated selectivity between nAChR subtypes. A 3-fold selectivity α4β2
receptor subtype over the α2β2 receptor subtype and a 10-fold selectivity for the α4β4
receptor subtype over the α4β2 receptor subtype. Additionally, an approximate 100-fold
increase in selectivity for α4β4 receptors over α3β4 receptors was observed (Harvey and
Luetje 1996; Chavez-Noriega et al. 1997; Khiroug et al. 2004). DHβE binds similarly to
NIC, and the receptor blockade can be overcome with high concentrations of NIC or
another agonist.

DHβE does not act as an antagonist at α7* receptor subtypes

(McQuinston and Madison 1999). Erysodine (18), a structurally related DHβE analog,
also isolated from Erythrina seeds, has also been investigated. Erysodine is more active
at α4β2* receptor subtypes than DHβE, but like DHβE has relatively weak affinity for
α7* nAChRs (Decker et al. 1995). Erysodine also exhibits antagonistic properties
similar to those of DHβE at nAChR subtypes mediating DA release.

Methyllycaconitine (MLA, 19) isolated from Delphinium brownii, is a tertiary
diterpenoid alkaloid.

It is a potent and competitive antagonist at the homologously

expressed and native α7* nAChR subtypes with a low nanomolar affinity (Ki =1 nM).
MLA also has the ability to block α7 mediated currents recorded from Xenopus oocytes
or hippocampal neurons (Alkondon et al. 1992; Palma et al. 1996; Davies et al. 1999). In
33

addition to the homomeric α7* nAChR subtypes, MLA has been shown to inhibit a
population of α7-like nAChR subtypes which are not labeled by other α7 antagonists
(Yum et al. 1995; Davies et al. 1999). When compared to other receptor subtypes, both
muscle and α4β2* subtypes require micromolar concentrations of MLA to achieve
inhibition of nAChR function (Wonnacott et al. 1993). Early studies have shown MLA
has little antagonistic activity in the nicotine-evoked dopamine release assay (Drasdo et
al. 1992). However, more recent studies have demonstrated that MLA may antagonize
α6-containing nAChR subtypes, one of the purported nAChR subtypes involved in
mediating DA release (Mogg et al. 2002; Karadsheh et al. 2004). SAR on the MLA
molecule reveals the ring E moiety is an important feature for activity, specifically the
succinimide moiety of the multi-ring structure. Removal of various portions of the
succinimide moiety significantly decreases binding affinity 20- to 2000- fold (Hardick et
al. 1995). In addition, Ring E racemic analogs of MLA exhibited moderate to equivalent
activity compared to that of MLA, and demonstrates the importance of the methyl group
in the succinimide moiety (Jacyno et al. 1996; Bergmeier et al. 1999).
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Figure 2.6 Structures of Competitive nAChR Antago nists and Neurotoxins
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Neurotoxins
Several small peptide antagonists have been identified from the venom of Bungarus
multicinctus, the Formosan banded krait. α-Bungarotoxin (α-Btx), the most studied of
these peptides, is an 8kDa protein that was found to have high affinity at neuronal α7*
homomeric nAChR subtypes (Ki = 1 nM) (Marks et al. 1986; Davies et al. 1999).
Homomeric avian α8* nAChRs and α9* nAChRs of cochlear hair cells are also inhibited
with low nanomolar concentrations of α-Btx (Gotti et al. 1994; Elgoyhen et al. 2001). α-
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Btx does not seem to antagonize any neuronal heteromeric nAChR assemblies (McGehee
and Role 1995).

A minor component of the venom of Bungarus multicinctus, is neuronal bungarotoxin (nBtx or κ-Btx). n-Btx has been shown to inhibit some α3*- and α6*- containing neuronal
nicotinic receptor subtypes, as well as α7* subtypes (Chiappinelli 1983; Luetje et al.
1998; Luetje 2004).

n-Btx inhibits nicotine-evoked dopamine release, as well as

inhibiting [3 H]-(+)-epibatidine non-α4β2* binding sites (Grady et al. 1992; Houghtling et
al. 1995). Due to its limited availability and non-selective pharmacological profile, n-Btx
is not as widely utilized in research as other nAChR antagonists.

Other neurotoxins exist in nature that act at various nAC hRs, including neosurugatoxin
(NSTX, 20) from the Japanese mollusk Babylonia japonica, which exhibits noncompetitive antagonism at several different nAChR subtypes and lophotoxin (LTX, 21)
and its analog LTX-1 are cyclic diterpenes isolated from coral, which block
neurotransmission of muscle type and ganglionic nAChRs (Abramson et al. 1988;
Groebe and Abramson 1995). Additionally, other toxins identified, include α-cobratoxin
(α-CBT), erabutoxin-a (ETX-a) and erabutoxin-b (ETX-b), and histrionicotoxin, all of
which have been isolated from various species of snake (Luetje et al. 1990; Adams and
Olivera 1994). ETX-a has been identified as an inhibitor of NIC-evoked DA release in
rat striatal tissue, while α-CBT had no inhibitory effect in the same system (DajasBailador et al. 1998).

36

a-Conotoxins
Venoms from the Conus marine snails have been isolated and found to target various
nAChR subtypes. The α-conotoxin compounds are peptides of 12-19 amino acids in
length and contain key disulphide bonds integral to maintaining their structure (Janes
2005). α-Conotoxin MII (22a) has been shown to potently and selectively antagonize
α3β2 nAChRs expressed in Xenopus oocytes at concentrations of 100 nM, which was 2
to 4 orders of magnitude higher than any other subtype tested (Harvey et al. 1997; Kaiser
et al. 1998). Partial inhibition of nicotine-evoked dopamine release was observed when
rat striatal synaptosomes were exposed to α-conotoxin MII (Kaiser et al. 1998). This
partial inhibition was due to the presence of two classes of nAChR subtypes involved in
mediating DA release. The α6-containing α-ctx MII sensitive receptor subtypes are
blocked by α-ctx MII (Salminen et al. 2004). Related α-conotoxins, α-conotoxin ImI
(22b) and α-conotoxin AuBI (22c), were shown to be selective for α7 and α3β4
receptors, respectively (Johnson et al. 1995; Grady et al. 2001). However, recent
evaluation of a-ImI and a close analog, a-ImII (75% homology), both demonstrate
activity at a3ß2 (IC 50 = 40.8 nM and 9.61 µM, respectively) and a7 (IC 50 = 595 nM and
571 nM, respectively) receptor subtypes expressed in Xenopus oocytes. Therefore, the
evaluation of the selectivity of a-ImI is undecided at this time. a-ImII did act at a
different a7 binding region than traditional a7 antagonists, including a-ImI. This aconotoxin could act as a potential probe for a novel a7 binding site (Ellison et al. 2003;
Ellison et al. 2004).

a-Conotoxin BuIA (22d), isolated from Conus bullatus,

demonstrated a broad spectrum of activity at several nAChR subtypes expressed in
Xenopus oocytes. BuIA was most active in the inhibiting a6/a3ß2 nAChRs (IC 50 = 0.258
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nM) followed by a6/a3ß4 nAChRs (IC 50 = 1.54 nM). a7 and a4ß2 nAChR subtypes
were not as active with IC 50 values of 272 nM and 10.4 µM, respectively. Additionally,
BuIA was able to differentiate between ß2- and ß4-containing subtypes due to different
dissociation rates when a common a-subunit was used (Azam et al. 2005).

Nicotinium Salts
N-n-alkylnicotinium iodide salts have been prepared by regioselective N-alkylation of the
S-(-)-nicotine pyridino-N moiety (Crooks et al. 1995; Dwoskin et al. 1999). These
compounds exhibited a range of inhibitory potency at various nAChR subtypes.
Compounds 23a-d were the most potent inhibitors. In [3 H]-NIC binding experiments
utilizing rat striatal slices, NDNI (Ki = 93 nM) and NDDNI (140 nM) had similar
affinities for the α4β2* receptor subtype, with NNNI (840 nM) having moderate affinity,
and NONI (20 µM) demonstrating weaker affinity for this receptor subtype. Functional
responses (IC 50 ) were also determined in NIC-evoked

86

Rb+ efflux assays, IC 50 values

obtained were: NDNI (14 nM) = NNNI (9 nM) > NDDNI (40 nM) > NONI (10 µM).
Nicotine-evoked [3 H]-DA release assays, these N-alkylnicotinium salts exhibited a
different inhibitory profile than that observed in the

86

Rb+ efflux assays, with inhibitory

potencies (IC 50 ) ranging from the low nanomolar to high micromolar range; IC 50 values
were as follows: NDDNI (9 nM) > NNNI (140 nM) > NONI (620 nM) > NDNI (>100
µM). From the functional and binding data, it can be concluded that NNNI and NDDNI
are nonselective antagonists at α4β2* nAChR subtypes and at nAChR subtypes
mediating NIC-evoked DA release, while NDNI and NONI, due to their functional
profiles, are selective and competitive receptor antagonists at α4β2* nAChR subtypes
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and at nAChR subtypes mediating NIC-evoked DA release, respectively. In addition,
none of the N-alkylated compounds 23a-d had any affinity for α7 [3 H]-MLA binding
sites (Wilkins et al. 2003). When unsaturation was introduced to the alkyl chains of the
N-n-alkylnicotinium salts, the NONI analogs gained affinity for α4β2* nAChR subtypes
(0.08 – 4.49 µM), while maintaining or increasing their activity at nAChR subtypes
mediating NIC-evoked DA release (80 – 250 nM). Additionally, the NDNI analogs
maintained or lost affinity for α4β2* nAChR subtypes (0.05 – 7.47 µM), but
demonstrated antagonist activity at nAChR subtypes mediating NIC-evoked DA release
(20 – 140 nM) (Sumarithan et al. 2005).

Figure 2.7 Structures of Nicotinium and Structurally Modified Nicotinium Salts
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A second series of conformationally restricted nicotinium analogs (24 and 25) were
alkylated with various long carbon chain lengths (Crooks et al. 2000). Restriction of the
pyrrolidine ring rotation about the pyridine moiety caused complete loss of affinity for
the α4β2* nAChR subtype, and none of these compounds had any activity in the [3 H]MLA binding assay. However, analysis of these compounds in the [3 H]-nicotine-evoked
dopamine release assay demonstrated that a general increase in carbon chain length from

39

C8 to C12 produced a nearly 100-fold increase in antagonism at the nAChR mediating DA
release (IC 50 = 30 – 660 nM). The sole exception was the dodecyl analog BCDD, which
was devoid of inhibitory activity at this receptor, although interestingly the isomeric
analog ACDD exhibited an IC 50 of 220 nm.

Other Antagonists
Lobeline (LOB, 26), an alkaloid found in Lobelia inflata plants is the active ingredient in
what is referred to as “Indian tobacco”. LOB has many pharmacological effects related
to those of nicotine, and has historically been regarded as an agonist at nicotinic
receptors; however, it may bind to the nicotinic receptor in a novel manner (Decker et al.
1995; Damaj et al. 1997). Both LOB and nicotine bind to the α4β2* nAChR with low
nanomolar affinity (Ki = 4 - 30 nM), while exhibiting little or no α7 affinity (>10,000
nM) (Abood et al. 1988; Reavill et al. 1990; Bhat et al. 1991; Court et al. 1994; Brioni et
al. 1997).

LOB has recently been shown to competitively inhibit NIC-evoked

[3 H]dopamine overflow (IC 50 = 300 nM), as well as inhibiting NIC-evoked

86

Rb+ efflux

(IC 50 = 700 nM) in rat striatal slices and in rat thalamus synaptosomes, respectively
(Miller et al. 2000). It should be noted that at concentrations greater than 1 µM, LOB
potently releases dopamine from rat striatal slices in a manner that is not nAChR
mediated, since the release cannot be inhibited by mecamylamine (Teng et al. 1997).
These data lead to the classification of LOB as a competitive, nonselective antagonist at
α4β2* nAChR subtypes and at nAChR subtypes mediating NIC-evoked DA release.
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Strychnine (27) has been shown to competitively inhibit the α7* nAChR subtype, in
addition to its original use as an antagonist at the glycine-gated chloride channel
(Matsubayashi et al. 1998).

In Xenopus oocytes expressing nAChRs individually

composed of homomeric α7, α8, and α9 nAChR subtypes, strychnine acts as an inhibitor
at toxicologically relevant concentrations (Gerzanich et al. 1994; Peng et al. 1994).
Additionally, strychnine has also been found to block α4β2* nAChRs non-competitively
(Matsubayashi et al. 1998).

bis-Isoquinolines, tetrandrine, hernandezine and E6 -berbamine were evaluated as ligands
to block ACh-evoked currents at α3* and α7 nAChR subtypes endogenously expressed
in PC12 cells.

Tetrandrine, hernandezine and E6 -berbamine exhibited antagonistic

activity at the α3* nAChR subtypes (IC 50 = 8.1, 5.8, and 5.1 µM, respectively).
[3 H]MLA binding studies revealed that all three compounds displaced the radiolabeled
ligand (IC 50 = 8.1 µM (tetrandrine), 5.8 µM (hernandezine), and 5.1 µM (E6 -berbamine)).
Additionally, the functional assay demonstrated that tetrandrine and hernandezine
inhibited ACh-evoked currents at α7 nAChR subtypes (IC 50 = 407 and 372 nM,
respectively) (Virginio et al. 2005).
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Figure 2.8 Structures of nAChR Antagonists
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Prevailing drug discovery endeavors have lead researchers to explore structural
modifications of tobacco alkaloids in an attempt to find novel agonists that are potent and
subtype-selective. More recently, there has been a growing interest in the development
of novel receptor antagonists that are selective and potent at various nAChR subtypes.
Abbot laboratories have disclosed several antagonist candidates that have stemmed from
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their development of a series of pyridyl ether agonists. Compounds 29-36 have been
evaluated in the IMR-32 expressed cell assay utilizing the nicotine-evoked

86

Rb+ efflux

assay to determine the extent of α3β4* nAChR antagonist activity. Compound 29a and
29b inhibited 50% of the

86

Rb+ efflux at concentrations of 1 µM, although 29b had 15%

intrinsic activity at the same concentration implying that it is a partial agonist. Under the
same conditions, compound 30a produced 50% inhibition (1 µM) and 60% inhibition (10
µM), while compound 30b exhibited 20-90% inhibition over the concentration range 110 µM. Two compounds in the 3-(2-pyrrolidinylethoxy)pyridine series (31a and 31b)
produced moderate antagonist activity (IC 50 = 75 and 6 µM, respectively), with no
observed intrinsic activity and compound 32 (1 µM) also exhibited 55% inhibition of
NIC-evoked

86

Rb+ efflux and produced no intrinsic activity. Therefore, a pyridyl ether

linkage can demonstrate antagonist activities at the α3β4* nAChR subtype.

The

substituted pyridyl ethers (33-36) were also assessed using IMR-32 expressed cells in
nicotine (100 µM)-evoked 86 Rb+ efflux assays. Compound 33a at a 1 µM exhibited 66%
inhibition of NIC-evoked

86

Rb+ efflux, while compound 33b at 10 µM exhibited 100%

inhibition, indicating potent α3β4* antagonism. The 5-substituted pyridyl ethers 34a and
34b were found to inhibit 90% of NIC-evoked

86

Rb+ efflux at 10 µM; while 34b

exhibited an IC 50 = 2 µM. Compounds 35a and 35b, exhibited ~50% inhibition, while
the R- and S- enantiomers of 35c (only S-(-) shown) had comparable IC 50 values of 9
µM. Compound 36 (1 µM) produced 50% inhibition of NIC-evoked 86 Rb+ efflux. Taken
together the substituted pyridyl ethers demonstrate an ability to inhibit α3β4* nAChR
subtypes at the µM level. The inclusion of a chlorine molecule on either aromatic ring in
compounds 33a or 33b resulted in the most potent compounds in this series.
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Additionally, this series of compounds demonstrates that the 5-position of the pyridine
ring can be altered with large substituents and still fit into the binding site.

Figure 2.9 Conformationally Restricted Pyridyl Ether Analogs
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Compounds 37-40 were assayed in the IMR-32 cell assay described above and/or in
K177 cells expressing the α4β2* nAChR subtype. A rigid aromatic analog of compound
30b, compound 37, exhibits nonselective antagonist activity in both the K177 cell assay
(55% inhibition and 6% intrinsic activity) and the IMR cell assay (38% inhibition and 7%
intrinsic activity). This indicates a significant difference in inhibitory capability, since
30b was assayed in the IMR cell assay at 10 µM (90% inhibition). The difference in
IMR cell assay activities between 37 and 30b may be attributed to increased aromatic
characteristics of 37 as well as the additional flexibility of 30b. Compounds 38-40
incorporate an extra degree of conformational rigidity, due to the substitution of a
hexahydro-1H-pyrrolizine moiety for the N- methyl pyrrolidine ring. The 7a-substituted
hexahydro-1H-pyrrolizine analog, 38, was a low-potency antagonist (43% inhibition,
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with minimal intrinsic activity). Compound 39 (30 µM), a dehalogenated, rigid analog of
37, exhibited no intrinsic activity, while exhibiting 50% inhibition in the IMR cell assay.
The 55% inhibition produced by compound 40 is not significantly different from that
afforded by its stereoisomer 39 in the IMR cell assay.

Figure 2.10 Structural Analogs of Anabaseine and NIC
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In addition to the structural modifications of the agonist molecules listed above, other
researchers have attempted to structurally modify the minor tobacco alkaloids,
anabaseine and anabasine, in order to identify possible new nAChR antagonists. The
partial agonist GTS-21 (7; also known as DMXB) is a structural analog of anabaseine and
has been discussed previously in this chapter (de Fiebre et al. 1995; Meyer et al. 1997;
Meyer et al. 1998). 3-Trans-cinnamylidene analogs have been developed to alter the
agonist/antagonist profile of GTS-21 in an attempt to create antagonists that are more
potent. Using an Xenopus oocyte α7 expression system, compounds 41a, 41b, and 41c
were shown to exhibit nanomolar affinities for [125 I]-α-Btx binding sites (IC 50 = 8-80
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nM), and cause activation of α7 receptor channels (EC 50 = 3.2 – 15.9 µM). These
compounds also inhibited acetylcholine-elicited electrical responses after incubation for
five minutes with various concentrations of the analog. The following order of potencies
(IC 50 ) was obtained: 2-MeOCA (41b) (2.3 µM) > 4-MeOCA (41c) (5.0 µM) > 3-CA
(41a) (15 µM). Due to the similar concentration ranges for both IC 50 and EC 50 values,
these compounds have antagonist characteristics but are viewed as partial agonists, rather
than antagonists (Meyer et al. 1998).

Conformationally restricted piperidine ring analogs of anabasine have been shown to be
potent antagonists at α4β2* nAChRs. Compound 42 has high affinity for the [3 H]nicotine binding site (Ki = 1 nM) in rat brain membranes, and blocks nicotine (10µM)evoked 86 Rb+ efflux in rat thalamic synaptosomes (IC 50 = 154 nM) (Crooks et al. 1998).
However, in the nicotine-evoked [3 H]-dopamine release assay using rat striatal
synaptosomes, compound 42 had an EC 50 of 2 nM, Emax = 40%, and this compound
activated α3β4* (EC 50 = 1100 nM) and muscle-type (EC 50 = 59 nM) nAChRs (Bencherif
et al. 1998). Therefore, 42 is potent antagonist at α4β2* nAChRs and an agonist at other
nAChR subtypes. The R- isomer appears to be the more active of the two enantiomers,
with a Ki value of 0.5 µM at α4β2* nAChRs, and an EC 50 value of 9 nM, Emax = 55% at
nAChR subtypes mediating NIC-evoked DA release (Dwoskin and Crooks 2001).
Compounds 43a and 43b are adamantane analogs of anabasine, developed by R. J.
Reynolds (Co. 1999, 1999, 1999, 2000). Compound 43b was found to antagonize NIC
(100 µM)-evoked

86

Rb+ efflux in rat thalamic synaptosomes with an IC 50 value of 630

nM. Additionally, both 43a and 43b were found to inhibit NIC-evoked [3 H]-DA release
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using rat striatal synaptosomes with values in the high nanomolar range (IC 50 =659 and
846 µM respectively) and were devoid of intrinsic activity. Thus, these 1-aza-2-(5ethoxy-(3-pyridyl))tricyclo-[3.3.1.13,7]decanes appear to be nonselective and potent
antagonist at α4β2* nAChR subtypes and nAChR subtypes mediating NIC-evoked DA
release. Compounds 44 and 45 are methylene bridged analogs of 2-(3-pyridyl-)-1azabicyclo[2.2.2]octane (42) and have high affinity for the [3 H]-NIC binding site in rat
cortical membranes (Ki = 37 and 73 nM respectively).
antagonism has been reported in the

86

Although no functional

Rb+ efflux assay, no agonist activity was observed

in the 86 Rb+ efflux assay, using rat thalamic synaptosomes. Also, no agonist activity was
observed in either muscle-type (α1β1γδ) or α3β4* nAChRs (Dwoskin et al. 2000;
Dwoskin and Crooks 2001).

2.8.

Channel Blockers

One of the first nAChR open channel blockers (OCB) was identified as hexamethonium
(HEX, 46), a six-carbon bis-trimethylammonium alkyl compound, which acts within the
pores of nAChR subtypes on autonomic ganglia (Paton and Zaimis 1951; Blackman et al.
1963; Ascher et al. 1979). HEX is considered a prototypical OCB, since it meets the
following criteria: (1) it causes a voltage dependent blocking effect, (2) it displays a usedependent mode of action, and (3) it produces a more pronounced inhibitory effect when
there is an increase in agonist concentrations (Ascher et al. 1979; Buisson and Bertrand
1998). Compound 46 has also been shown to exhibit antagonist effects on reconstituted
chick and rat α4β2* nAChRs (Bertrand et al. 1990; Charnet et al. 1992).
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Figure 2.11 Structures of Open Channel Blockers of the nAChR
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Mecamylamine (MEC, 47) has become one of the most utilized nAChR blockers due to
its ability to block the physiological, behavioral, and reinforcing effects of nicotine
(Papke et al. 2001). MEC, a neuronal and peripheral OCB, has been shown to block
several neuronal nAC hR subtypes at low micromolar affinities, but has lower activities at
muscle- like nAChRs (Cachelin and Rust 1995; Briggs and McKenna 1996). Moderate
nanomolar inhibition (IC 50 = 150 – 190 nM) of rat and Xenopus oocyte-expressed α3β4
nAChRs has been observed (Cachelin and Rust 1995; Webster et al. 1999). Separation of
the R- and S-enantiomers of MEC demonstrated very little pharmacological benefit.
However, S-(+)-MEC enantiomer appears to dissociate more slowly than R-(-)-MEC at
α4β3* and α4β2* nAChRs (Papke et al. 2001). Suchocki et al. (1991) prepared a series
of C1, C2, C3, and C7 analogs of MEC and showed that compounds with methyl
substituents at the C3 position were important for channel blockage activity (Suchocki et
al. 1991).

Creasy et al. (1996) determined that substitutions on the C2 amino

functionality with large groupings were detrimental to antinociception and hypomotility
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activities (Creasy et al. 1996). Webster et al. (1999) found that point mutations of the
M2 region of the β4 subunit in Xenopus oocytes expressing ganglionic (α4β3) neuronal
nAChRs, caused a decrease in sensitivity to MEC, indicating a possible binding location
of MEC. Another well studied OCB is the bis-quaternary antagonist, chlorisondamine
(48).

This compound has no effect on [3 H]-ACh or [3 H]-NIC binding to rat brain

(Schwartz et al. 1982). However, chlorisondamine does block NIC-evoked DA release
from rat striatal synaptosomes both in vitro and when administered over a period of
weeks in vivo (10 mg/kg/day) (el-Bizri and Clarke 1994, 1994). This suggests that the
quaternary ammonium molecule is able to pass the blood brain barrier, although the exact
mechanism is not known. In addition, it is not known if metabolic changes could account
for its CNS activity. Central nervous system accumulation of chlorisondamine has been
suggested to explain the blockade effects; however, this cannot provide a complete
explanation of the long-term blockade effects of the drug (el-Bizri and Clarke 1994;
Reuben et al. 1998). Buisson and Bertrand have demonstrated that several OCBs have
activity at human α4β2* receptors.

Classical NMDA OCBs, amantadine (49),

memantine (50), and dizocilipine ((+)-MK-801, 51), as well as, the Ca2+ channel
antagonist 8-(N,N-diethylamino)-octyl 3,4,5,-trimetho xybenzoate (TMB-8, 52) were
evaluated using stably expressed α4β2* receptors from embryonic kidney 293 cells.
ACh-elicited electrophysiological current blockade was measured in the presence of
various concentrations of each of a number of antagonist molecules. Potency values
(IC 50 ) were as follows: amantadine (3 µM) > memantine (7 µM) > TMB-8 (15 µM) ~
MK-801 (15 µM).

These studies demonstrated that OCBs tested non-competitively

antagonized α4β2* nAChRs and were supported by a mechanism of action mathematical
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model detailing the interaction between the nAChR and OCBs (Buisson and Bertrand
1998). TMB-8 has also been shown to potently inhibit agonist- induced flux through
muscle-type and ganglionic type nAChRs (IC 50 ~400 nM), as well as, exhibiting potent
inhibition (IC 50 ~500 nM) in NIC-evoked [3 H]DA release assays using rat brain
synaptosomes (Benc herif et al. 1995). However, all nAChR binding affinities for TMB-8
were in the moderate to high micromolar range (IC 50 = 30 - 200 µM). Additionally, in
the muscle-type nAChR ion flux assay, in the presence of TMB-8, increased agonist
(ACh) concentration caused a more potent blockade of the receptor. MK-801 was also
examined in human α7 nAChRs expressed in Xenopus oocytes, and exhibited a noncompetitive inhibition of ACh elicited currents (IC 50 = 14 - 15 µM). Stereoselectivity
was not a criteria for blockade since both the (+)- and (-)-MK-801 isomers had similar
activities and the blockade observed was dependent on cell potential, a hallmark of
channel blockade (Briggs and McKenna 1996).

2.9.

The Nicotinic Pharmacophore

The nicotinic pharmacophore has been studied for over fifty years. Theories in the early
1950s and 60s suggested a positive center located near an onium site (e.g. N+) (Hey 1952;
Sekul and Holland 1961). In the late sixties, the theory was revised to include a partially
negative site near (4.85 Å) an onium site (Kier 1968). Beers and Reich proposed a model
that is considered to be the first for the nicotinic pharmacophore. They proposed a two
element system using both agonist and antagonist molecules: element 1- a protonated
nitrogen, and element 2- an electronegative atom that can act as a hydrogen bond
acceptor. They also proposed a specific distance of 5.9 Å as the optimum length between
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the center of the charged moiety and a van derWaals interaction area in the receptor
binding site (Beers and Reich 1970). Sheridan et al. (1986) suggested that a third
element, an aryl centroid moiety, was needed for binding site recognition, a point or atom
that was close to the H-bond acceptor site and that was in-line with the acceptor atom, in
addition to altering the Beers-Reich distance to 4.8 Å (See Figure 2.12A) (Sheridan et al.
1986).

Over the last decade, several nAChR ligands have been identified and

modifications to the Sheridan model have been necessary. One major issue was some
compounds with affinity for the nAChR were not in accordance the Sheridan distance.
Therefore, a model had to be developed for “long” and “short” ligands.

It is also

important to note that stereochemistry plays an important part in receptor recognition,
and since several enantiomerically pure ligands have dramatically different affinities
compared to their optical isomers (Hacksell and Mellin 1989). Tonder et al. (2001)
proposed the following nAChR pharmacophore: 1- interaction between the protonated
atom of the ligand (N +) with an anionic site (a) located on the receptor, 2- a hydroge n
bond acceptor moiety (X) on the ligand that is paired with a H-bond donator (b) on the
receptor surface, 3- π-system interaction of the ligand with π-systems (or positively
charged residues) of the receptor (aryl centroid, c), 4- interactions between a protonated
N-atom in the ligand and π-systems of the receptor (possibly Trp-149), and steric
interactions around the aliphatic and heteroaromatic portions of the molecule (Figure
2.12b) (Tonder and Olesen 2001; Tonder et al. 2001; Glennon and Dukat 2004). Another
model proposed involved the use of a water molecule to change “short” ligands into
“long” ligands.

This water molecule may interact with the protonated atom or the

hydrogen bonding acceptor (Glennon et al. 2004). Many ligands, however, have shown
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different affinities and activities at various nAChRs. Therefore, different pharmacophore
models may need to be developed for each individual receptor subtype, and maybe even
for the assays as well, due to the varied characteristics of the pharmacological tools used.

Figure 2.12 Pharmacophore models proposed for the α4β2* receptor subtype

Reprinted from Bioorg Med Chem Lett, 14, Glennon and Dukat, a4ß2 nACh Receptor pharmacophore
models, 1841-1844, Copyright (2004), with permission from Elsevier

The pharmacological tools themselves pose a challenge as it is unclear which molecular
species is interacting with the binding site. Huang et al. (2005) modeled multiple free
base and protonation states of NIC and (R)-descholoroepibatidine (DCEH) using a
variety of molecular modeling and docking techniques to explore a general strategy of
“from- microscopic-to-phenomenological” approach. This procedure involved prediction
of binding energies to each of the different states of NIC and DCEH. Furthermore,
hydrogen-bonding and cation-π interactions were found to be the dominant forces that
differentiated the binding strengths of the molecular states of NIC and DCEH. These
types of studies increase modeling ability beyond a static structure to a more dynamic

52

approach that can correlate binding energies with multiple states of molecule (Huang et
al. 2005).

2.10.

Disease States

Alzheimer’s Disease
Alzheimer’s disease (AD) is diagnosed as the loss of ability to learn by memory and
attention deficits and usually affect the population over the age of 65 years and older
(Lindstrom 1997; Tuppo and Arias 2005). As mentioned above, NIC improves cognitive
function in healthy humans.

Additionally, treatment of Alzheimer’s patients with

nicotine has attenuated the decline of cognitive deficits (Everitt and Robbins 1997;
Lawrence and Sahakian 1998). Diagnosed Alzheimer’s patients also had a decreased
number of high affinity [3 H]-NIC binding sites in various brain regions (Flynn and Mash
1986; Whitehouse et al. 1988; Sugaya et al. 1990; Nordberg et al. 1995; Rusted et al.
2000). On a genetic level, β2 knockout mice (e.g. mice unable to express β2 subunits)
lack high affinity nicotine binding sites. In addition, these knockout mice demonstrated
learning and memory abnormalities, implicating the α4β2* receptor subtype as playing a
key role in cognitive function (Picciotto et al. 1995; Zoli et al. 1999).
Neuroinflammation has also been linked to the onset of Alzheimer’s disease, although the
role it plays is not fully understood (Tuppo and Arias 2005). α7* binding sites are
unaffected in Alzheimer’s patients; however, a high concentration of Ca2+ ions may
implicate this receptor subtype in neurodegeneration, due to the high Ca2+ permeability of
the α7* nAChR (Sugaya et al. 1990; Perry et al. 2000). Additionally, strong correlations
have been found between expression of α7* nAChR subtypes and the presence and rate
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of accumulation of amyloid beta (1-42), the predominant Aβ species in amyloid plaques.
The two proteins strongly interact and interference in this interaction may lead to the
neurodegeneration. With this information, α7* nAChR subtypes may be targets for the
treatment of Alzheimer’s disease (D'Andrea et al. 2002; D'Andrea and Nagele 2006). To
date, several subtype selective nAChR ligands are being investigated for their potential
therapeutic value. Among them are ABT-418 (Abbott Laboratories), RJR-2403 (R. J.
Reynolds/Targacept), and GTS-21 (Decker et al. 1994; Lippiello et al. 1996; Kem 1997;
Gotti et al. 2000).

Administration of the nAChR channel blocker, mecamylamine,

decreased cognitive function in all populations tested. This blockade of the channel is
over come by administration of NIC. Interestingly, younger healthy volunteers had a
decreased sensitivity to the mecamylamine induced cognitive deficits, while AD patients
had the highest sensitivity (Rusted et al. 2000)

Parkinson’s Disease
Parkinson’s disease (PD) has been closely associated with Alzheimer’s disease in that
patients in both disease states are found to have deficiencies in neurotransmitter systems,
as well as decreased nAChR expression within the CNS. Parkinsonian patients suffer
from an inability to control hyper- motor function. This is manifested as difficulties in
initiating and sustaining motions (Lloyd et al. 1975; Olanow 2004; Samii et al. 2004).
These motor control problems occur due to loss of dopaminergic neurons in the
substantia nigra (German et al. 1989). L-Dihydroxyphenylanine (L-DOPA), a dopamine
prodrug, treatments have been used as a form of dopamine substitute therapy, after
conversion of L-DOPA to dopamine in the CNS. Although not a cure for the disease, L-
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DOPA treatments can retard the degenerative effects for three to five years before
peripheral side effects prevent it use. Nicotine has also been linked to the treatment of
Parkinson’s disease. Monkeys given NIC with L-DOPA experienced a synergistic effect
to reverse parkinsonian symptoms (Schneider et al. 1998; Domino et al. 1999). An
inverse relationship exists between smoking cigarettes and staving off the effects of PD.
The occurrence of PD was decreased in smokers and non-smokers were two times as
likely to contract PD (Fratiglioni and Wang 2000).

Studies suggest that targeting

heterologously expressed receptors, non-α7, may be a valuable treatment for PD (Quik et
al. 2005). α6* nAChR subtypes involved in mediating DA release have recently been
suggested as a therapeutic target for PD. Stimulation of these nAChR subtypes may
result in relief from the PD symptoms without the side effects (O'Neill et al. 2002; Quik
et al. 2004; Quik and McIntosh 2006). Nicotine is thought to be acting as a protective
agent in the CNS (Morens et al. 1995; Baron 1996). SIB-1508Y (Sibia) has entered
Phase 2 trials as a possible drug treatment for PD, due to its lower toxicity and increased
potency for various nicotinic receptors (Sacaan et al. 1997; Arneric and Brioni 1999).

Schizophrenia
An excess of dopamine in the CNS has been hypothesized to cause Schizophrenia.
Symptoms of this disease include delusions, hallucinations, blunt affect, and chaotic
thinking and speech (Arnold and Trojanowski 1996).

Schizophrenics have sensory

imbalances, thereby making it difficult to regulate auditory and visual stimuli. Smoking
is pervasive among the schizophrenic community (Lohr and Flynn 1992). It is postulated
that those suffering from this disease smoke cigarettes in order to self- medicate
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themselves with nicotine (Freedman et al. 1997; Sacco et al. 2005). Nicotine normalizes
the gating deficit seen in patients participating in the P50 auditory-evoked response test
(Adler et al. 1993; Bencherif and Schmitt 2002).

Due to this finding, it has been

suggested that nAChRs may be involved in schizophrenia. α7* receptors are decreased
in schizophrenics (Freedman et al. 1995). Additionally, α7* antagonists impair auditory
gating in rodents, indicating a possible loss, or reduced function of α7* nAChRs in
schizophrenics’ gating response (Luntz-Leybman et al. 1992; Lena and Changeux 1997).
A genetic polymorphism in the a7* nicotinic receptor D15S1360 has been linked to a
deficiency in the normal inhibition of the P50 auditory-evoked response (Freedman et al.
1997). De Luca et al. (2004) demonstrated a genetic difference in the D15S1360 marker
between Parkinson’s patients who smoke and those that do not, though larger studies are
still needed to determine the relevance of these findings (De Luca et al. 2004).

Pain Management
Pain therapies have traditionally centered around two classes of compounds, nonsteroidal
anti- inflammatory drugs (NSAIDs) and opioids. Nicotine in higher doses, however,
affords a moderate and short-lived antinociceptive effect (Sahley and Berntson 1979;
Tripathi et al. 1982). The discovery of the non-selective nAChR agonist, epibatidine,
stimulated interest in the pain management aspect of nicotinic receptors. Epibatidine has
demonstrated a potent mecamylamine-sensitive antinociceptive effect in animals (Badio
and Daly 1994; Sullivan et al. 1994). However, due to its non-selectivity, epibatidine is
not considered a drug candidate for the treatment of pain (Decker and Meyer 1999).
Specific nAChR subtypes involved in analgesia have yet to be identified, although α4β2*
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and α3β4* ganglionic receptor subtypes have been implicated (Badio et al. 1997; Badio
et al. 1997; Marubio et al. 1999). Additionally, nicotinic agonist- induced antinociceptive
behavior is most likely resulting from involvement of the α4β2* subtype causing or
mediating neurotransmitter release in the spinal cord (Hogg and Bertrand 2004). Affinity
for the α4β2* subtype, however, does not necessarily denote antinociceptive activity in a
compound (Meyer et al. 2000). Studies assessing the possible role of α7* nAChRs in
pain therapy have had mixed results.

MLA and α-Btx were unable to block the

antinociceptive effects of nicotine, cytosine, and other nAChR agonists in the tail- flick
latency test (Rao et al. 1996; Damaj et al. 1998). When choline, an α7-specific agonist,
was used to elicit the effect of analgesia, MLA and α-Btx were able to block the
antinociceptive effect (Damaj et al. 2000).

Tourette’s Syndrome
Tourette’s syndrome is a hyperkinetic motor disorder characterized by involuntary
movements and vocalizations. Although the exact mechanism of action is unknown,
antipsychotics (e.g. haloperidol) are used to attenuate the symptoms of the condition.
However, this treatment is not effective in ~30% of the cases and the drug causes some
side effects (Erenberg et al. 1987; Shapiro et al. 1989). Nicotine reduces the symptoms
of Tourette’s syndrome in animal models, as well as in human subjects (Moss et al. 1989;
Sanberg et al. 1989; Sanberg et al. 1997). Presently, the nicotinic mechanism of these
therapies is thought to be the inactivation of α4β2* or α7* receptor subtypes, as well as a
prolonged desensitization period (Lindstrom 1997; Sanberg et al. 1997). Mecamylamine
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has also been used as a potential therapy for the attenuation of the tics associated with
this disease (Silver et al. 2000; Young et al. 2001).

Smoking Cessation
Due to the addictive properties of NIC, the active alkaloid in tobacco products, smoking
cessation has long been associated with the nicotinic receptors (Benowitz 1996; Rose
1996). Nicotine replacement therapy has been employed via nicotine gums, patches, and
nasal sprays in order to achieve abatement of smoking (Hajek et al. 1999). Further
research has also shown that the combination of the channel blocker mecamylamine with
nicotine patches decreases cravings for cigarettes (Rose et al. 1994; Rose et al. 1998;
Rose et al. 2001). Researchers uses the Rose et al. studies as the basis for using a partial
agonist, which combines agonist and antagonist properties, to provide relief to smoking
cessation patients. Cystine analogs, including varenicline, a α4β2* nicotinic receptor
subtype partial agonist, have been evaluated as agents for smoking cessation by Pfizer
Laboratories (Coe et al. 2005; Coe et al. 2005). The alkaloid (-)- lobeline was in clinical
trials as treatment for smoking cessation (Schneider and Olsson 1996). However, further
study revealed that lobeline use in patient groups was not statistically different than those
of the placebo group, though one of three sites did demonstrate significant improvements
(Glover et al. 1998). Therefore, the use of lobeline as a smoking cessation agent is not
fully understood and not a viable option currently (Dwoskin and Crooks 2002).
Bupropion, a phenylaminoketone atypical antidepressant, has been utilized as a sustained
release therapy for smoking cessation (George and O'Malley 2004). The mechanism of
action is not known but Bupropion is a nicotinic antagonist at a3ß2, a4ß2, and a7
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receptor subtypes expressed in Xenopus oocytes (IC 50 = 1.3, 8.0, and 60 µM,
respectively) (Slemmer et al. 2000). However, given its limited effectiveness and cost,
Bupropion is not considered a long term solution (Sweet 2003).

Copyright © Joshua Thomas Longen Ayers 2006

59

Chapter 3: Synthesis and Evaluation of mono- and bis-Alkylated Quaternary
Ammonium Salts
3.1.

Introduction

The neuronal nicotinic acetylcholine receptor (nAChR) belongs to a superfamily of
ligand gated ion channel receptors, and has several diverse and complicated
substructures.

Each receptor is composed of five individual subtypes either

heterologously or homologously expressed. Selected heterogeneous subtypes include
combinations of α3, α4, α5, α6 and β2 or β4 (e.g. α4β2*) subunits, while the
predominant homologous subtype is composed of α7 subunits (α 7*) (Holladay et al.
1997). The endogenous ligand, acetylcholine (ACh), as well as NIC are agonists at the
receptor binding site.

NIC has been studied as a potential treatment in several

pathologies (e.g. Alzheimer’s and Parkinson’s disease, schizophrenia, and analgesia) and
has been used as a treatment in smoking cessation programs (Lindstrom 1997).
However, NIC is a nonspecific agonist interacting with several receptor subtypes, both in
the periphery, as well as in the central nervous system (CNS). Therefore, a large amount
of research has been devoted to the discovery of agonists that may increase the potential
beneficial therapeutic effects and decrease the side effects of NIC (Holladay et al. 1997).
These efforts have afforded a number of agonist compounds that are both potent and
selective for nAChR subtypes. Surprisingly, very little research has focused on structure
activity relationships (SARs) involving nAChR antagonists that are subtype selective
(Dwoskin et al. 2000; Dwoskin and Crooks 2001).
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mono-Substituted Quaternary Ammonium Molecules
Crooks et al. (1995) synthesized a small series of N-alkylated nicotinium compounds that
demonstrated selective antagonist activities at different neuronal nAChR subtypes.
Alkylating the pyridino N-atom of the NIC molecule with an n-octyl carbon chain
afforded a compound that was both potent and selective for the nAChRs mediating
dopamine (DA) release, a purported α6 containing receptor (Crooks et al. 1995).
Incorporating an n-decyl carbon chain was later shown to afford an analog that was a
selective antagonist at the α4β2* receptor subtype (Dwoskin et al. 1999). Thus, subtle
changes in the alkyl chain length of these N-n-alkylnicotinium analogs produced a
surprising difference in the antagonist activities of the compounds. Conformationally
restricted analogs of the NIC molecule were also N-n-alkylated and these compounds
retained antagonist activity at the nAChRs mediating DA rele ase, with chain lengths of 812 carbons in the syn-conformation (24a-e) and 8-11 carbons in the anti-conformation
(25a-d) affording various degrees of antagonist activity (Xu et al. 2001). Unlike the N-nalkylnicotinium analogs, none of these conformationally restricted molecules antagonized
the α4β2* nAChR subtype. Therefore, structural modification of the nicotine molecule
can result in compounds with potent and selective nAChR antagonist characteristics.

bis-Substituted Quaternary Ammonium Molecules
bis-Quaternary ammonium salts have also been used as ligands in several receptor
systems. For example, bis-quinolinium cyclophans have been used to block Apaminsensitive Ca2+-activated K+ channels (Chen et al. 2000). Investigators determined that
altering the chain lengths of alkane spacers between the quaternary ammonium centers
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could effectively afford analogs that inhibit receptor function. Additionally, like the
mono-substituted N-alkyl quaternized ammonium salts, bis-substituted quaternized
ammonium salts have demonstrated selective inhibition of peripheral nicotinic
acetylcholine receptor subtypes.

Peripheral nicotinic receptor antagonists, such as

hexamethonium (HEX, 46) and decamethonium (DEC), were originally prepared as
simple analogs of the ne uromuscular blocking agent, d-tubocurarine (d-Tub, 16). The ten
carbon analog, DEC, demonstrated competitive inhibition of nicotinic receptors at the
neuromuscular junction, while HEX primarily antagonized nerve-nerve terminals
(ganglionic receptors). These two bis-quaternary ammonium compounds were among
the first to be used to differentiate between the different subtypes of peripheral nicotinic
receptors, muscle and ganglionic.

Although their mechanisms of action are quite

different, DEC and HEX have been shown to have the optimum chain lengths for binding
to their respective receptor subtypes in the periphery. In the CNS, HEX and DEC have
been evaluated for NIC binding at a4ß2* receptors and found to exhibit weak affinities
(Ki = 31.9 and 4.27, respectively) for the receptor subtype (Ayers et al. 2005). d-Tub, a
more complex bis-quaternary structure, also has activity at the muscle-type peripheral
nAChR subtype, but it also has activities at the ganglionic receptor subtypes and at a4ß2*
subtypes (Ascher et al. 1979; Colquhoun et al. 1979; Ogden and Colquhoun 1985;
Bertrand et al. 1990). Therefore, bis-quaternary ammonium structures have been used
mainly as antagonists peripherally, and ha ve the potential to differentiate between these
nAChR subtypes by both altering the chain length and the quaternary ammonium
headgroup.

62

In order to assess the pyrrolidine moiety’s importance to the antagonist activity of these
interesting series of compounds, a series of quaternized aza-aromatic compounds (e.g.
pyridine, 3-picoline, nicotinamide, and NIC) were evaluated (53-56). In addition to the
assessment of the importance of the pyrrolidine ring, alkyl chain lengths of between one
to twenty carbon units were attached to the pyridino functionality to evaluate the
relationship between alkyl chain length and inhibition of and selectivity for various
nAChR subtypes.

Figure 3.1 mono-Alkylated Quaternary Ammonium Salts
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Additionally, bis-quaternary ammonium salts (57-61) were evaluated for their effect on
various nAChR subtypes as analogs of the existing peripheral antagonists HEX, DEC,
and d-Tub to determine if such analogs antagonized neuronal nicotine receptors. Varying
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chain lengths and different pyridinium moieties (e.g. pyridinium, 3-picolinium,
quinolinium, isoquinolinium, and nicotinium) were utilized to determine if selective
nicotinic receptor subtype antagonism could be achieved.

Figure 3.2 bis-Alkylated Quaternary Ammonium Salts
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bNHxI
bNOI
bNNB
bNDI
bNUB
bNDDB

n = 2; X = I
n = 4; X = I
n = 5; X = Br
n = 6; X = I
n = 7; X = Br
n = 8; X = Br

n
n
n
n
n
n

= 2; X = I
= 4; X = I
= 5; X = Br
= 6; X = I
= 7; X = Br
= 8; X = Br

3.2.

Experimental

3.2.1.

Chemicals

S-(-)-Nicotine, pyridine, 3-picoline, nicotinamide, quinoline, isoquinoline, iodomethane,
iodoethane, 1- iodopropane, 1- iodobutane, 1-iodopentane, 1- iodohexane, 1-iodoheptane,
1-iodooctane, 1-iodononane, 1- iododecane, 1- iodoundecane, 1-iodododecane, 1bromopentadecane,

1-bromoecosane,

1,5-diiodopentane,

1,6-diiodohexane,

1,8-

diiodooctane, 1,9-dibromononane, 1,10-diiododecane, 1,11-dibromoundecane, 1,12dibromododecane, diethylether, chloroform, deuterium oxide (100% atom D), deuterium
chloride solution (20% W/W solution in D2 O, 99.5% atom D), 3-(trimethylsilyl)-2,2,3,3d4 -propionate, and α-D-glucose were purchased from Aldrich Chemical Company Inc.
(Milwaukee, WI). Acetic acid, was obtained from Fisher Scientific (Pittsburgh, PA). S(-)-Nicotine ditartrate, nomifensine maleate, and mecamylamine hydrochloride (MEC)
were purchased from Research Biochemicals, Inc. (Natick, MA).
pargyline
(HEPES),

hydrochloride,

S-(-)-Cytisine,

N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic

Tris[hydroxymethyl]-aminomethane

Tris[hydroxymethyl]aminomethane

(Trizma

hydrochloride

base),

(Trizma

polyethylenimine

(PEI),

acid]
HCl),
and

dihydroxy-β-erythroidine hydrobromide (DHβE) were purchased from Sigma Chemical
Co. (St. Louis, MO). Ascorbic acid, and TS-2 tissue solubilizer were purchased from
Fluka (Ronkonkona, NY), AnalaR (BHD Ltd., Poole, U.K.), and Research Products
International (Mount Prospect, IL), respectively. [3 H]Dopamine ([3 H]DA); 3,4-ethyl-2[N- 3 H]dihydroxyphenylethylamine; specific activity, 25.6 Ci/mmol) and [3 H]nicotine (L(−)-[N-methyl- 3 H]; specific activity, 78.4 Ci/mmol) were obtained from New England
Nuclear (Boston, MA).
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3.2.2.

Synthetic Procedures

3.2.3.

Synthetic Procedures for the Prepara tion of mono-Substituted Pyridinium
Derivatives

3.2.3.1.

Pyridinium Salts

The appropriate 1- iodoalkane or 1-bromoalkane (5.01-16.1 mmol) was added to a
solution (30 mL) of dry pyridine and the solution was heated for 24 h at 65°C. The
resulting solid precipitates were filtered and washed five times with dry diethyl ether.
For liquid products, the excess pyridine was decanted off, the resulting liquid precipitates
were washed with diethyl ether five times, and the remaining liquid was dried under
vacuum. The resulting solids or liquids were isolated in 56-95% yields.

N-Methylpyridinium Iodide (NMPI, 53a)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.01 (2H, d, C2&C6-H), 8.58 (1H, t, C4-H), 8.13

(2H, t, C3&C5-H), 4.37 (3H, s, C’1-CH3 );

13

C NMR (75 MHz, DMSO-D6 ), δ 145.3,

144.8, 127.5, 48.0. The resulting tan solid was isolated in 95% yield, with a melting
point of 117°C. Combustion Analysis: calculated for C6 H8 IN, C, 32.60; H, 3.65; N, 6.35.
Found: C, 32.51; H, 3.62; N, 6.34.

N-Ethylpyridinium Iodide (NEPI, 53b)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.14 (2H, d, C2&C6-H), 8.60 (1H, t, C4-H), 8.16

(2H, t, C3&C5-H), 4.67 (2H, q, C’1-CH2 ), 1.53 (3H, t, C’2-CH3 ); 13 C NMR (75 MHz,
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DMSO-D6 ), δ 145.5, 144.0, 127.8, 56.0, 16.0. The resulting yellow solid was isolated in
92% yield, with a melting point of 88-89°C. Combustion Analysis: calculated for
C7 H10 IN, C, 35.77; H, 4.29; N, 5.96. Found: C, 35.86; H, 4.33; N, 5.94.

N-n-Propylpyridinium Iodide (NPrPI, 53c)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.19 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.17

(2H, t, C3&C5-H), 4.64 (2H, t, C’1-CH2 ), 1.89 (2H, m, C’2-CH2 ), 0.80 (3H, t, C’3-CH3 );
C NMR (75 MHz, DMSO-D6 ), δ 144.7, 143.8, 127.1, 61.1, 23.4, 9.4. The resulting

13

brown liquid was isolated in 87% yield. Combustion Analysis: calculated for C8 H12 IN,
C, 38.57; H, 4.86; N, 5.62. Found: C, 38.73; H, 4.92; N, 5.61.

N-n-Butylpyridinium Iodide (NBuPI, 53d)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.19 (2H, d, C2&C6-H), 8.64 (1H, t, C4-H), 8.18

(2H, t, C3&C5-H), 4.67 (2H, t, C’1-CH2 ), 1.90 (2H, p, C’2-CH2 ), 1.25 (2H, m, C’3-CH2 ),
0.86 (3H, t, C’4-CH3 ); 13 C NMR (75 MHz, DMSO-D6 ), δ 146.2, 144.5, 127.9, 60.4, 32.4,
18.4, 13.1. The resulting orange liquid was isolated in 90% yield, with a melting point of
59-62°C. Combustion Analysis: calculated for C9 H14 IN, C, 41.08; H, 5.36; N, 5.32.
Found: C, 41.14; H, 5.41; N, 5.32.

N-n-Pentylpyridinium Iodide (NPePI, 53e)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.16 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.17

(2H, t, C3&C5-H), 4.83 (2H, t, C’1-CH2 ), 1.89 (2H, p, C’2-CH2 ), 1.23 (4H, m, C’3&C’4CH2 ), 0.80 (3H, t, C’5-CH3 );

C NMR (75 MHz, DMSO-D6 ), δ 146.2, 144.5, 127.9,

13
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60.4, 30.0, 27.2, 21.3, 13.7. The resulting orange solid was isolated in 93% yield, with a
melting point of 62°C. Combustion Analysis: calculated for C10 H16 IN, C, 43.34; H, 5.82;
N, 5.05. Found: C, 43.47; H, 5.87; N, 5.04.

N-n-Hexylpyridinium Iodide (NHxPI, 53f)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.17 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.19

(2H, t, C3&C5-H), 4.85 (2H, t, C’1-CH2 ), 2.00 (2H, p, C’2-CH2 ), 1.24 (6H, m, C’3-C’5CH2 ), 0.80 (3H, t, C’6-CH3 );

C NMR (75 MHz, DMSO-D6 ), δ 145.5, 144.6, 128.1,

13

60.6, 30.6, 30.4, 24.9, 21.8, 13.8. The resulting yellow solid was isolated in 94% yield,
with a melting point of 62 °C. Combustion Analysis: calculated for C11 H18 IN, C, 45.37;
H, 6.23; N, 4.81. Found: C, 45.30; H, 6.20; N, 4.85.

N-n-Heptylpyridinium Iodide (NHpPI, 53g)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.17 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.18

(2H, t, C3&C5-H), 4.65 (2H, t, C’1-CH2 ), 1.90 (2H, p, C’2-CH2 ), 1.22 (8H, m, C’3-C’6CH2 ), 0.80 (3H, t, C’7-CH3 );

C NMR (75 MHz, DMSO-D6 ), δ 145.5, 144.6, 128.1,

13

60.6, 31.1, 30.6, 27.9, 25.2, 21.8, 13.9. The resulting yellow solid was isolated in 89%
yield, with a melting point of 63°C. Combustion Analysis: calculated for C12 H20 IN, C,
47.22; H, 6.61; N, 4.59. Found: C, 47.40; H, 6.72; N, 4.58.

N-n-Octylpyridinium Iodide (NOPI, 53h)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.16 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.17

(2H, t, C3&C5-H), 4.83 (2H, t, C’1-CH2 ), 1.89 (2H, p, C’2-CH2 ), 1.22 (10H, m, C’3-C’7-

68

CH2 ), 0.80 (3H, t, C’8-CH3 );

C NMR (75 MHz, DMSO-D6 ), δ 145.0, 144.2, 127.6,

13

60.1, 30.6, 30.2, 27.9, 27.8, 24.8, 21.4, 13.4. The resulting brown liquid was isolated in
87% yield. Combustion Analysis: calculated for C13 H22 IN, C, 48.91; H, 6.95; N, 4.39.
Found: C, 49.01; H, 7.08; N, 4.39.

N-n-Nonylpyridinium Iodide (NNPI, 53i)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.14 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.17

(2H, t, C3&C5-H), 4.62 (2H, t, C’1-CH2 ), 1.90 (2H, p, C’2-CH2 ), 1.22 (12H, m, C’3-C’8CH2 ), 0.82 (3H, t, C’9-CH3 );

C NMR (75 MHz, DMSO-D6 ), δ 145.5, 144.6, 128.1,

13

60.7, 31.3, 30.6, 28.6, 28.5, 28.3, 25.3, 22.0, 13.9. The resulting yellow solid was
isolated in 88% yield, with a melting point of 76°C. Combustion Analysis: calculated for
C14 H24 IN, C, 50.46; H, 7.26; N, 4.20. Found: C, 50.42; H, 7.34; N, 4.21.

N-n-Decylpyridinium Iodide (NDPI, 53j)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.15 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.17

(2H, t, C3&C5-H), 4.82 (2H, t, C’1-CH2 ), 1.92 (2H, p, C’2-CH2 ), 1.22 (14H, m, C’3-C’9CH2 ), 0.82 (3H, t, C’10-CH3 );

13

C NMR (75 MHz, DMSO-D6 ), δ 145.5, 144.7, 128.1,

60.8, 31.2, 30.7, 28.8, 28.7, 28,6, 28.4, 25.3, 22.0, 13.9. The resulting pale yellow solid
was isolated in 84% yield, with a melting point of 71 °C.

Combustion Analysis:

calculated for C15 H26 IN, C, 51.88; H, 7.55; N, 4.03. Found: C, 51.91; H, 7.54; N, 4.00.
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N-n-Undecylpyridinium Iodide (NUPI, 53k)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.12 (2H, d, C2&C6-H), 8.61 (1H, t, C4-H), 8.17

(2H, t, C3&C5-H), 4.61 (2H, t, C’1-CH2 ), 2.00 (2H, p, C’2-CH2 ), 1.24 (16H, m, C’3C’10-CH2 ), 0.83 (3H, t, C’11-CH3 );

13

C NMR (75 MHz, DMSO-D6 ), δ 145.2, 144.4,

127.8, 60.1, 31.0, 30.3, 28.6 (x2), 28.4, 28,3, 28.1, 25.0, 21.7, 13.6. The resulting pale
yellow solid was isolated in 82% yield, with a melting point of 91 °C. Combustion
Analysis: calculated for C16 H28 IN, C, 53.19; H, 7.81; N, 3.88. Found: C, 53.24; H, 7.80;
N, 3.89.

N-n-Dodecylpyridinium Iodide (NDDPI, 53l)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.13 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.18

(2H, t, C3&C5-H), 4.73 (2H, t, C’1-CH2 ), 1.89 (2H, p, C’2-CH2 ), 1.24 (18H, m, C’3C’11-CH2 ), 0.84 (3H, t, C’12-CH3 );

13

C NMR (75 MHz, DMSO-D6 ), δ 145.4, 144.6,

128.0, 60.7, 31.2, 30.8, 28.9 (x3), 28.8, 28,7, 28.6, 25.4, 22.0, 13.9. The resulting yellow
solid was isolated in 85% yield, with a melting point of 84°C. Combustion Analysis:
calculated for C17 H30 IN, C, 54.40; H, 8.06; N, 3.73. Found: C, 54.59; H, 7.97; N, 3.73.

N-n-Pentadecylpyridinium Bromide (NPeDPB, 53m)
1

H NMR (300 MHz, CDCl3 ), δ 9.44 (2H, d, C2&C6-H), 8.49 (1H, t, C4-H), 8.11 (2H, t,

C3&C5-H), 5.02 (2H, t, C’1-CH2 ), 2.01 (2H, p, C’2-CH2 ), 1.35 (24H, m, C’3-C’14-CH2 ),
0.86 (3H, t, C’15-CH3 ); 13 C NMR (75 MHz, CDCl3 ), δ 145.2, 145.1, 128.4, 62.6, 32.3,
32.2, 30.0, 29.9(x3), 29.8, 29.7, 29.6, 29.3, 26.4, 22.1, 14.5. The resulting tan solid was

70

isolated in 65% yield, with a melting point of 76°C. Combustion Analysis: calculated for
C20 H36 BrN. 1.0 H2 O, C, 61.84; H, 9.86; N, 3.61. Found: C, 61.73; H, 9.62; N, 3.60.

N-Ecosylpyridinium Bromide (NEcPB, 53n)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.13 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.17

(2H, t, C3&C5-H), 4.61 (2H, t, C’1-CH2 ), 1.80 (2H, p, C’2-CH2 ), 1.25 (34H, m, C’3C’19-CH2 ), 0.85 (3H, t, C’20-CH3 );

13

C NMR (75 MHz, DMSO-D6 ), δ 145.3, 144.6,

127.9, 60.7, 31.3, 30.7, 29.0 (x10), 28.9, 28.8, 28.7, 28.4, 25.4, 22.1, 14.0. The resulting
white solid was isolated in 56% yield, with a melting point of 73°C. Combustion
Analysis: calculated for C25 H46 BrN. 1.75 H2O, C, 63.61; H, 10.57; N, 2.97. Found: C,
63.45; H, 10.27; N, 3.00.

3.2.3.2.

Picolinium Salts

The appropriate 1-iodoalkane (5.01-16.1 mmol) was added to a solution (30 mL) of 3picoline, and the solution heated for 24 h at 65°C. The resulting liquid precipitates had
the excess picoline decanted off and the resulting oil precipitates were washed with
diethyl ether five times, and the remaining oil was dried under vacuum. The resulting oil
was isolated in yields ranging from 89-94%.

N-n-Octylpicolinium Iodide (NOPiI, 54a)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.04 (1H, s, C2 -H), 8.94 (1H, s, C6-H), 8.45 (1H, d,

C4-H), 8.06 (1H, t, C5-H), 4.55 (2H, t, C’1-CH2 ), 2.50 (3H, s, C3-CH3 ), 1.91 (2H, p,
C’2-CH2 ), 1.25 (10H, m, C’3-C’7-CH2 ), 0.85 (3H, t, C’8-CH3 );
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13

C NMR (75 MHz,

DMSO-D6 ), δ 145.5, 144.0, 141.8, 138.5, 127.2, 60.5, 31.1, 30.6, 28.4 (x2), 25.4, 22.1,
17.9, 14.0.

The resulting dark brown oil was isolated in 92% yield.

Combustion

Analysis: calculated for C14 H24 IN, C, 50.46; H, 7.26; N, 4.20. Found: C, 50.26; H, 7.28;
N, 4.18.

N-n-Nonylpicolinium Iodide (NNPiI, 54b)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.00 (1H, s, C2 -H), 8.94 (1H, s, C6-H), 8.45 (1H, d,

C4-H), 8.06 (H, t, C5-H), 4.55 (2H, t, C’1-CH2 ), 2.50 (3H, s, C3-CH3 ), 1.91 (2H, p, C’2CH2 ), 1.25 (10H, m, C’3-C’7-CH2 ), 0.85 (3H, t, C’8-CH3 ); 13 C NMR (75 MHz, DMSOD6 ), δ 145.5, 144.0, 141.8, 138.5, 127.2, 60.5, 31.2, 30.6, 28.7, 28.6, 28.4, 25.4, 22.1,
17.9, 14.0.

The resulting dark brown oil was isolated in 94% yield.

Combustion

Analysis: calculated for C15 H26 IN, C, 51.88; H, 7.55; N, 4.03. Found: C, 51.99; H, 7.54;
N, 4.04.

N-n-Decylpicolinium Iodide (NDPiI, 54c)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.02 (1H, s, C2 -H), 8.93 (1H, s, C6-H), 8.45 (1H, d,

C4-H), 8.06 (1H, t, C5-H), 4.53 (2H, t, C’1-CH2 ), 2.50 (3H, s, C3-CH3 ), 1.91 (2H, p,
C’2-CH2 ), 1.23 (14H, m, C’3-C’9-CH2 ), 0.84 (3H, t, C’10-CH3 );

13

C NMR (75 MHz,

DMSO-D6 ), δ 145.5, 144.0, 141.8, 138.5, 127.2, 60.5, 31.3, 30.6, 28.9, 28.8, 28.7, 28.4,
25.4, 22.1, 17.9, 14.0.

The resulting dark brown oil was isolated in 90% yield.

Combustion Analysis: calculated for C16 H28 IN, C, 53.19; H, 7.81; N, 3.88. Found: C,
53.24; H, 7.79; N, 3.89.
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N-n-Undecylpicolinium Iodide (NUPiI, 54d)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.04 (1H, s, C2 -H), 8.94 (1H, s, C6-H), 8.46 (1H, d,

C4-H), 8.07 (1H, t, C5-H), 4.55 (2H, t, C’1-CH2 ), 2.50 (3H, s, C3-CH3 ), 1.91 (2H, p,
C’2-CH2 ), 1.24 (18H, m, C’3-C’11-CH2 ), 0.85 (3H, t, C’12-CH3 );

13

C NMR (75 MHz,

DMSO-D6 ), δ 145.5, 144.0, 141.7, 138.5, 127.2, 60.5, 31.3, 30.6, 29.0, 28.9, 28.8, 28.7,
28.4, 25.4, 22.1, 17.9, 14.0. The resulting dark brown oil was isolated in 89% yield.
Combustion Analysis: calculated for C17 H30 IN, C, 54.40; H, 8.06; N, 3.73. Found: C,
54.53; H, 7.99; N, 3.75.

N-n-Dodecylpicolinium Iodide (NDDPiI, 54e)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.03 (1H, s, C2 -H), 8.94 (1H, s, C6-H), 8.46 (1H, d,

C4-H), 8.17 (1H, t, C5-H), 4.54 (2H, t, C’1-CH2 ), 2.50 (3H, s, C3-CH3 ), 1.92 (2H, p,
C’2-CH2 ), 1.25 (18H, m, C’3-C’11-CH2 ), 0.86 (3H, t, C’12-CH3 );

13

C NMR (75 MHz,

DMSO-D6 ), δ 145.7, 144.1, 141.9, 138.7, 127.3, 60.6, 31.2, 30.5, 28.9 (x2), 28.8, 28.7,
28.6, 28.3, 25.3,22.0, 17.8, 13.9. The resulting dark brown oil was isolated in 91% yield.
Combustion Analysis: calculated for C18 H32 IN, C, 55.53; H, 8.28; N, 3.60. Found: C,
55.70; H, 8.20; N, 3.59.

3.2.3.3.

N-Alkylated Nicotinamide Salts

The appropriate 1-iodoalkane (5.01-16.1 mmol) was added to a solution (30 mL) of
nicotinamide (40.94 mmol) in methanol. The solution was heated for 24 h at 65°C. The
resulting precipitate was filtered, and the product washed five times with dry diethyl
ether. The remaining solid was then dissolved in water and extracted with chloroform (3
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x 25 mL). The organic layer was dried over anhydrous magnesium sulfate, filtered, and
the solvent removed. The resulting solid was isolated in yields ranging from 70-83%.

N-n-Octylnicotinamide Iodide (NONAI, 55a)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.47 (1H, s, C2 -H), 9.20 (1H, d, C6-H), 8.92 (1H, d,

C4-H), 8.54 (1H, s, N1’-H), 8.27 (2H, t, C5-H), 8.18 (1H, s, N1’-H), 4.64 (2H, t, C’1CH2 ), 1.93 (2H, p, C’2-CH2 ), 1.27 (10H, m, C’3-C’7-CH2 ), 0.87 (3H, t, C’8-CH3 );

13

C

NMR (75 MHz, DMSO-D6 ), δ 162.6, 146.2, 144.6, 143.0, 133.7, 127.7, 61.1, 31.1, 30.6,
28.4 (x2), 25.4, 22.1, 14.0. The resulting golden solid was isolated in 83% yield, with a
melting point of 154-155°C. Combustion Analysis: calculated for C14 H23 IN 2O 0.25 H2 O,
C, 45.85; H, 6.46; N, 7.64. Found: C, 45.60; H, 6.36; N, 7.71.

N-n-Nonylnicotinamide Iodide (NNNAI, 55b)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.48 (1H, s, C2 -H), 9.22 (1H, d, C6-H), 8.92 (1H, d,

C4-H), 8.54 (1H, s, N1’-H), 8.28 (2H, t, C5-H), 8.17 (1H, s, N1’-H), 4.63 (2H, t, C’1CH2 ), 1.93 (2H, p, C’2-CH2 ), 1.25 (12H, m, C’3-C’8-CH2 ), 0.85 (3H, t, C’9-CH3 );

13

C

NMR (75 MHz, DMSO-D6 ), δ 162.6, 146.2, 144.6, 143.0, 133.7, 127.7, 61.1, 31.2, 30.6,
28.7, 28.6, 28.4, 25.4, 22.1, 14.0. The resulting yellow solid was isolated in 80% yield,
with a melting point of 164°C. Combustion Analysis: calculated for C15 H25 IN2 O 0.5
H2 O, C, 46.76; H, 6.80; N, 7.27. Found: C, 46.55; H, 6.69; N, 7.30.
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N-n-Decylnicotinamide Iodide (NDNAI, 55c)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.48 (1H, s, C2 -H), 9.22 (1H, d, C6-H), 8.92 (1H, d,

C4-H), 8.54 (1H, s, N1’-H), 8.28 (2H, t, C5-H), 8.18 (1H, s, N1’-H), 4.65 (2H, t, C’1CH2 ), 1.92 (2H, p, C’2-CH2 ), 1.24 (14H, m, C’3-C’9-CH2 ), 0.86 (3H, t, C’10-CH3 ); 13 C
NMR (75 MHz, DMSO-D6 ), δ 162.6, 146.1, 144.5, 143.1, 133.7, 127.7, 61.1, 31.3, 30.6,
28.9, 28.8, 28.7, 28.4, 25.4, 22.1, 14.0. The resulting yellow solid was isolated in 77%
yield, with a melting point of 170 °C. Combustion Analysis: calculated for C16 H27 IN 2O
0.33 H2 O, C, 48.49; H, 7.04; N, 7.07. Found: C, 48.38; H, 6.85; N, 6.95.

N-n-Undecylnicotinamide Iodide (NUNAI, 55d)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.48 (1H, s, C2 -H), 9.21 (1H, d, C6-H), 8.92 (1H, d,

C4-H), 8.54 (1H, s, N1’-H), 8.28 (2H, t, C5-H), 8.18 (1H, s, N1’-H), 4.64 (2H, t, C’1CH2 ), 1.93 (2H, p, C’2-CH2 ), 1.25 (16H, m, C’3-C’10-CH2 ), 0.85 (3H, t, C’11-CH3 ); 13 C
NMR (75 MHz, DMSO-D6 ), δ 162.6, 146.1, 144.6, 143.0, 133.7, 127.7, 61.1, 31.3, 30.6,
29.0, 28.9, 28.8, 28.7, 28.4, 25.4, 22.1, 14.0. The resulting dark yellow solid was isolated
in 70% yield, with a melting point of 175°C. Combustion Analysis: calculated for
C17 H29 IN 2O 0.25 H2 O, C, 49.94; H, 7.27; N, 6.85. Found: C, 49.81; H, 7.33; N, 6.83.

N-n-Dodecylnicotinamide Iodide (NDDNAI, 55e)
1

H NMR (300 MHz, DMSO-D6 ), δ 9.47 (1H, s, C2 -H), 9.21 (1H, d, C6-H), 8.92 (1H, d,

C4-H), 8.54 (1H, s, N1’-H), 8.27 (2H, t, C5-H), 8.18 (1H, s, N1’-H), 4.64 (2H, t, C’1CH2 ), 1.92 (2H, p, C’2-CH2 ), 1.23 (18H, m, C’3-C’11-CH2 ), 0.84 (3H, t, C’12-CH3 ); 13 C
NMR (75 MHz, DMSO-D6 ), δ 162.6, 146.1, 144.5, 143.1, 133.7, 127.7, 61.2, 31.3, 30.6,
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29.0 (x2), 28.9, 28.8, 28.7, 28.4, 25.4, 22.1, 14.0. The resulting golden solid was isolated
in 72% yield, with a melting point of 181°C. Combustion Analysis: calculated for
C18 H31 IN 2O 0.33 H2 O, C, 50.95; H, 7.52; N, 6.60. Found: C, 50.73; H, 7.48; N, 6.43.

3.2.3.4.

Nicotinium Salts

S-(-)-Nicotine (30.8 mmol) was dissolved in glacial acetic acid (35 mL) and the solution
was stirred at ambient temperature for five minutes. The appropriate 1-iodoalkane (30.8
mmol) was added to the solution, and the mixture was refluxed for three days. The
mixture was then evaporated under reduced pressure to remove the solvent, and the
resulting oil was treated with an aqueous solution of sodium bicarbonate. Diethyl ether
(3 x 50 mL) and chloroform (3 x 50 mL) were added successively to the resulting mixture
to extract the unreacted NIC and quaternized analog, respectively. The chloroform layers
were collected, combined, and dried over magnesium sulfate. The chloroform was then
filtered and evaporated to dryness on a rotary evaporator. The resulting oil was triturated
with dry diethyl ether as needed, and the ether washings discarded. The remaining
residue was utilized as a homogenous viscous oil in the pharmacological assays. The
resulting oil was isolated in yields ranging from 60-72%.
N-n-Butylnicotinium Iodide (NnBNI, 56d)
1

H NMR (300 MHz, DMSO-D6 ),δ 9.05 (1H, s, C2-H), 8.99 (1H, d, C6-H), 8.54 (1H, d,

C4-H), 8.12 (1H, t, C3-H), 4.61 (2H, t, C’’1-CH2 ), 3.43 (1H, t, pyrrolidine CH2 ), 3.18
(1H, t, pyrrolidine CH2 ), 2.34 (2H, m, C’’2-CH2 ), 2.15 (3H, s, pyrrolidine N-CH3 ), 1.88
(4H, m, pyrrolidine CH2 CH2 ), 1.65 (1H, m, pyrrolidine CH), 1.30 (2H, m, C’’3-CH2 ),
0.92 (3H, t, C”-CH3 ); 13 C NMR (75 MHz, DMSO-D6 ) δ 144.3, 143.9, 143.3, 127.8, 66.5,
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60.5, 56.3, 34.7, 32.8 (x2), 22.6, 18.8, 13.4. The resulting dark brown oil was isolated in
60% yield. Combustion Analysis: calculated for C14 H23 IN2 0.125 H2 O, C, 48.25; H,
6.72; N, 8.04. Found: C, 48.02; H, 6.58; N, 8.02.

N-n-Pentylnicotinium Iodide (NPeNI, 56e)
1

H NMR (300 MHz, CDCl3 ) δ 9.37 (1H, d, C6-H), 9.18 (1H, s, C2-H), 8.50 (1H, d, C4-

H), 8.11 (1H, t, C3-H), 4.92 (2H, t, C’’1-CH2 ), 3.64 (1H, t, pyrrolidine CH2 ), 3.25 (1H, t,
pyrrolidine CH2 ), 2.46 (2H, m, C’’2-CH2 ), 2.25 (3H, s, pyrrolidine N-CH3 ), 1.80- 2.02
(4H, m, pyrrolidine CH2 CH2 ), 1.67 (1H, m, pyrrolidine CH), 1.36 (4H, m, C’’3&’’4CH2 ), 0.87 (3H, t, C”-CH3 );

13

C NMR (75 MHz, CDCl3 ) δ 146.7, 144.3, 143.7, 143.2,

128.6, 67.1, 62.4, 57.0, 40.9, 36.1, 31.9, 28.4, 23.6, 22.5, 14.2. The resulting light brown
oil was isolated in 72% yield. Combustion Analysis: calculated for C15 H25 IN 2 0.25 H2 O,
C, 45.93; H, 6.49; N, 7.14. Found: C, 45.76; H, 6.34; N, 7.15.

N-n-Dodecylnicotinium Iodide (NDDNI, 56l)
1

H NMR (300 MHz, CDCl3 ) δ 9.30 (1H, d, C6-H), 9.08 (1H, s, C2-H), 8.52 (1H, d, C4-

H), 8.11 (1H, t, C5-H), 4.90 (2H, t, C’’1-CH2 ), 3.69 (1H, t, pyrrolidine CH2 ), 3.30 (1H, t,
pyrrolidine CH2 ), 2.50 (2H, m, C’’2-CH2 ), 2.30 (3H, s, pyrrolidine N-CH3 ), 1.65-2.12
(5H, m, pyrrolidine CH2 CH2 CH), 1.18-1.50 (18H, m, C’’3-11-CH2 ), 0.89 (3H, t, C”12CH3 ); 13 C NMR (75 MHz, CDCl3 ) δ 146.7, 144.3, 143.6, 143.0, 128.6, 67.1, 62.6, 56.9,
40.9, 36.1, 32.1 (x2), 29.8 (x2), 29.7, 29.6 (x2), 29.3, 26.3, 23.5, 23.0, 14.4.

The

resulting dark brown oil was isolated in 65% yield. Combustion Analysis: calculated for
C22 H39 IN 2 0.25 HI, C, 53.88; H, 8.07; N, 5.71. Found: C, 53.74; H, 8.04; N, 5.58.
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3.2.4.

3.2.4.1.

Synthetic Procedures for the Preparation of bis-Pyridinium Derivatives

bis-Pyridinium Salts

1,X-dihalogenoalkane, where X denotes the appropriate carbon length, (6.09-12.13
mmol) was added to a solution (30 mL) of dry pyridine, and the solution heated for 24 h
at 65°C. The resulting solid precipitates were filtered and washed five times with dry
diethyl ether. For liquid products, the excess pyridine was decanted off, the resulting
liquid precipitates were washed with diethyl ether five times, and the remaining liquid
was dried under vacuum. The resulting solid or liquid was isolated yields ranging from
87-93%.

N,N’-Pentane-1,5-diyl-bis-pyridinium Diiodide (bPPeI, 57a)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.14 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.19 (2H,

t, C3&C5-H), 4.62 (2H, t, C’1-CH2 ), 1.92 (2H, m, C’2-CH2 ), 1.25 (1H, m, C’3-CH2 ); 13 C
NMR (75 MHz, DMSO-D6 ) δ 145.3, 144.5, 127.9, 60.1, 29.9, 21.7. The resulting yellow
solid was isolated in 90% yield, with a melting point of 146-147°C. Combustion
Analysis: calculated for C15 H20 I2N2 , C, 37.37; H, 4.18; N, 5.81. Found: C, 37.51; H,
4.20; N, 5.73.

N,N’-Hexane-1,6-diyl-bis-pyridinium Diiodide (bPHxI, 57b)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.13 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.18 (2H,

t, C3&C5-H), 4.52 (2H, t, C’1-CH2 ), 1.93 (2H, m, C’2-CH2 ), 1.34 (2H, m, C’3-CH2 ); 13 C
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NMR (75 MHz, DMSO-D6 ) δ 145.3, 144.5, 127.9, 60.5, 30.7, 24.8. The resulting pale
yellow solid was isolated in 92% yield, with a melting point of 242-243°C. Combustion
Analysis: calculated for C16 H22 I2N2 , C, 38.73; H, 4.47; N, 5.65. Found: C, 38.62; H,
4.53; N, 5.87.

N,N’-Octane-1,8-diyl-bis-pyridinium Diiodide (bPOI, 57c)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.11 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.18 (2H,

t, C3&C5-H), 4.59 (2H, t, C’1-CH2 ), 1.89 (2H, m, C’2-CH2 ), 1.28 (4H, m, C’3&4-CH2 );
C NMR (75 MHz, DMSO-D6 ) δ 145.3, 144.5, 127.9, 60.5, 30.6, 28.1, 25.2. The

13

resulting pale yellow solid was isolated in 93% yield, with a melting point of 203-204°C.
Combustion Analysis: calculated for C18 H26 I2 N2 , C, 41.24; H, 5.00; N, 5.43. Found: C,
41.20; H, 5.08; N, 5.68.

N,N’-Nonane-1,9-diyl-bis-pyridinium Dibromide (bPNB, 57e)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.17 (2H, d, C2&C6-H), 8.61 (1H, t, C4-H), 8.18 (2H,

t, C3&C5-H), 4.63 (2H, t, C’1-CH2 ), 1.89 (2H, m, C’2-CH2 ), 1.22 (5H, m, C’3-5-CH2 );
C NMR (75 MHz, DMSO-D6 ) δ 145.3, 144.5, 127.9, 60.5, 30.7, 28.4, 28.2, 25.3,

13

C19 H28 Br2N2 .

The resulting clear liquid was isolated in 87% yield.

Combustion

Analysis: calculated for C19 H28 Br2 N2 , C, 51.37; H, 6.35; N, 6.31. Found: C, 51.42; H,
6.31; N, 6.25.

N,N’-Decane-1,10-diyl-bis-pyridinium Diiodide (bPDI, 57f)
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1

H NMR (300 MHz, DMSO-D6 ) δ 9.10 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.19 (2H,

t, C3&C5-H), 4.60 (2H, t, C’1-CH2 ), 1.89 (2H, m, C’2-CH2 ), 1.24 (6H, m, C’3-5-CH2 );
C NMR (75 MHz, DMSO-D6 ) δ 145.3, 144.5, 127.9, 60.6, 30.6, 28.8, 28.1, 25.2. The

13

resulting pale yellow solid was isolated in 90% yield, with a melting point of 162-163°C.
Combustion Analysis: calculated for C20 H30 I2 N2 , C, 43.50; H, 5.48; N, 5.07. Found: C,
43.53; H, 5.67; N, 5.29.

N,N’-Undecane-1,11-diyl-bis-pyridinium Dibromide (bPUB, 57g)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.18 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.19 (2H,

t, C3&C5-H), 4.63 (2H, t, C’1-CH2 ), 1.88 (2H, m, C’2-CH2 ), 1.22 (7H, m, C’3-6-CH2 );
C NMR (75 MHz, DMSO-D6 ) δ 145.3, 144.6, 127.9, 60.6, 30.8, 28.8 (x2), 28.4, 25.4.

13

The resulting amber liquid was isolated in 91% yield. Combustion Analysis: calculated
for C21 H32 Br2 N2 , C, 53.40; H, 6.83; N, 5.93. Found: C, 53.39; H, 6.91; N, 5.88.

N,N’-Dodecane-1,12-diyl-bis-pyridinium Dibromide (bPDDB, 57h)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.15 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.19 (2H,

t, C3&C5-H), 4.61 (2H, t, C’1-CH2 ), 1.88 (2H, m, C’2-CH2 ), 1.22 (8H, m, C’3-6-CH2 );
C NMR (75 MHz, DMSO-D6 ) δ 145.3, 144.6, 127.9, 60.7, 30.8, 28.9, 28.8, 28.5, 25.4.

13

The resulting white solid was isolated in 93% yield, with a melting point of 222-223°C.
Combustion Analysis: calculated for C22 H34 Br2N2 , C, 54.33; H, 7.05; N, 5.76. Found: C,
54.40; H, 7.00; N, 5.86.
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3.2.4.2.

bis-Picolinium Salts

1,X-dihalogenoalkane, where X denotes the appropriate carbon length, (6.09-12.13
mmol) was added to a solution (30 mL) of 3-picoline, and the solution heated for 24 h at
65°C. The resulting precipitate was filtered, and the product washed five times with dry
diethyl ether. The precipitate was the n dissolved in water (30 mL) and extracted with
chloroform (3 x 30 mL). The organic layer was collected and evaporated to dryness on a
rotary evaporator. The resulting solid or liquid was isolated in yields ranging from 9094%.

N,N’-Hexane-1,6-diyl-bis-picolinium Diiodide (bPiHxI, 58a)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.06 (1H, s, C2-H), 8.94 (1H, d, C6-H), 8.46 (1H, d,

C4-H), 8.07 (1H, t, C5-H), 4.56 (2H, t, C’1-CH2 ), 2.50 (3H, s, C3-CH3 ), 1.86 (2H, m,
C’2-CH2 ), 1.33 (2H, m, C’3-CH2 ); 13 C NMR (75 MHz, DMSO-D6 ) δ 145.6, 144.0, 141.7,
138.5, 127.1, 60.3, 30.3, 24.8, 17.9. The resulting pale yellow solid was isolated in 91%
yield, with a melting point of 214-215°C.

Combustion Analysis: calculated for

C18 H26 I2 N2 , C, 41.24; H, 5.00; N, 5.34. Found: 41.03; H, 5.32; N, 5.22.

N,N’-Octane-1,8-diyl-bis-picolinium Diiodide (bPiOI, 58b)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.18 (1H, s, C2-H), 8.96 (1H, d, C6-H), 8.46 (1H, d,

C4-H), 8.07 (1H, t, C5-H), 4.62 (2H, t, C’1-CH2 ), 2.50 (3H, s, C3-CH3 ), 1.94 (2H, m,
C’2-CH2 ), 1.27 (4H, m, C’3&4-CH2 );

13

C NMR (75 MHz, DMSO-D6 ) δ 145.5, 143.9,

141.7, 138.5, 127.1, 60.4, 30.5, 28.1, 25.2, 17.9. The resulting canary yellow solid was
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isolated in 94% yield, with a melting point of 161-162°C.

Combustion Analysis:

calculated for C20 H30 I2N2 , C, 43.50; H, 5.48; N, 5.07. Found: C, 43.32; H, 5.47; N, 4.98.

N,N’-Nonane-1,9-diyl-bis-picolinium Dibromide (bPiNB, 58c)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.17 (1H, s, C2-H), 9.04 (1H, d, C6-H), 8.47 (1H, d,

C4-H), 8.08 (1H, t, C5-H), 4.60 (2H, t, C’1-CH2 ), 2.50 (3H, s, C3-CH3 ), 1.92 (2H, m,
C’2-CH2 ), 1.27 (5H, m, C’3-5-CH2 );

13

C NMR (75 MHz, DMSO-D6 ) δ 145.5, 144.1,

141.8, 138.5, 127.1, 60.4, 30.7, 28.5, 28.3, 25.4, 17.9. The resulting tan liquid was
isolated in 90% yield. Combustion Analysis: calculated for C21 H32 Br2N2 . 0.5 H2O, C,
52.40; H, 6.91; N, 5.82. Found: C, 52.26; H, 6.89; N, 5.70.

N,N’-Decane-1,10-diyl-bis-picolinium Diiodide (bPiDI, 58d)
1

H NMR (300 MHz, CDCl3 ) δ 9.04 (1H, s, C2-H), 8.94 (1H, d, C6-H), 8.46 (1H, d, C4-

H), 8.06 (1H, t, C5-H), 4.58 (2H, t, C’1-CH2 ), 2.50 (3H, s, C3-CH3 ), 1.90 (2H, m, C’2CH2 ), 1.27 (6H, m, C’3-5-CH2 ) ;

13

C NMR (75 MHz, DMSO-D6 ) δ 145.6, 144.0, 141.7,

138.6, 127.2, 60.5, 30.6, 28.7, 28.4, 25.4, 18.0. The resulting tan solid was isolated in
92% yield, with a melting point of 161-162°C. Combustion Analysis: calculated for
C22 H34 I2 N2 . 1.5 H2 O, C, 43.51; H, 6.14; N, 4.61. Found: C, 43.82; H, 6.02; N, 4.61.

N,N’-Undecane-1,11-diyl-bis-picolinium Dibromide (bPiUB, 58e)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.10 (1H, s, C2-H), 8.98 (1H, d, C6-H), 8.46 (1H, d,

C4-H), 8.07 (1H, t, C5-H), 4.58 (2H, t, C’1-CH2 ), 2.50 (3H, s, C3-CH3 ), 1.90 (2H, m,
C’2-CH2 ), 1.26 (7H, m, C’3-6-CH2 );

13

C NMR (75 MHz, DMSO-D6 ) δ 145.5, 144.0,
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141.8, 138.5, 127.1, 60.5, 30.7, 28.8, 28.7, 28.4, 25.4, 17.9. The resulting tan liquid was
isolated in 90% yield. Combustion Analysis: calculated for C23 H36 Br2N2 . 0.33 H2 O, C,
54.56; H, 7.30; N, 5.53. Found: C, 54.23; H, 7.43; N, 5.41.

N,N’-Dodecane-1,12-diyl-bis-picolinium Dibromide (bPiDDB, 58f)
1

H NMR (300 MHz, CDCl3 ) δ 9.04 (1H, s, C2-H), 8.94 (1H, d, C6-H), 8.46 (1H, d, C4-

H), 8.16 (1H, t, C5-H), 4.55 (2H, t, C’1-CH2 ), 2.50 (3H, s, C3-CH3 ), 1.90 (2H, m, C’2CH2 ), 1.25 (8H, m, C’3-6-CH2 ); 13 C NMR (75 MHz, DMSO-D6 ) δ 145.5, 144.1, 141.8,
138.5, 127.2, 60.4, 30.7, 28.9, 28.8, 28.4, 25.4, 17.9. The resulting tan liquid was
isolated in 92% yield. Combustion Analysis: calculated for C24 H38 Br2 N2 , C, 56.04; H,
7.45; N, 5.45. Found: C, 55.89; H, 7.62; N, 5.32.

3.2.4.3.

bis-Quinolinium Salts

1,X-dihalogenoalkane, where X denotes the appropriate carbon length, (6.09-12.13
mmol) was added to a solution (30 mL) of dry quinoline, and the solution heated for 24 h
at 65°C. The resulting precipitate was filtered, and the product washed five times with
dry diethyl ether. The resulting solid was isolated in yields ranging from 87-92%.

N,N’-Hexane-1,6-diyl-bis-quinolinium Diiodide (bQHxI, 59a)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.53 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d,

C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t, C5-H), 8.07 (1H, d, C6-H),
5.09 (2H, t, C’1-CH2 ), 1.96 (2H, m, C’2-CH2 ), 1.25 (2H, m, C’3-CH2 );

13

C NMR (75

MHz, DMSO-D6 ) δ 149.4, 147.2, 137.2, 135.5, 130.6, 129.7, 129.6, 122.0, 118.8, 57.2,
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29.3, 25.3. The resulting mustard yellow solid was isolated in 89% yield, with a melting
point of 234-235°C. Combustion Analysis: calculated for C24 H26 I2N2 , C, 48.34; H, 4.39;
N, 4.70. Found: C, 48.29; H, 4.43; N, 4.85.

N,N’-Octane-1,8-diyl-bis-quinolinium Diiodide (bQOI, 59b)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.53 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d,

C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t, C5-H), 8.07 (1H, d, C6-H),
5.09 (2H, t, C’1-CH2 ), 1.96 (2H, m, C’2-CH2 ), 1.25 (4H, m, C’3&4-CH2 ); 13 C NMR (75
MHz, DMSO-D6 ) δ 149.5, 147.4, 137.4, 135.6, 130.7, 129.9, 129.7, 122.1, 118.9, 57.3,
29.5, 28.5, 25.7. The resulting canary yellow solid was isolated in 89% yield, with a
melting point of 222-223°C. Combustion Analysis: calculated for C26 H30 I2 N2 . 0.25
H2 O, C, 49.54; H, 4.90; N, 4.44. Found: C, 49.41; H, 5.19; N, 4.11.

N,N’-Nonane-1,9-diyl-bis-quinolinium Dibromide (bQNB, 59c)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.68 (1H, d, C2-H), 9.34 (1H, d, C3-H), 8.67 (1H, d,

C8-H), 8.55 (1H, d, C4-H), 8.27 (2H, m, C5&C7-H), 8.07 (1H, d, C6-H), 5.09 (2H, t,
C’1-CH2 ), 1.95 (2H, m, C’2-CH2 ), 1.19-1.45 (5H, m, C’3-5-CH2 );

13

C NMR (75 MHz,

DMSO-D6 ) δ 149.5, 147.2, 137.2, 135.5, 130.6, 129.7, 129.5, 122.0, 118.9, 57.2, 29.6,
28.6, 28.4, 25.7. The resulting dark purple solid was isolated in 92% yield, with a
melting point of 185-186°C. Combustion Analysis: calculated for C27 H32 Br2 N2 . 0.25
H2 O, C, 59.08; H, 5.97; N, 5.10. Found: C, 59.01; H, 6.09; N, 5.05.
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N,N’-Decane-1,10-diyl-bis-quinolinium Diiodide (bQDI, 59d)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.53 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d,

C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t, C5-H), 8.06 (1H, d, C6-H),
5.04 (2H, t, C’1-CH2 ), 1.96 (2H, m, C’2-CH2 ), 1.32 (6H, m, C’3-5-CH2 ); 13 C NMR (75
MHz, DMSO-D6 ) δ 149.5, 147.4, 137.4, 135.6, 130.7, 129.9, 129.7, 122.1, 118.9, 57.3,
29.5,28.9, 28.5, 25.7. The resulting canary yellow solid was isolated in 91% yield, with a
melting point of 235-236°C. Combustion Analysis: calculated for C28 H34 I2N2 . 0.66 H2O,
C, 50.62; H, 5.36; N, 4.22. Found: C, 50.48; H, 5.52; N, 4.19.

N,N’-Undecane-1,11-diyl-bis-quinolinium Dibromide (bQUB, 59e)
1

H NMR (300 MHz, CDCl3 ) δ 9.54 (1H, d, C2-H), 9.28 (1H, d, C3-H), 8.60 (1H, d, C8-

H), 8.48 (1H, d, C4-H), 8.27 (1H, t, C7-H), 8.16 (1H, t, C5-H), 8.05 (1H, d, C6-H), 5.03
(2H, t, C’1-CH2 ), 1.95 (2H, m, C’2-CH2 ), 1.15-1.48 (7H, m, C’3-6-CH2 ); 13 C NMR (75
MHz, DMSO-d6 ) δ 149.5, 147.4, 137.4, 135.6, 130.7, 129.9, 129.7, 122.1, 118.9, 57.3,
29.5,28.9, 28.8, 28.5, 25.7. The resulting dark purple solid was isolated in 87% yield,
with a melting point of 188-189°C. Combustion Analysis: calculated for C29 H36 Br2 N2 .
1.0 H2 O, C, 58.99; H, 6.49; N, 4.75. Found: C, 59.23; H, 6.56; N, 4.62.

N,N’-Dodecane-1,12-diyl-bis-quinolinium Dibromide (bQDDB, 59f)
1

H NMR (300 MHz, DMSO-D6 ) δ 9.58 (1H, d, C2-H), 9.29 (1H, d, C3-H), 8.61 (1H, d,

C8-H), 8.50 (1H, d, C4-H), 8.29 (1H, t, C7-H), 8.18 (1H, t, C5-H), 8.04 (1H, d, C6-H),
5.04 (2H, t, C’1-CH2 ), 1.95 (2H, m, C’2-CH2 ), 1.2-1.4 (8H, m, C’3-6-CH2 );

13

C NMR

(75 MHz, DMSO-D6 ) δ 149.5, 147.4, 137.4, 135.6, 130.7, 129.9, 129.7, 122.1, 118.9,
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57.3, 29.5,28.9, 28.8, 28.5, 25.7. The resulting dark purple solid was isolated in 92%
yield, with a melting point of 187-188°C.

Combustion Analysis: calculated for

C30 H38 Br2N2 . 0.33 H2O, C, 60.82; H, 6.58; N, 4.73. Found: C, 61.01; H, 6.63; N, 4.64.

3.2.4.4.

bis-Isoquinolinium Salts

1,X-dihalogenoalkane, where X denotes the appropriate carbon length, (6.09-12.13
mmol) was added to a solution (30 mL) of isoquinoline, and the solution heated for 24 h
at 65°C. The resulting precipitate was filtered, and the product washed five times with
dry diethyl ether. The resulting solid was isolated in yields ranging from 89-92%.

N,N’-Hexane-1,6-diyl-bis-isoquinolinium Diiodide (bIQHxI, 60a)
1

H NMR (300 MHz, DMSO-D6 ) δ 10.09 (1H, d, C1-H), 8.80 (1H, d, C3-H), 8.61 (1H, d,

C8-H), 8.48 (1H, d, C4-H), 8.36 (1H, d, C7-H), 8.27 (1H, t, C5-H), 8.08 (1H, t, C6-H),
4.71 (2H, t, C’1-CH2 ), 2.03 (2H, m, C’2-CH2 ), 1.40 (4H, m, C’3&4-CH2 ); 13 C NMR (75
MHz, DMSO-D6 ) δ 149.7, 136.7 (x2), 134.7, 131.0, 130.1, 127.1, 127.0, 125.7, 60.6,
30.2, 25.0. The resulting pale yellow solid was isolated in 87% yield, with a melting
point of 233°C. Combustion Analysis: calculated for C24 H26 I2 N2 , C, 48.34; H, 4.39; N,
4.70. Found: C, 48.46; H, 4.57; N, 4.98.

N,N’-Octane-1,8-diyl-bis-isoquinolinium Diiodide (bIQOI, 60b)
1

H NMR (300 MHz, DMSO-D6 ) δ 10.05 (1H, d, C1-H), 8.77 (1H, d, C3-H), 8.58 (1H, d,

C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.26 (1H, t, C5-H), 8.07 (1H, t, C6-H),
4.68 (2H, t, C’1-CH2 ), 2.00 (2H, m, C’2-CH2 ), 1.30 (4H, m, C’3&4-CH2 ); 13 C NMR (75
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MHz, DMSO-D6 ) δ 149.7, 136.9 (x2), 134.8, 131.3, 130.3, 127.3, 127.2, 125.9, 60.9,
30.6, 28.4, 25.6.

The resulting yellow solid was isolated in 92% yield, with

decomposition at 250 °C. Combustion Analysis: calculated for C26 H30 I2 N2 , C, 50.02; H,
4.84; N, 4.49. Found: C, 50.22; H, 4.61; N, 4.53.

N,N’-Nonane-1,9-diyl-bis-isoquinolinium Dibromide (bIQNB, 60c)
1

H NMR (300 MHz, DMSO-D6 ) δ 10.17 (1H, d, C1-H), 8.85 (1H, d, C3-H), 8.62 (1H, d,

C8-H), 8.49 (1H, d, C4-H), 8.36 (2H, d, C7-H), 8.26 (2H, t, C5-H), 8.08 (1H, t, C6-H),
4.72 (2H, t, C’1-CH2 ), 2.02 (2H, m, C’2-CH2 ), 1.11-1.45 (5H, m, C’3-5-CH2 ); 13 C NMR
(75 MHz, DMSO-D6 ) δ 149.8, 136.7 (x2), 134.8, 131.0, 130.1, 127.1, 127.1, 125.7, 60.7,
30.5, 28.6, 28.4, 25.5. The resulting light purple solid was isolated in 92% yield, with a
melting point of 162°C. Combustion Analysis: calculated for C27 H32 Br2 N2 . 0.33 H2 O C,
58.92; H, 5.98; N, 5.09. Found: C, 58.76; H, 5.92; N, 4.90.

N,N’-Decane-1,10-diyl-bis-isoquinolinium Diiodide (bIQDI, 60d)
1

H NMR (300 MHz, DMSO-D6 ) δ 10.07 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.58 (1H, d,

C8-H), 8.48 (1H, d, C4-H), 8.36 (1H, d, C7-H), 8.26 (1H, t, C5-H), 8.07 (1H, t, C6-H),
4.69 (2H, t, C’1-CH2 ), 2.0 (2H, m, C’2-CH2 ), 1.15-1.50 (6H, m, C’3-5-CH2 ); 13C NMR
(75 MHz, DMSO-D6 ) δ 149.7, 136.9 (x2), 134.9, 131.2, 130.0, 127.3, 127.2, 125.9, 60.9,
30.7, 28.9, 28.6, 25.7. The resulting dark yellow solid was isolated in 92% yield, with a
melting point of 192°C. Combustion Analysis: calculated for C28 H34 I2 N2 . 0.33 H2 O C,
51.08; H, 5.31; N, 4.25. Found: C, 50.88; H, 5.42; N, 4.13.
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N,N’-Undecane-1,11-diyl-bis-isoquinolinium Dibromide (bIQUB, 60e)
1

H NMR (300 MHz, DMSO-D6 ) δ 10.07 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.57 (1H, d,

C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.25 (1H, t, C5-H), 8.07 (1H, t, C6-H),
4.69 (2H, t, C’1-CH2 ), 2.0 (2H, m, C’2-CH2 ), 1.05-1.45 (7H, m, C’3-6-CH2 ); 13 C NMR
(75 MHz, DMSO-D6 ) δ 149.8, 136.7 (x2), 134.8, 131.0, 130.2, 127.1 (x2), 125.7, 60.7,
30.5, 28.9, 28.8, 28.5, 25.6. The resulting purple solid was isolated in 89% yield, with a
melting point of 166°C. Combustion Analysis: calculated for C29 H36 Br2 N2 , C, 60.85; H,
6.34; N, 4.89. Found: C, 60.65; H, 6.43; N, 4.92.

N,N’-Dodecane-1,12-diyl-bis-isoquinolinium Dibromide (bIQDDB, 60f)
1

H NMR (300 MHz, DMSO-D6 ) δ 10.06 (1H, d, C1-H), 8.78 (1H, d, C3-H), 8.58 (1H, d,

C8-H), 8.48 (1H, d, C4-H), 8.35 (1H, d, C7-H), 8.25 (1H, t, C5-H), 8.07 (1H, t, C6-H),
4.70 (2H, t, C’1-CH2 ), 2.0 (2H, m, C’2-CH2 ), 1.15-1.40 (8H, m, C’3-6-CH2 ); 13 C NMR
(75 MHz, DMSO-D6 ) δ 149.8, 136.7 (x2), 134.8, 131.0, 130.1, 127.1 (x2), 125.7, 60.6,
30.5, 28.9, 28.8, 28.5, 25.5. The resulting gray-purple solid was isolated in 91% yield,
with a melting point of 225°C. Combustion Analysis : calculated for C30 H38 Br2 N2 . 0.5
H2 O, C, 60.51; H, 6.60; N, 4.70. Found: C, 60.75; H, 6.56; N, 4.54.

3.2.4.5.

bis-Nicotinium Salts

S-(-)-Nicotine (30.8 mmol) was dissolved in glacial acetic acid (35 mL) and the solution
was stirred at ambient temperature for five minutes. The 1,X-dihalogenoalkane, where X
denotes the appropriate carbon length, (15.4 mmol) was added to the solution and the
mixture stirred with refluxing for three days. The mixture was then evaporated under

88

reduced pressure to remove the solvent, and the resulting oil was treated with an aqueous
solution of sodium bicarbonate.

The resulting aqueous mixture was extracted with

diethyl ether (3 x 50 mL), and then chloroform (3 x 50 mL) and the remaining aqueous
layer separated and evaporated to dryness on a rotary evaporator. The resulting solid was
dissolved in chloroform (200 mL) and filtered. The filtrate was collected and evaporated
to dryness under pressure. The resulting oil was isolated in yields ranging from 15-35%.

N,N’-Hexane-1,6-diyl-bis-nicotinium Diiodide (bNHxI, 61a)
1

H NMR (300 MHz, CDCl3 ),δ 9.44 (1H, s, C2-H), 9.38 (1H, d, C6-H), 8.44 (1H, d, C4-

H), 8.13 (1H, m, C5-H), 4.95 (2H, t, C’’1-CH2 ), 4.03 (1H, t, pyrrolidine CH2 ), 3.25 (1H,
t, pyrrolidine CH2 ), 2.49 (2H, m, C’’2-CH2 ), 2.23 (3H, s, pyrrolidine N-CH3 ), 1.60-2.19
(5H, m, pyrrolidine CH2 CH2 ), 1.30-1.55 (2H, m, C’’3-CH2 ); 13 C NMR (75 MHz, CDCl3 )
δ 146.8, 143.9, 143.7 (x2), 128.2, 66.8, 61.1, 57.0, 40.8, 36.0, 31.3, 24.7, 23.5. The
resulting brown viscous oil was isolated in 25% yield. Combustion Analysis: calculated
for C26 H40 I2N4 . 0.75 H2O, C, 46.20; H, 6.19; N, 8.29. Found: C, 46.08; H, 6.27; N, 8.23.

N,N’-Octane-1,8-diyl-bis-nicotinium Diiodide (bNOI, 61b)
1

H NMR (300 MHz, CDCl3 ),δ 9.58 (1H, s, C2-H), 9.50 (1H, d, C6-H), 8.47 (1H, d, C4-

H), 8.03 (1H, m, C5-H), 4.96 (2H, t, C’’1-CH2 ), 3.65 (1H, t, pyrrolidine CH2 ), 3.24 (1H,
t, pyrrolidine CH2 ), 2.49 (2H, m, C’’2-CH2 ), 2.25 (3H, s, pyrrolidine N-CH3 ), 1.60-2.19
(5H, m, pyrrolidine CH2 CH2 ), 1.40-1.60 (4H, m, C’’3&4-CH2 );

13

C NMR (75 MHz,

CDCl3 ) δ 146.9, 143.8, 143.6, 143.5, 128.3, 66.8, 61.7, 57.0, 40.8, 36.1, 32.0, 27.7, 25.2,
23.5. The resulting yellow viscous oil was isolated in 15% yield. Combustion Analysis:
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calculated for C28 H44 I2 N4 . 0.25 H2O, C, 48.39; H, 6.45; N, 8.06. Found: C, 48.13; H,
6.61; N, 7.98.

N,N’-Nonane-1,9-diyl-bis-nicotinium Dibromide (bNNB, 61c)
1

H NMR (300 MHz, CDCl3 ),δ 9.75 (1H, s, C2-H), 9.56 (1H, d, C6-H), 8.49 (1H, d, C4-

H), 8.08 (1H, m, C5-H), 5.05 (2H, t, C’’1-CH2 ), 3.65 (1H, t, pyrrolidine CH2 ), 3.25 (1H,
t, pyrrolidine CH2 ), 2.48 (2H, m, C’’2-CH2 ), 2.25 (3H, s, pyrrolidine N-CH3 ), 1.60-2.23
(5H, m, pyrrolidine CH2 CH2 ), 1.30-1.60 (5H, m, C’’3-5-CH2 );

13

C NMR (75 MHz,

CDCl3 ) δ 146.5, 144.2, 143.7, 143.6, 128.3, 66.9, 61.7, 56.9, 40.7, 36.0, 32.1, 28.2, 28.0,
25.5, 23.4. The resulting yellow viscous oil was isolated in 27% yield. Combustion
Analysis: calculated for C29 H46 Br2 N4 . 0.33 H2 O, C, 56.50; H, 7.63; N, 9.09. Found: C,
56.18; H, 7.81; N, 9.01.

N,N’-Decane-1,10-diyl-bis-nicotinium Diiodide (bNDI, 61d)
1

H NMR (300 MHz, CDCl3 ) δ 9.55 (1H, s, C2-H), 9.44 (1H, d, C6-H), 8.53 (1H, d, C4-

H), 8.09 (1H, m, C5-H), 4.98 (2H, t, C’’1-CH2 ), 3.74 (1H, t, pyrrolidine CH2 ), 3.30 (1H,
t, pyrrolidine CH2 , 2.50 (2H, m, C’’2-CH2 ), 2.29 (3H, s, pyrrolidine N-CH3 ), 1.65-2.20
(5H, m, pyrrolidine CH2 CH2 ), 1.30-1.57 (6H, m, C’’3-5-CH2 );

13

C NMR (75 MHz,

CDCl3 ) δ 146.6, 143.9 x 2, 143.4, 128.4, 66.9, 61.9, 57.0, 40.8, 36.1, 32.1, 28.5, 28.2,
25.8, 23.5. The resulting yellow viscous oil was isolated in 27% yield. Combustion
Analysis: calculated for C30 H48 I2 N4 . 1.0 H2 O, C, 48.92; H, 6.84; N, 7.61. Found: C,
48.64; H, 6.58; N, 7.48.
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N,N’-Undecane-1,11-diyl-bis-nicotinium Dibromide (bNUB, 61e)
1

H NMR (300 MHz, CDCl3 ) δ 9.70 (1H, s, C2-H), 9.47 (1H, d, C6-H), 8.49 (1H, d, C4-

H), 8.12 (1H, m, C5-H), 5.02 (2H, t, C’’1-CH2 ), 3.65 (1H, t, pyrrolidine CH2 ), 3.26 (1H,
t, pyrrolidine CH2 ), 2.49 (2H, m, C’’2-CH2 ), 2.25 (3H, s, pyrrolidine N-CH3 ), 1.60-2.20
(5H, m, pyrrolidine CH2 CH2 ), 1.20-1.50 (8H, m, C’’3-6-CH2 );

13

C NMR (75 MHz,

CDCl3 ) δ 146.5, 144.2, 143.7, 143.5, 128.4, 66.9, 61.9, 56.9, 40.7, 36.1, 32.2, 28.8, 28.7,
28.6, 25.9, 23.4. The resulting yellow viscous oil was isolated in 30% yield. Combustion
Analysis: calculated for C31 H50 Br2 N4 . 0.33 H2 O, C, 57.76; H, 7.92; N, 8.69. Found: C,
57.55; H, 7.99; N, 8.61.

N,N’-Dodecane-1,12-diyl-bis-nicotinium Dibromide (bNDDB, 61f)
1

H NMR (300 MHz, CDCl3 ) δ 9.66 (1H, s, C2-H), 9.38 (1H, d, C6-H), 8.46 (1H, d, C4-

H), 8.10 (1H, t, C5-H), 5.01 (2H, t, C’’1-CH2 ), 3.61 (1H, t, pyrrolidine CH2 ), 3.25 (1H, t,
pyrrolidine CH2 ), 2.45 (2H, m, C’’2-CH2 ), 2.23 (3H, s, pyrrolidine N-CH3 ), 1.60-2.19
(5H, m, pyrrolidine CH2 CH2 ), 1.20-1.50 (8H, m, C’’3-6-CH2 );

13

C NMR (75 MHz,

CDCl3 ) δ 146.6, 144.2, 143.7, 143.4, 128.5, 67.0, 62.0, 60.0, 40.8, 36.1, 32.4, 29.0, 28.8,
28.7, 26.0, 23.5. The resulting yellow viscous oil was isolated in 35% yield. Combustion
Analysis: calculated for C32 H52 Br2 N4 . 0.5 H2 O, C, 58.09; H, 8.07; N, 8.47. Found: C,
57.86; H, 8.12; N, 8.39.
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3.2.5.

Binding Assays for α 4β2* and α 7* Nicotinic Receptor Subtypes

[3H]Nicotine Binding Assay (α 4β2*)
The interaction of the compounds with the high affinity [3H]NIC binding site of the
α4β2* nAChR was studied utilizing a modification of the methodology of Marks et al.
(1986). Rat striata were dissected, pooled, and homogenized in 10 vol ice-cold modified
Krebs-HEPES buffer (in mM: 20 HEPES, 118 NaCl, 4.8 KCl, 2.5 CaCl2, 1.2 MgSO4,
pH 7.5). Homogenates were incubated at 37°C for 5 min, and then centrifuged at 27,000
g for 20 min at 4°C. The pellets were resuspended in 10 vol ice-cold MilliQ water and
incubated for 5 min at 37°C, followed by centrifugation at 27,000 g for 20 min at 4°C.
The second and third pellets were resuspended in 10 vol fresh, ice-cold 10% KRH buffer,
incubated for 5 min at 37°C, and centrifuged as above.

The final pellets were

resuspended in 20 vol of ice-cold MilliQ water, which afforded ~200 µg membrane
protein/100 µL aliquot [Bradford, 1976], using BSA as the protein standard. Binding
assays were performed in duplicate in a final vol of 200 µL Krebs-HEPES buffer
containing 200 mM Tris (pH 7.5 at 4°C). Assays were initiated by the addition of 100 µL
of membrane suspension to assay tubes containing final concentrations of 3 nM [3 H]NIC (50 µL) and one of 9 concentrations of compound being evaluated. Nonspecific
binding was defined in the presence of 10 µM NIC. After a 90 min incubation at 4°C,
reactions were terminated by dilution with 3 mL ice-cold Krebs-HEPES buffer, followed
immediately by filtration through Schleicher and Schuell #32 glass fiber filters (presoaked in 0.5% polyethyleneimine) using a Brandel cell harvester (Biomedical Research
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and Development Laboratories, Inc., Gaithersburg, MD). Filters were rinsed three times
with 3 mL of ice-cold Krebs-HEPES buffer and transferred to scintillation vials, 3 mL of
scintillation cocktail was added, and radioactivity was determined by liquid scintillation
spectroscopy (Marks et al. 1986).

[3H]MLA Binding Assay (α 7*)
[3 H]MLA binding probes the α7 nAChR subtype, and assays were carried out using a
modification of the method of Davies et al. (1999). Whole brain minus cortex, striatum
and cerebellum was homogenized in 20 vol of ice-cold hypotonic buffer (in mM: 2
HEPES, 14.4 NaCl, 0.15 KCl, 0.2 CaCl2 and 0.1 MgSO4, pH 7.5). Homogenates were
incubated at 37°C for 10 min and centrifuged at 29,000 g for 17 minutes at 4°C. Pellets
were washed three times by resuspension in 20 vol of the same buffer followed by
centrifugation as described above. Final pellets were resuspended in the incubation
buffer to yield ~150 µg membrane protein/100 µL membrane suspension. Binding assays
were performed in duplicate, in a final volume of 250 µL of incubation buffer (in mM: 20
HEPES, 144 NaCl, 1.5 KCl, 2 CaCl2, and 1 MgSO4, pH 7.5). Binding assays were
initiated by the addition of 100 µL of membrane suspensio n to 150 µL of sample
containing 2.5 nM [3 H]MLA and the desired concentration of the test compound, and
incubated for 2 hrs at ambient temperature. Nonspecific binding was determined in the
presence of 1 mM nicotine. Assays were terminated by dilution of samples with 3 mL of
ice-cold incubation buffer, followed by immediate filtration through Schleicher and
Schuell #32 glass fiber filters (pre-soaked in 0.5% polyethyleneimine) using a Brandel
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cell harvester (Davies et al. 1999). Filters were processed as described above for the
[3 H]NIC binding assay.

3.2.6.

Functional Assays for the Nicotinic Receptors Modulating DA Release and

α4β2* Nicotinic Receptor Subtype

[3H]Dopamine Overflow Assay
Quaternary ammonium analog effects on [3 H]overflow from rat striatal slices preloaded
with [3 H]DA, were determined using a modification of a previously published method
(Dwoskin and Zahniser 1986; Wilkins et al. 2002). Briefly, rat striata were dissected and
coronal slices (500 µm, 6-8 mg) were obtained using a McIlwain tissue chopper. Slices
were incubated for 30 min in Krebs buffer (in mM: 118 NaCl, 4.7 KCl, 1.3 CaCl2, 1.2
MgCl2, 1.0 NaH2PO4, 11.1 α-D-glucose, 25 NaHCO3, 0.11 L-ascorbic acid and 0.004
disodium EDTA; pH 7.4, saturated with 95% O2 / 5% CO2) at 34°C in a metabolic
shaker. Slices were then incubated for an additional 30 min in fresh buffer containing 0.1
µM [3H]DA, after rinsing, each slice was transferred to a glass superfusion chamber,
maintained at 34 °C and superfused (1.0 mL/min) with oxygenated Krebs’ buffer
containing nomifensine (10 µM), a DA reuptake inhibitor), and pargyline (10 µM), a
monoamine oxidase inhibitor, to ensure that [3 H]overflow represented [3 H]DA, rather
than [3 H]DA metabolites.

Following superfusion for 60 min, three 5- min samples (5 mL/sample) were collected to
determine basal [3 H]outflow. After collection of the third basal sample, slices from an
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individual rat were superfused for 60 min in the absence (0 nM; control) or presence of
analog (1 nM-10 µM) to determine the intrinsic activity of the analog, e.g., ability of the
analog to evoke [3 H]overflow. Each slice was exposed to only one concentration of
analog, which remained in the buffer through the completion of the experiment. After a
60 min superfusion in the absence or presence of analog, NIC (10 µM) was added to the
superfusion buffer and samples were collected for an additional 60 min to determine the
ability of the analog to inhibit NIC-evoked [3 H]DA overflow. At least one striatal slice in
each experiment was superfused for 60 min in the absence of analog, followed by
superfusion with only NIC (10 µM) to determine a NIC control for NIC-evoked [3 H]DA
overflow in the absence of analog. Using a repeated- measures design, striata from a
single rat were used to determine the ability of an analog to evoke [3 H]DA release
(intrinsic activity) and to determine analog-induced inhibition of NIC-evoked [3 H]DA
overflow (antagonist activity).

After collection of the superfusate samples, slices were retrieved from the chambers and
solubilized using 1 mL TS-2 tissue solubilizer. Scintillation cocktail (10 mL) was added
to the superfusate samples. The pH and volume of the solubilized tissue samples were
adjusted to those of the superfusate samples. Radioactivity in the superfusate and tissue
samples was determined by liquid scintillation spectroscopy (Packard model B1600 TR
Scintillation Counter, Downer’s Grove, IL).
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Rb+ Efflux Assay (α 4β2*)

Quaternary ammonium analog effects on

86

Rb+ efflux were determined using a

previously published method (Marks et al. 1995). Rat thalamus was homogenized and
centrifuged at 1000xg for 10 min at 4°C. The supernatant fraction was centrifuged at
12,000xg for 20 min at 4°C to obtain the synaptosomal fraction. Synaptosomes were
incubated for 30 min in 35 µl of uptake buffer (140 mM NaCl, 1.5 mM KCl, 2.0 mM
CaCl2 , 1.0 mM MgSO4 , 20 mM α-D-glucose; pH 7.5) containing 4 µCi of

86

Rb+.

86

Rb+

uptake was terminated by filtration of the synaptosomes onto glass fiber filters (6 mm;
Type A/E, Gelman Sciences, Ann Arbor, MI) under gentle vacuum (0.2 atm), followed
by three washes with superfusion buffer (0.5 ml each).
containing the

86

Subsequently, each filter

Rb+-loaded synaptosomes (39 ± 4.8 µg protein/µl) was placed on a 13

mm glass fiber filter (Type A/E) mounted on a polypropylene platform.

86

Rb+ efflux

assay buffer (125 mM NaCl, 5 mM CsCl, 1.5 mM KCl; 2 mM CaCl2 , 1 mM MgSO4 , 25
mM HEPES, 20 mM α-D-glucose, 0.1 µM TTX, 1.0 g/l bovine serum albumin; pH 7.5)
was superfused onto the synaptosomes at a rate of 2.5 ml/min. TTX and CsCl were
included in the buffer to block voltage-gated Na+ and K+ channels, respectively, and to
reduce the rate of basal

86

Rb+ efflux (Marks et al. 1995).

The intrinsic activity of the quaternary ammonium analog as well as the ability to inhibit
86

Rb+ efflux evoked by 1 µM NIC was determined. After 8 min of superfusion, samples

were collected (sample/18 s) for 5 min to determine basal

86

Rb+ efflux. Subsequently,

synaptosomes were superfused for 3 min with the quaternary ammonium analog to
determine the intrinsic properties of the analog. The exposure to the analog was followed
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by superfusion with buffer containing both the quaternary ammonium analog and NIC for
an additional 3 min, to determine the ability of the analog to inhibit NIC-evoked
efflux.

86

Rb+

Each aliquot part of thalamic synaptosomes was exposed to only one

concentration of quaternary ammonium analog. In each experiment, one synaptosomal
aliquot part was superfused in the absence of either compound to determine basal

86

Rb+

efflux over the course of the superfusion period, and another aliquot was superfused with
NIC (1 µM) to determine the effect of NIC on
quaternary ammonium analog.

86

Rb+ efflux in the absence of the

Samples were analyzed by liquid scintillation

spectroscopy (Packard model B1600 TR Scintillation Counter).

3.2.7.

Data Analysis

For analog induced inhibition of [3 H]NIC and [3 H]MLA binding, data were expressed as
specific [3 H]NIC or [3 H]MLA bound as a percentage of control and plotted as a function
of log analog concentration. The concentration (IC 50 ) of analog that inhibited specific
[3 H]NIC or [3 H]MLA binding by 50% were fit by a one-site binding competition model,
using nonlinear least-squares regression, such that Y = Bt + (Tp – Bt)/[1 + 10(logIC50 – X)•n ],
where Y is the specific [3 H]NIC or [3 H]MLA binding expressed as a percentage, X is the
logarithm of analog concentration, Bt and Tp are the minimum and maximum specific
[3 H]NIC and [3 H]MLA binding densities, respectively, and n is the pseudo-Hill
coefficient. The inhibition constant (Ki) for each analog was calculated from IC 50 values
using the Cheng-Prusoff equation [K i

= IC 50 /(1 + ligand/K d)], where c is the

concentration of free radioligand and Kd is the equilibrium dissociation constant of the
ligand.

97

In [3 H]DA overflow assays, fractional release of each superfusate sample was calculated
by dividing the total [3 H] collected in each sample by the total [3 H] present in the tissue at
the time of sample collection and was expressed as a percentage of total tissue tritium.
Basal [3 H]outflow was calculated from the average of the fractional release in three five
minute samples collected prior to the addition of analog to the superfusion buffer. Total
[3 H]overflow was calculated by summing the increases of [3 H] above the basal
[3 H]outflow, resulting from exposure to the analog, NIC, or both and subtracting the
basal [3 H]outflow for an equivalent period of analog exposure. The data were expressed
as percent of control and were fitted by non- linear, non-weighted least-squares regression
using the sigmoidal function, Y = Bt + (Tp – Bt)/[1 + 10(logIC50 – X)], where Y is the total
[3 H]overflow expressed as a percentage of NIC-evoked response, X is the logarithm of
analog concentration, Bt and Tp are the minimum response (held constant at 0%) and
maximum response (held constant at 100%), respectively, and log IC 50 value represents
the logarithm of analog concentration required to decrease NIC (10 µM)-evoked [3 H]DA
overflow by 50% of control levels. The effect of each analog on [3 H]DA overflow
(intrinsic activity) and its ability to inhibit NIC-evoked [3 H]DA overflow (inhibition
effect) was analyzed by one-way repeated- measure analysis of variance (ANOVA),
where analog concentration was a within subject factor (SPSS version 9.0, Chicago, IL);
where appropriate, Dunnett’s post hoc tests were performed to determine the
concentration of analog that significantly evoked or inhibited [3 H]DA overflow relative
to the control (buffer or NIC-evoked [3 H]DA overflow, respectively).

A two-way

repeated- measures ANOVA was performed to analyze the time course of the NIC-
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induced increase in the fractional release (within-subjects factor) for different
concentrations of the analog (within-subject factor).

IC 50 values for analog- induced

inhibition of NIC-evoked [3 H]DA overflow were determined using an iterative non-linear
least squares curve- fitting program, (PRISM version 3.0, Graph PAD Software, Inc., San
Diego, CA).

3.3.

Results and Discussion

Chemistry
Several N-n-alkyl quaternized ammonium salts were successfully synthesized. monoSubstituted N-n-alkylpyridinium, N-n-alkylpicolinium, and N-n-alkylnicotinamide salts
were prepared in similar manners, however, their purification work- up varied. All three
precipitated from solution upon reaction and were filtered to afford the crude salts. The
N-n-alkylpyridinium and N-n-alkylpicolinium salts were triturated with diethyl ether to
afford the pure quaternary ammonium salts.

The nicotinamide series were isolated

differently, due to the low solubility of the nicotinamide starting material in the diethyl
ether. These salts were isolated using both an initial diethyl ether wash, followed by an
aqueous dissolution and subsequent extraction with chloroform.

The N-n-

alkylnicotinium salts were synthesized in a different manner to ensure that the pyridino
nitrogen was selectively alkylated over the pyrrolidino nitrogen. Previous research by
Menshutkin demonstrated that tertiary amines react with alkyl halides resulting in
quaternary ammonium salt (Figure 3.3a) (Menshutkin 1890). In the nicotine molecule,
the pyrrolidine nitrogen is more reactive than the pyridine nitrogen. Therefore, the
pyridine nitrogen would be quaternized only after, or at the same time as, the pyrrolidine
nitrogen, causing a doubly quaternized species (Figure 3.3b). Due to the reactive nature
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of both nitrogens and to avoid the double quaternization, a protection of the pyrrolidino
nitrogen was necessary. Using the higher reactivity of the pyrrolidino nitrogen, a simple
acid protection step may be utilized to direct the Menshutkin towards the pyridine
nitrogen.

Acetic acid was used by Crooks et al. (1995) to achieve this selective

alkylation of the pyridino nitrogen with excellent results (Figure 3.3c).

Figure 3.3 The Menshutkin reaction and its use in quaternizing nicotine
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However, the resulting work- up was modified in the current synthesis to increase the
yield and decrease the labor-intensive work- up. The existing synthetic route called for
the protonated NIC molecule and the iodoalkane reactant to be stirred for three days at
room temperature.

The increase in the reaction temperature due to the refluxing

increased the yield of the reaction in the present synthesis. The previous synthesis also
involved a time-consuming basification and subsequent removal of water at increased
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temperature followed by a 24-hour reflux in chloroform to remove the excess NIC. This
resulted in a loss of the N-n-alkylnicotinium salt due to the salt having some solubility in
chloroform.

In the current synthesis, after the basification step, the mixture was

sequentially treated with diethyl ether and chloroform to remove the excess NIC and the
corresponding N-n-alkylnicotinium salt, respectively, without evaporating the aqueous
layer. This procedure removed the two previous time-consuming steps, and increased the
overall yield of the product.

The bis-N,N’-alkyl quaternary ammonium salts were prepared similarly to their
corresponding mono-alkyl quaternized ammonium salts. bis-N,N’-Alkylpyridinium salts
and bis-N,N’-alkylpicolinium salts, as well as bis-N,N’-alkylquinolinium salts and bisN,N’-alkylisoquinolinium salts, were isolated in high yields when diethyl ether was
utilized to remove the excess reactant.

The bis-N,N’-alkylnicotinium salts were

synthesized via a similar synthetic route to that utilized for the corresponding monoalkylnicotinium salts, although the final purification step was modified. The diethyl ether
extraction step removed the unreacted NIC, but the subsequent chloroform extraction
revealed the presence of a product from an unexpected side reaction; a mono-substituted
N-alkylnicotinium salt with an acetate terminating the carbon chain instead of another
NIC molecule was synthesized and had greater solubility than the bis-N,N’alkylnicotinium salt in chloroform. During the reaction, it is possible that the acetate ion
displaced the iodide or bromide causing the impurity.

Alternatively, the bis-N,N’-

alkylnicotinium salt may have formed but over the course of the reaction the a carbon to
the quaternized pyridine nitrogen could have been attacked by the acetate ion, resulting in
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the mono-substituted N-alkylnicotinium salt with the terminal acetate moiety (Figure 3.4).
The aqueous layer containing the bis-N,N’-alkylnicotinium salt was evaporated under
reduced pressure and chloroform was added to extract the bis-N,N’-alkylnicotinium salt.
The chloroform layer was dried using magnesium sulfate, filtered, and evaporated under
reduced pressure to afford the final product.

Figure 3.4 Formation of the acetate impurity
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It is important to note, that despite several different functionalities and charges on the
molecules, the mono- and bis-quaternary ammonium salts all demonstrated chloroform
solubility.

Pharmacology of the mono-Substituted Quaternary Ammonium Salts
N-n-Alkylpyridinium salts
N-n-Alkylpyridinium salts with chain lengths ranging from one to twenty carbon units
weakly inhibited [3 H]NIC binding to rat striatal membranes (see Table 3.1 for affinity
values). Salts with chain lengths less than 15 carbons completely inhibited [3 H]NIC
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binding. The C20 analog NEcPB inhibited binding by only 25%. The binding affinities
(Ki) at the a4ß2* nAChR subtypes ranged from 9-20 µM for the C1 -C11 and C15 analogs.
The C12 and C20 chain length salts were not active (Ki > 100). No significant linear
relationship was found between compound affinity and carbon chain length. The N-nalkylpyridinium salts did not inhibit [3 H]MLA binding, and thus had no significant
affinity at the α7* nAChR subtype (Table 3.1).

Initial screens at two concentrations, i.e. 0.1 and 1.0 µM, of analog, C1 -C12 , were
determined for the N-n-alkylpyridinium series in the [3 H]DA overflow assay. Chain
lengths of nine or less carbons were not active; however, carbon chain lengths greater
than nine were found to significantly inhibit NIC-evoked [3 H]DA overflow by 70-90%.
Evaluation of the activities of these compounds, for both intrinsic and inhibitory activity,
over the full concentration range (0.01-100 µM) was performed. NUPI (C 11 ), NDDPI
(C 12 ), and NPDPB (C 15 ) increased [3 H]DA overflow at 10 µM and NDPI (C 10 ), NEcPB
(C 20 ) increase overflow at 100 µM. Concentrations that elicited intrinsic activity were
not included in the analysis of inhibition of NIC-evoked DA overflow. Carbon chain
lengths greater than nine carbons, i.e. NDPI, NUPI, NDDPI, NPDPB, and NEcPB all
inhibited NIC-evoked [3 H]DA overflow in the high nanomolar concentration range (IC 50
values = 120 – 490 nM, Table 3.1). For each analog, repeated measures one-way
ANOVA revealed significant concentration-dependent inhibition of nicotine-evoked
[3 H]DA overflow: NDPI (C10), F5,35 = 29.44, p < 0.0001; NUPI (C11), F4,29 = 24.58, p <
0.0001; NDDPI (C12), F3,23 = 11.07, p < 001; NPDPB (C15), F5,18 = 24.31, p < 0.001;
NEcPB (C20), F5,15 = 9.29, p < 0.001. NDPI, NUPI, and NDDPI all inhibited overflow
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completely (Imax = 100%), whereas NPDPB and NEcPB only inhibited overflow by a
maximum of 45-55%.

N-n-Alkylpicolinium salts
N-n-Alkylpicolinium salts exhibited similar properties to the N-n-alkylpyridinium salts in
their binding affinities at α4β2* and α7* nAChR subtypes. Analogs with chain lengths
of C8 -C12 had weak or no affinity in the [3 H]NIC binding assay, and had no affinity in the
[3 H]MLA binding assay (Table 3.2). In the NIC-evoked [3 H]DA overflow assay, NOPiI
(C8 ) and NDPiI (C10 ) did not exhibit intrinsic activity up to 1.0 µM, but NDDPiI (C12 ) did
evoke overflow at > 1.0 µM. Due to the intrinsic activity, the concentration 1.0 µM of
NDDPiI was not used in determining the inhibitory concentration of the compound. In
this series of compounds, NDDPiI was the most potent of the N-n-alkylpicolinium salts
tested at the nAChR subtypes mediating NIC-evoked DA overflow (IC 50 = 30 nM) and
there was an increase of inhibitory activity in this series as the carbon chain increased
(Table 3.2). Interestingly, NDDPiI only inhibited overflow by 63%.

N-n-alkylnicotinamide salts
N-n-alkylnicotinamide salts were not active in either of the binding assays and were not
tested in the NIC-evoked DA release assay (Table 3.3).
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I

NPrPI
NBuPI
NPePI
NHxPI
NHpPI
NOPI
NNPI

53d
53e
53f
53g
53h
53i

NEPI

53b
53c

NMPI

Name

53a

N
R

Compound

Nonyl

Octyl

Heptyl

Hexyl

Pentyl

Butyl

Propyl

Ethyl

Methyl

R

19.0 (19.0 – 22.1)

20.1 (16.3 – 24.8)

15.0 (13.0 – 17.2)

9.07 (6.12 – 13.5)

8.72 (5.68 – 13.4)

9.65 (7.57 - 12.3)

42.3 (30.2 – 59.3)

28.7 (22.3 – 37.0)

20.1 (15.6 – 25.9)a

Assay, Ki (µM)

[3 H]NIC Binding

61.8 (3.35 – 1142)

>100

>100

>100

67.7 (2.31 -1980)

>100

>100

>100

>100

Assay, Ki (µM)

[3 H]MLA Binding

Pharmacological Assays

Table 3.1 Pharmacological Data Derived from the mono-Alkylated Pyridinium Salts

>1.0

>1.0

>1.0

>1.0

>1.0

>1.0

>1.0

>1.0

>1.0

Assay, IC 50 (µM)

[3 H]DA Release
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a

NUPI
NDDPI
NPeDPB
NEcPB

53l
53m
53n

NDPI

Name

53k

53j

N
R

Ecosinyl

Pentdecyl

Dodecyl

Undecyl

Decyl

R

>100

38.0 (28.2 – 51.3)

>100

17.0 (14.4 – 20.1)

16.7 (13.6 – 20.4)

Assay, Ki (µM)

[3 H]NIC Binding

Data represent mean (95% confidence intervals)

X

Compound

>100

>100

>100

>100

>100

Assay, Ki (µM)

[3 H]MLA Binding

Pharmacological Assays

0.12 (0.01 – 2.38)

0.32 (0.11 – 0.87)

0.26 (0.02 – 4.23)

0.49 (0.01 – 16.9)

0.13 (0.02 – 0.87)

Assay, IC 50 (µM)

[3 H]DA Release

Table 3.1 (continued) Pharmacological Data Derived from the mono-Alkylated Pyridinium Salts
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a

NNPiI
NDPiI
NUPiI
NDDPiI

54c

54d

54e

NOPiI

Name

54b

54a

R

Data represent mean + S.E.M

I

N

CH3

Compound

b

>100

>100

>100

>100

26 + 3.6b
>100

>100

>100

62 + 17a

>100

Assay, Ki (µM)

[3 H]MLA Binding

From 3 concentrations, c ND = Not Determined

Dodecyl

Undecyl

Decyl

Nonyl

Octyl

R

Assay, Ki (µM)

[3 H]NIC Binding

Pharmacological Assays

Table 3.2 Pharmacological Data Derived from the mono-Alkylated 3-Picolinium Salts

0.03 + 0.02

ND

0.3 + 0.05

NDc

1.0 + 0.09

Assay, IC 50 (µM)

[3 H]DA Release
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a

NNNAI
NDNAI
NUNAI
NDDNAI

55c

55d

55e

NONAI

Name

55b

55a

N
R

NH2

ND = Not Determined

I

O

Dodecyl

Undecyl

Decyl

Nonyl

Octyl

R

>100

>100

>100

>100

>100

Assay, Ki (µM)

[3 H]NIC Binding

>100

>100

>100

>100

>100

Assay, Ki (µM)

[3 H]MLA Binding

Pharmacological Assays

Table 3.3 Pharmacological Data Derived from the mono-Alkylated Nicotinamide Salts

ND

ND

ND

ND

NDa

Assay, IC 50 (µM)

[3 H]DA Release
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I

NENI
NPNI
NnBNI
NPeNI
NHxNI
NHpNI
NONI
NNNI

56c
56d
56e
56f
56g
56h
56i

NMNI

56a
56b

Name

CH3

N
N
R

H

Compound

Nonyl

Octyl

Heptyl

Hexyl

Pentyl

Butyl

Propyl

Ethyl

Methyl

R

0.84 (0.73 – 0.95)

19.7 (15.4 – 25.1)

2.06 (1.85 – 2.28)

< 100

28.3 (18.4 – 43.5)

76.0 (13.5 – 429)

92.4 (24.0 –375)

>100

NDa
0.53 (0.46 – 0.60)

>100

>100

<100

>100

Assay, Ki (µM)

[3 H]MLA Binding

10.9 (9.70 – 12.3)

21.5 (18.2 – 25.3)

1.04 (0.76 – 1.43)

3.53 (2.77 – 4.48)

Assay, Ki (µM)

[3 H]NIC Binding

Pharmacological Assays

Table 3.4 Pharmacological Data Derived from the mono-Alkylated Nicotinium Salts

0.21 (0.09 – 0.48)

0.62 (0.20 – 1.94)

0.80 (0.37 – 1.71)

3.45 (3.15 – 26.3)

ND

9.07 (3.15 – 26.3)

37.4 (9.88 – 141)

ND

24.6 (1.65 – 367)

Assay, IC 50 (µM)

[3 H]DA Release
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a

NUNI
NDDNI

56l

NDNI

56j

56k

Name

Dodecyl

Undecyl

Decyl

R

0.14 (0.11 – 0.17)

NDb

0.09 (0.08 – 0.11)a

Assay, Ki (µM)

[3 H]NIC Binding

>100

<100

~100

Assay, Ki (µM)

[3 H]MLA Binding

Pharmacological Assays

Data represent mean (95% confidence intervals) b ND = Not Determined

I

CH3

N

N
R

H

Compound

Table 3.4 continued Pharmacological Data Derived from the mono-Alkylated Nicotinium Salts

0.009 (0.003 – 0.03)

ND

>100

Assay, IC 50 (µM)

[3 H]DA Release

N-n-Alkylnicotinium salts
N-n-Alkylnicotinium salts demonstrated a wide range of affinities in the [3 H]NIC binding
assay (90 nM –20 µM, Table 3.4). The C10 and C12 analogs (NDNI and NDDNI) had the
highest affinities, Ki = 90 nm and 140 nm, respectively. A linear relationship between Nn-alkyl chain length and analog affinity was determined, with the exception of the N-noctyl compound, NONI, which had one of the lowest affinities in the series. The N-nalkylnicotinium salts all demonstrated low affinity in the [3 H]MLA binding assay (Table
3.4).

In the evaluation of the N-n-alkylnicotinium salts to inhibit NIC-evoked [3 H]DA
overflow, analogs with chain lengths greater than six carbons demonstrated intrinsic
activity at concentrations greater than 1 µM. Longer chain compounds were more likely
to evoke significant amounts of [3 H]overflow. NDNI (C 10 ) had the lowest concentration
necessary for evoking [3 H]overflow at 1 µM, followed by NDDNI (C 12 ) at 10 µM, and
NONI (C8 ), NHpNI (C 7 ), and NHxNI (C 6 ) at 100 µM.

NNNI (C 9 ) did not evoke

[3 H]overflow at any concentration tested. For each analog, repeated measures one-way
ANOVA revealed significant concentration-dependent inhibition of nicotine-evoked
[3 H]DA overflow: NMNI (C 1 ), F3,15 = 5.02, p < 0.05; NPNI (C3 ), F6,38 = 4.33, p < 0.005;
NnBNI (C 4 ), F3,19 = 8.83, p < 0.005; NHxNI (C 6 ), F5,20 = 3.81, p < 0.05; NHpNI (C 7 ),
F5,24 = 26.3, p < 0.0001; NONI (C8 ), F5,27 = 10.5, p < 0.0001; NNNI (C 9 ), F5,23 = 4.58, p
< 0.01; and NDDNI (C 12 ), F4,18 = 9.00, p < 0.001. Evaluation of the inhibition of NICevoked [3 H]DA overflow by the N-n-alkylnicotinium salts revealed that NPNI was the
least potent of the N-n-alkylnicotinium analogs (IC 50 = 37 µM), while NnBNI and
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NHxNI also exhibited low micromolar activity (IC 50 = 9 and 3 µM, respectively).
NHpNI, NONI, and NNNI had IC 50 values in the range 0.2 - 0.8 µM. NDDNI, the C12
analog, had the highest inhibitory potency with an IC 50 value of 9 nM (Table 3.4).

Structure Activity Relationship of the mono-Substituted Quaternary Ammonium
Salts
The affinities of N-n-alkylnicotinium compounds in the [3 H]NIC binding assay revealed
that as the carbon chain was increased so was the affinity for the α4β2* receptor.
Subsequent evaluation of these compounds in the functional Rb 86+ efflux assay
demonstrated that N-n-alkylnicotinium compounds with good affinity in the [3 H]NIC
binding assay, were receptor antagonists at the α4β2* nAChR subtype. Analogs with
longer n-alkyl chain lengths of nine, ten, and twelve all had nanomolar affinities for the
α4β2*

nAChR

subtype,

with

the

N-n-decylnicotinium

(NDNI)

and

N-n-

dodecylnicotinium (NDDNI) having the highest affinities for the receptor with Ki values
of 90 nM and 140 nM, respectively. These Ki values are comparable to that of the
classical nAChR antagonist DHβE, which has a Ki value of 149 nM at the α4β2*
receptor subtype (Wilkins et al. 2003). Interestingly, a one-carbon deletion from the
nine-carbon chain analog, to afford the N-n-nonylnicotinium salt (NNNI), results in a
twenty-fold decrease in affinity for the α4β2* receptor subtype. Therefore, a subtle
change to the length of the carbon chain may cause a large difference in activity. This is
further supported by the inactivity of the C8 compound, N-n-octylnicotinium, which had
low affinity in the [3 H]NIC binding assay. The higher affinities in the longer chain
compounds may be due to an increase in the lipophilic interaction of the carbon chain and
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the hydrophobic regions of the binding site. This interaction may have a stabilizing
effect on the compound-receptor complex, increasing the affinity for the C9 -C12
compounds of this series of compounds.

In addition to the carbon chain length, the pyrrolidine ring of this series of compounds
also appears to play an important role in the interaction at the binding site. The N-nalkylnicotinium salts with increased numbers of carbon units all demonstrated a greater
affinity for the α4β2* binding site over their corresponding N-n-alkylpyridinium, N-nalkylpicolinium, and N-n-alkylnicotinamide salts. Complete removal of the pyrrolidine
ring in the N-n-alkylpyridinium series resulted in a complete loss in affinity for the
α4β2* receptor. In the N-n-alkylpicolinium series, the importance of a 3-substituent was
explored. However, the low affinity of these salts in the [3 H]NIC binding assay indicates
that a simple methyl group in the three position of the pyridine ring does not afford
compounds with high affinity for the α4β2* binding site. The nicotinamide moiety is a
somewhat larger and more polar substituent that incorporates a second nitrogen atom into
the receptor-ligand model. Due to the lack of activity of these molecules at the α4β2*
binding site, and since the nicotinamide nitrogen is not basic in nature, it can be assumed
that it is not necessarily the size of the 3-substituent that promotes interaction with the
receptor but rather the incorporation of an appropriate functional moiety. Therefore, a
basic nitrogen, such as that in the pyrrolidine ring may be important for recognition by
the high affinity [3 H]NIC binding site on the α4β2* receptor subtype.
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Several of the quaternized ammonium salts were potent antagonists in the NIC-evoked
[3 H]DA overflow assay, with the N-n-dodecylnicotinium analog (NDDNI) exhibiting the
greatest activity at the nAChR subtypes mediating DA release (IC 50 = 9 nM); this
inhibition is significantly greater than that exhibited by DHβE (IC50 = 1.6 µM).
However, the N-n-alkylpyridinium and N-n-alkylpicolinium salts with similar N-n-alkyl
chain lengths also antagonized the receptor subtype at higher nanomolar concentrations,
with IC 50 values of 260 nM (NNDPI) and 30 nM (NDDPiI). The N-n-alkylpicolinium
and N-n-alkylnicotinium salts both demonstrate a linear relationship between antagonist
activity and carbon chain length at the nAChR subtypes that mediate DA release. The
removal of the pyrrolidine ring did not completely eliminate the ability of these N-nalkylpyridinium salts to interact with this class of nAChR subtypes

The quaternary ammonium salts demonstrated low activities in the [3 H]MLA binding
assay. The N-n-alkylnicotinium molecules only inhibited binding with carbon chain
lengths of C6 , C7 , C8 (Ki = 28.3-92.4 µM). These values are at least ten fold less active at
the receptor than NIC, a weak agonist. The N-n-alkylpyridinium compounds also did not
exhibit affinity for α7* nAChRs, with only two compounds, NPePI (C 6 ) and NNPI (C 9 ),
having Ki values below 100 µM (67.7 and 61.8 µM, respectively). Therefore, these
compounds are not active at the α7* receptor subtype.

Pharmacology of the bis-Substituted Quaternary Ammonium Salts
N,N’-bis-Alkylpyridinium salts
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N,N’-bis-Alkylpyridinium salts with n-alkyl chain lengths ranging from six to twelve
carbon atoms were evaluated in the [3 H]NIC binding assay and had weak affinities for the
α4β2* nAChR subtype binding site (Table 3.5). These compounds did show a general
trend of increasing affinity as the n-alkyl carbon chain length was increased. Compound
bPDDB, had the highest affinity for the α4β2* receptor subtype with a Ki value of 9.15
µM.

The N,N’-bis-alkylpyridinium salts with cha in lengths ranging from C6 -C12

demonstrated low affinity or no affinity with respect to [3 H]MLA binding, and thus
exhibited no significant interaction with the α7* nAChR subtype (Table 3.5).

The C12 analog, bPDDB, had no intrinsic activity at any of the concentrations tested
(0.001-10 µM) in the [3 H]DA overflow assay. bPDDB inhibited NIC-evoked [3 H]DA
overflow with an IC 50 value of 1.0 µM. No other N,N’-bis-alkylpyridinium compounds
were evaluated at nAChR subtypes mediating DA release (Table 3.5).

N,N’-bis-Alkylnicotinium salts
N,N’-bis-Alkylnicotinium salts were also evaluated in the [3 H]NIC binding assay. The
C10 (bNDI) and C11 (bNUB) analogs had the highest affinities for the α4β2* receptor
subtype, with Ki values of 330 and 430 nM, respectively (Table 3.6). Moreover, bNDI
and bNUB inhibited NIC-evoked
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Rb+ efflux from rat thalamic synaptosomes (IC 50 =

3.76 + 1.1 µM and 5.22 + 1.4 µM, respectively), without producing intrinsic activity.
Several other compounds, i.e. the C6 -C9 and C12 analogs, had low micromolar affinities
(Ki = 1.54 - 20.0 µM). None of the N,N’-bis-alkylnicotinium salts were active in the
[3 H]MLA binding assay (Table 3.6).
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In addition to the α4β2* and α7 receptor subtype assays, the N,N’-bis-alkylnicotinium
C12 analog, bNDDB, was evaluated for both intrinsic and inhibitory activity in the
[3 H]DA overflow assay. bNDDB had intrinsic activity at 10 µM. The C12 salt afforded
an IC50 value of 3.30 µM in the NIC-evoked [3 H]DA overflow assay (Table 3.6).

N,N’-bis-Alkylpicolinium salts
N,N’-bis-Alkylpicolinium salts generally did not exhibit high affinities at the α4β2*
nAChR subtype, with Ki values for the C9 , C11 , C12 analogs in the high micromolar range
(48.6-79.9 µM) and the C6 , C10 and C11 compounds had no affinity at this nAChR subtype
(>100 µM). The N,N’-bis-alkylpicolinium salts were not active in the [3 H]MLA binding
assay (Table 3.7).

The C12 N,N’-bis-alkylpicolinium analog, bPiDDB, was evaluated for its intrinsic and
inhibitory behavior in the [3 H]DA overflow assay. bPiDDB had no intrinsic activity in
[3 H]DA overflow assay at any of the concentrations tested (0.001-10 µM).

The

compound was very potent in inhibiting NIC-evoked [3 H]DA overflow. With an IC 50
value of 2 nM, this compound is one of the most potent compounds in inhibiting NICevoked DA release (Table 3.7). Interestingly, bPiDDB inhibited NIC-evoked [3 H]DA
overflow by a maximum of only 50%.

Due to the high potency of bPiDDB to inhibit NIC-evoked [3 H]DA overflow, all the
N,N’-bis-alkylpicolinium analogs were tested for intrinsic activity and for their ability to
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inhibit [3 H]DA overflow. Generally, N,N’-bis-alkylpicolinium analogs did not exhibit
intrinsic activity in this assay. One-way ANOVAs revealed significant concentrationdependent inhibition for each analog: bPiOI (C 8 ), F5,19 = 4.441, p = 0.007; bPiNB (C 9 ), F
5,19 =

4.053, p = 0.011; bPiDI (C 10 ), F5,23 = 7.346, p < 0.001; bPiUB (C 11 ), F5,28 = 11.750,

p < 0.001, bPiDDB (C 12 ), F5,23 = 13.282, p < 0.001. Contrary to what was observed in
the pyridinium series, the shorter chain length compounds, i.e. C8 and C10 , were potent
antagonists at the nAChR subtype responsible for mediating DA release. However, the
antagonism pattern did not seem to increase as carbon chain length increased, as has been
observed in several of the other series. The C8 (bPiOI) and C10 (bPiDI), analogs had low
nanomolar activities (IC 50 = 10 and 30 nM, respectively), while the C9 (bPiNB) and C11
(bPiUB), analogs had low micromolar activities (IC 50 = 1.5 - 1.6 µM) and the C6 analog
(bPiHxI), was inactive (Table 3.7).

All the active N,N’-bis-alkylpicolinium salts

inhibited NIC-evoked [3 H]DA overflow similar to bPiDDB, with a maximum of ~50%
(Imax = 50%).

N,N’-bis-Alkylisoquinolinium and N,N’-bis-alkylquinolinium salts
N,N’-bis-Alkylisoquinolinium and N,N’-bis-alkylquinolinium salts were evaluated in the
[3 H]NIC binding assay and generally had low affinities for the α4β2* nAChR (Tables 3.8
and 3.9). The C6 , C8 , C9 , C11 , and C12 N,N’-bis-alkylisoquinolinium analogs had low to
moderate micromolar affinities (Ki = 6.10-65.5 µM) for the α4β2* nAChR subtype,
while the C10 analog had no affinity (Ki > 100 µM). The pharmacological profile of the
N,N’-bis-alkylquinolinium salts was similar to that of the N,N’-bis-alkylisoquinolinium
salts in the [3 H]NIC binding assay, with the C6 , C9 , and C11 analogs exhibiting only
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moderate micromolar affinities (Ki = 22.5-39.3 µM) for the α4β2* nAChR subtype,
while the C8 , C10 , and C12 analogs had no affinity (Ki > 100 µM). Interestingly, analogs
in both the N,N’-bis-alkylisoquinolinium series and the N,N’-bis-alkylquinolinium series
were all active in the [3 H]MLA binding assay, with Ki values in the low micromolar
range (1.61-16.0 µM, Tables 3.8 and 3.9); the two most potent analogs in these two
groups

were

the

C12

analogs,

(Ki = 1.61 and 2.21 µM, respectively).
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bQDDB

and

bIQDDB
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a

bPNB
bPDI
bPUB
bPDDB

57d

57e

57f

57g

Data represent mean + S.E.M

bPOI

bPPeI

Name

57c

n

bPHxI

57a

N

57b

2X

N

Compound

b

>100

9.15 + 0.17

14.0 + 3.21

18.7 + 3.09

24.2 + 1.19

34.3 + 2.74

97.8 + 17.5a

ND = Not Determined

12

11

10

9

8

6

5

n

Assay, Ki (µM)

[3 H]NIC Binding

33 + 4.6

57.0 + 4.89

>100

>100

>100

>100

>100

Assay, Ki (µM)

[3 H]MLA Binding

Pharmacological Assays

Table 3.5 Pharmacological Data Derived from the bis-Alkylpyridinium Salts

1.0 + 0.38

ND

>1.0

ND

>1.0

NDb

>1.0

Assay, IC 50 (µM)

[3 H]DA Release

a

bNNB
bNDI
bNUB
bNDDB

61c
61d
61e
61f

bNHxI
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bNOI

n

61b

61a

H

N

N
CH3

Compound

12

11

10

9

8

6

n

Data represent mean + S.E.M b ND = Not Determined

N

2X

N

H

1.95 + 0.19

0.43 + 0.06

0.33 + 0.01

5.03 + 0.80

1.54 + 0.17

20.0 + 2.84a

Assay, Ki (µM)

[3 H]NIC Binding

>100

>100

>100

>100

>100

>100

Assay, Ki (µM)

[3 H]MLA Binding

Pharmacological Assays

Table 3.6 Pharmacological Data Derived from the bis-Alkylnicotinium Salts

CH3
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0.17 + 0.13

ND

ND

ND

ND

NDb

Assay, IC 50 (µM)

[3 H]DA Release
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a

bPiNB
bPiDI
bPiUB
bPiDDB

58c

58d

58e

58f

bPiHxI

Name

bPiOI

n

58b

58a

N

Data represent mean + S.E.M

H3C

2X

N

CH3

Compound

12

11

10

9

8

6

n

48.6 + 17.2

69.2 + 28.9

>100

>100

>100

>100

79.9 + 16.6a
>100

>100

>100

Assay, Ki (µM)

[3 H]MLA Binding

>100

>100

Assay, Ki (µM)

[3 H]NIC Binding

Pharmacological Assays

Table 3.7 Pharmacological Data Derived from the bis-Alkylpicolinium Salts

0.002 + 0.001

1.12 + 0.65

0.18 + 0.11

5.81 + 5.07

0.30 + 0.18

>100

Assay, IC 50 (µM)

[3 H]DA Release
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a

bIQNB
bIQDI
bIQUB
bIQDDB

60c

60d

60e

60f

bIQHxI

Name

bIQOI

n

60b

60a

N

N

Data represent mean + S.E.M

2X

Compound

12

11
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9

8

6

n

6.10 + 0.73

9.02 + 1.56

>100

7.89 + 0.92

65.5 + 14.5

17.9 + 3.59a

Assay, Ki (µM)

[3 H]NIC Binding

2.21 + 0.25

5.46 + 0.78

7.25 + 3.02

5.95 + 1.01

11.7 + 5.63

16.0 + 1.92

Assay, Ki (µM)

[3 H]MLA Binding

Pharmacological Assays

Table 3.8 Pharmacological Data Derived from the bis-Alkylisoquinolinium Salts

0.04 + 0.03

0.05 + 0.03

0.09 + 0.04

>100

1.69 + 1.18

1.87 + 1.11

Assay, IC 50 (µM)

[3 H]DA Release
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a

bQNB
bQDI
bQUB
bQDDB

59c

59d

59e

59f

bQHxI

Name

bQOI

n

59b

59a

N

N

Data represent mean + S.E.M

2X

Compound

Dodecyl

Undecyl

Decyl

Nonyl

Octyl

Hexyl

n

>100

37.8 + 8.65

>100

22.5 + 1.30

>100

39.3 + 5.59a

Assay, Ki (µM)

[3 H]NIC Binding

1.61 + 0.25

2.58 + 0.46

7.81 + 1.90

3.58 + 0.45

2.39 + 0.69

13.3 + 2.12

Assay, Ki (µM)

[3 H]MLA Binding

Pharmacological Assays

Table 3.9 Pharmacological Data Derived from the bis-Alkylquinolinium Salts

0.02 + 0.008

0.21 + 0.18

>1

0.24 + 0.17

0.06 + 0.03

0.50 + 0.46

Assay, IC 50 (µM)

[3 H]DA Release

The compounds in the N,N’-bis-alkylisoquinolinium and N,N’-bis-alkylquinolinium
series were evaluated for both intrinsic activity and their ability to inhibit NIC-evoked
[3 H]DA overflow. The C8 and C12 N,N’-bis-alkylquinolinium salts, bQOI and bQDDB,
and the C10 N,N’-bis-alkylisoquinolinium salt, bIQDDB, elicited [3 H]DA overflow at 10
µM. The other N,N’-bis-alkylquinolinium and N,N’-bis-alkylisoquinolinium salts, did
not exhibit intrinsic activity at any concentration tested N,N’-bis-alkylquinolinium. Oneway ANOVA revealed significant concentration-dependent inhibition for bQHxI (C 6 ),
F5,24 = 5.055, p = 0.002; bIQOI (C8 ), F4,14 = 6.428, p = 0.003; bQNB (C 9 ), F5,19 = 4.872,
p = 0.004; bQDI (C 10 ), F4,14 = 3.294, p = 0.033; bQUB (C 11 ), F5,19 = 7.873, p < 0.001;
bQDDB (C 12 ), F5,24 = 9.16, p < 0.001; bIQOI (C8 ), F5,20 = 4.141, p = 0.01; bIQDI (C 10 ),
F4,16 = 4.835, p < 0.001, bIQUB (C 11 ), F5,20 = 4.157, p < 0.001; bIQDDB (C 12 ), F5,22 =
3.827, p < 0.05.

N,N’-bis-alkylisoquinolinium salts exhibited antagonist activity at

nAChR subtypes that mediate DA release (IC 50 = 20-90 nM). In addition, the analogs
only partially inhibited NIC-evoked [3 H]DA overflow (Imax = 62-78%).
, F5,19 = 4.441, p = 0.007; bPiNB (C 9 ), F

5,19

= 4.053, p = 0.011; bPiDI (C 10 ), F5,23 =

7.346, p < 0.001; bPiUB (C 11 ), F5,28 = 11.750, p < 0.001, bPiDDB (C 12 ),

Structure Activity Relationship of the bis-Substituted Quaternary Ammonium Salts
At muscle-type peripheral receptors, the compounds with only a trimethylammonium
headgroup, were found to require an optimum chain length of ten carbon units (DEC).
Although DEC had three orders of magnitude lower affinity for the α4β2* subtype
compared to NIC (Ki = 5.73 + 0.76 µM versus 0.0014 + 0.0001 µM) for the α4β2*
subtype and had no affinity for the α7* subtype, it is apparent that replacing the N,N’-
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trimethylammonium moieties of DEC with azaaromatic moieties, such as nicotinium
moieties (α4β2*) and quinolinium and isoquinolinium moieties (α7*), affords molecules
with good affinity for nAChR subtypes.

Of particular interest is the finding that two compounds in this study exhibited high
selectivity at the α4β2* nAChR subtype. In this respect, the N,N’-bis-alkylnicotinium
analogs, bNDI and bNUB exhibit low nanomolar affinities (330 and 430 nM,
respectively) for the α4β2* nAChR subtype, and functionally inhibited NIC-evoked
86

Rb+ efflux, while demonstrating no affinity for the α7* nAChR subtype, these data

indicate that these two analogs are selective α4β2* nAChR subtype antagonists. As seen
in the mono-quaternary ammonium series, the importance of the pyrrolidino moiety to
achieve activity at the α4β2* subtype is also seen in the bis-quaternary ammonium series.
The N,N’-bis-alkylnicotinium series, when compared to the N,N’-bis-alkylpyridinium and
N,N’-bis-alkylpicolinium series, demonstrates a two- fold decrease in affinity in the
[3 H]NIC binding assay for the most potent compounds.

Additionally, the N,N’-bis-

alkylisoquinolinium and N,N’-bis-alkylquinolinium series had low affinity for the α4β2*
subtype, indicating that increased aromaticity, i.e. 6π system to 10π system, is not
necessarily an important requirement for binding.

In contrast, replacing the bis- nicotinium headgroups with bis-quinolinium and bisisoquinolinium moieties afforded compounds with no affinity for the α4β2* nAChR, but
which had similar affinity to NIC and d-TBC (Ki values = 0.45 + 0.09 µM and 4.79 +
0.20 µM, respectively) at the α7* nAChR subtype. Although no correlation between
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carbon chain length and affinity was observed in either series, the C12 analogs in the
N,N’-bis-alkylisoquinolinium (bIQDDB) and N,N’-bis-alkylquinolinium (bQDDB) series
had the highest affinities, and when the bis-quinolinium and bis- isoquinolinium
headgroups were replaced with simple bis-pyridinium moieties, only the longer chain
molecules were active (C 11 and C12 analogs). The presence of a 3-position methyl
substituent in the pyridinium ring in the N,N’-bis-alkylpicolinium series appears to
decrease the affinity for the α7* nAChR subtype, as is seen in the loss of α7* affinity in
the bis-nicotinium and bis-picolinium series.

The bis-quinolinium analog, bQDDB

exhibited a Ki value of 1.61 µM for the α7* nAChR subtype and this compound had no
affinity for the α4β2* nAChR subtype. Therefore, it appears that increased aromaticity is
an important structural requirements for the α7* nAChR subtype and not for the α4β2*
nAChR subtype. The N,N’-bis-alkylisoquinolinium and N,N’-bis-alkylquinolinium series
is the first active compound in both the mono- and bis-azaaromatic series for the a7*
nAChR subtype.

In initial experiments, the C12 analogs of the bis- azaaromatic series were evaluated in the
NIC-evoked [3 H]DA overflow, because the C12 N-n-alkylnicotinium analog, NDDNI,
was the most potent antagonist at the nAChR subtypes mediating DA release. In all of
the bis-azaaromatic series, the C12 analogs were able to inhibit NIC-evoked [3 H]DA
overflow at low micromolar or low nanomolar concentrations.

The most potent

antagonist in the series was the C12 analog in the N,N’-bis-alkylpicolinium series. Taken
together with the data from the α4β2* and α7* assays, this compound is highly selective
as an antagonist at the nAChR subtype mediating DA release. Four to five orders of
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magnitude separate the affinity for the nAChR subtypes mediating DA release with those
for the α4β2* and α7* nAChR subtypes. Additionally, other analogs in the N,N’-bisalkylpicolinium series of compounds were evaluated and all were found to have
inhibitory activity in the NIC-evoked [3 H]DA overflow assay, although none were as
potent as bPiDDB. The simple C8 and C10 analogs N,N’-bis-alkylpyridinium series were
also tested to determine their activity and surprisingly, none of the N,N’-bisalkylpyridinium analogs had any activity at concentrations below 1 µM. This represents
a 10-fold decrease in potency for the corresponding C8 and C10 N,N’-bis-alkylpicolinium
analogs and a 1000- fold decrease for the C12 analogs. Surprisingly, the C12 N,N’-bisalkylnicotinium analog was not as active as bPiDDB, indicating that the bulky
pyrrolidino moiety maybe hindering binding at the nAChR subtypes mediating DA
release and therefore decreasing the activity. The increased aromaticity of the N,N’-bisalkylisoquinolinium and N,N’-bis-alkylquinolinium series also led to an increase in
antagonist activity at nAChR subtypes mediating NIC-evoked DA release but none of the
analogs in these series of compounds approached the inhibitory activity of bPiDDB.
Thus, the 3- methyl substituent on the picolinium ring is important for determining NICevoked [3 H]DA overflow at these receptor subtypes.

As stated previously, there is currently considerable debate as to the exact subunit
composition of nAChR subtypes mediating NIC-evoked DA release (Klink et al. 2001;
Azam et al. 2002; Champtiaux et al. 2002; Whiteaker et al. 2002; Zoli et al. 2002). The
discovery and use of the α-conotoxins (α-ctx), particularly the α-ctx MII, has greatly
increased our understanding of this receptor class. Two receptor subtypes, α-ctx MII
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sensitive and α-ctx MII resistant, have been determined as the nAChR subtypes
responsible for NIC-evoked DA release. Using knockout mice data coupled with the αctx MII data, Luetje (2004) has identified four distinct DA releasing subtypes, α-ctx MII
sensitive subtypes, α6β2β3 and α6α4β2β3, where α6 and α4 form with the β2 subunit to
form a functional receptor; and α-ctx MII resistant subtypes consist of α4β2 and α4α5β2
with the α4 and β2 subunits forming the agonist binding sites (Luetje 2004).
Interestingly, bPiDDB only partially blocks the effects of NIC-evoked [3 H]DA overflow
(Imax~50%), indicating that it is only antagonizing select subtypes that mediate DA
release, similar to α-ctx MII. The observed low affinity of bPiDDB for the α4β2*
nAChR subtype, in addition to the partial antagonism activity demonstrated by bPiDDB
in the NIC-evoked [3 H]DA overflow assay, indicates that bPiDDB most likely
antagonizes the α-ctx MII sensitive subtypes, α6β2β3 and α6α4β2β3 and not the ctx MII
resistant subtypes, α4β2 and α4α5β2.

Binding Model of Quaternized Azaaromatic Compounds at the nAChR subtypes
mediating DA release
In order to propose a binding model for these quaternary ammonium compounds, it is
important to identify if these antagonists are competing for the same receptor binding
site. It was determined that the C8 N-n-alkylnicotinium salt, NONI, was a competitive
antagonist in the NIC-evoked [3 H]DA overflow assay (Wilkins et al. 2002). Crooks et al.
(1995) reported that N-n-alkylation of the pyridyl nitrogen of NIC resulted in a change in
the physical properties of both the pyridyl nitrogen atom as well as the pyrrolidine
nitrogen atom of the molecule. The pyridyl alkylation caused the pKa of the pyrrolidine
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nitrogen to fall 2 pH units, resulting in it being mostly unprotonated at physiological pH.
Therefore, a nAChR binding model was hypothesized for the nAChR subtypes mediating
DA release, wherein the nAChR recognition points of the quaternized molecule were
reversed from those in the protonated NIC molecule, resulting in a novel interaction of
such molecules at the nAChR binding site (Crooks et al. 1995). In this model, the
cationic binding area of the nAChR receptor recognizes the quaternary ammonium
moiety of the N-n-alkylnicotinium compound, while the hydrogen-bonding site
accommodates the unprotonated pyrrolidine nitrogen (lone pair) (Figure 3.5).

Figure 3.5 Illustration of the different modes of interaction of protonated NIC and
NDDNI at the nAChR

Many compounds belonging to the mono- and bis-azaaromatic series were active in the
NIC-evoked [3 H]DA release assay. Therefore, a flexible model should be examined for
the nAChR subtypes mediating DA release. Because of the fact that the quaternized
pyridinium moiety is a constant structural feature in many compounds of the monoazaaromatic series, there must still be a cationic binding site that interacts with these
types of molecules. This interaction is not sufficient to inhibit release, as evidenced by

129

the lack inhibition exhibited by the smaller chain N-n-alkyl analogs; therefore, the carbon
chain length is also an important structural feature. The length of the carbon chain in
active molecules is found to be variable, depending on the substituent in the three
position of the pyridyl moiety. It is hypothesized that the N-n-alkylnicotinium molecules
fit into the receptor binding site at a unique angle, which allows the pyrrolidino moiety to
interact with a nearby H-bonding site, and an n-alkyl moiety with critical carbon chain
length is necessary to complete the strong interaction of the molecule with the DAreleasing nAChR at the N-n-alkyl binding site. The n-alkyl chain would likely interact
with residues adjacent to the binding site itself that are of a hydrophobic nature. This
hydrophobic interaction may also explain the observed decrease in activity seen with C10
N-n-alkylnicotinium salt, NDNI. In this case, the ten-carbon alkyl chain may not fit the
binding area due to a negative interaction of the chain with the receptor protein, leading
to a decrease in affinity. The C12 n-alkyl analog was a potent antagonist in the NICevoked DA release assay.

This may be due to an interaction that overcomes the

disruption that NDNI encounters. The longer alkyl chain may be able to bend to a
conformation that minimizes the interaction or that moves around the amino acid causing
the issue.

The recognition site also allows the N-n-alkylpyridinium and N-n-alkylpicolinium
molecules to interact with the binding site. However, the N-n-alkylpyridinium and N-nalkylpicolinium molecules still have a decreased affinity when compared to the N-nalkylnicotinium series. This points to the importance of the absence of the pyrrolidine
ring, decreasing the strength of the interaction with the binding site.
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Without the

pyrrolidine ring, these series of compounds may lack the ability to seat into the cationic
binding site as strongly as the N-n-alkylnicotinium molecules. Therefore, they require
longer chain lengths to create a more favorable ionic interaction at the cationic site while
maintaining the ability to interact at the N-n-alkyl binding site. However, the effect of
the increase in carbon chain length does not fully compensate for the loss of the
pyrrolidine ring, as the N-n-alkylpyridinium and N-n-alkylpicolinium series demonstrated
at least 10 fold decreased affinities (0.12 and 0.03 µM, respectively) when compared to
the N-n-alkylnicotinium series (0.009 µM). Taken overall, these data underline the
importance of the N-n-alkyl binding site, the H-binding site, and the cationic binding site
in the binding of this series of compounds.

The activity of compounds in the bis-azaaromatic series provides additional information
on the interaction of these quaternary ammonium compounds with nAChR subtypes
mediating DA release. Due to the presence of the second quaternized headgroup, the
carbon chain length and the quaternary ammonium center are not the only factors in
determining interaction between the molecule and the receptor.

The inclusion of a

second quaternary ammonium headgroup increases antagonist activity at the nAChR
subtypes mediating DA release for the N,N’-bis-alkylpicolinium series. This increased
activity is likely due to interaction of these molecules with a second quaternary
ammonium binding area remote from the first quaternary ammonium binding site. Due
to the poor activity of the C12 N,N’-bis-alkylnicotinium analog in the DA release assay,
the second quaternary ammonium binding site may be different than the first quaternary
ammonium binding site.

It is possible that site has a smaller area that cannot
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accommodate the entire nicotine molecule, but a smaller 3-position substituent may be fit
into the second binding site (Figure 3.6C).
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Figure 3.6 Potential binding pocket of the α6β2β3 nAChR subtype with NDDPiI,
NDDNI, bPiDDB, and bNDDB

Even though the exact sub-unit composition is not known, the heterologously assembled
DA-releasing nAChR subtype binding sites utilize an α-β interface (Kuo et al. 2005).
The main binding pocket of the mostly resides in the α subunit of the receptor site
(Karlin 2002; Unwin 2005). Recently, it was determined that the ß subunits may play a
dominant role in receptor inactivation (Fenster et al. 1997; Gentry et al. 2003).
Therefore, the β-subunit must be integral to the strong inhibitory activity of this series of
compounds at the nAChR subtypes mediating DA release. If the second binding pocket,
as well as, some of the hydrophobic residues that interact with the carbon chain of
quaternized molecule, resides on the β-subunit interface, the interaction of the molecule
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could prevent a conformational shift of the binding pocket and not allow the ionic pore to
open, inactivating the receptor.

3.4.

Conclusions

Several interesting mono- and bis-azaaromatic quaternary ammonium compounds have
emerged from this structure-activity study. bPiDDB was found to be a potent and
selective antagonist at the nAChRs mediating DA release, indicating it to be a possible
α6β2β3 or α6α4β2β3 nAChR subtype antagonist. The C10 mono- and bis-nicotinium
analogs, NDNI and bNDI, both had good antagonist activity and selectivity for α4β2*
nAChR subtypes. Additionally, bQDDB and bIQDDB have been shown to be the first
members of these series of quaternary ammonium molecules that have affinity for α7*
nAChR subtypes. The selectivity of these series of compounds for nAChR subtypes
demonstrates that these agents may be useful for both basic and clinical research aimed at
determining the pharmacological role of nAChR subtypes and their potential use as
therapeutic agents.

Copyright © Joshua Thomas Longen Ayers 2006
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Chapter 4: Molecular Modeling of mono- and bis-Quaternary Ammonium Salts at
α4β2* Receptor Subtypes

4.1.

Introduction

Over the past decade, the nAChR has become a target for drug development. The most
prevalent nAChR subtype in the mammalian brain is the heterologously expressed α4β2*
receptor subtype, which is the primary high affinity [3 H]nicotine binding site. Ligands
that specifically interact with this nAChR subtype are of interest in a number of
pathologies, including tobacco dependence and drug addiction, Alzheimer's disease,
Parkinson's disease, Tourette’s syndrome, schizophrenia, and pain (Lindstrom 1997;
Dwoskin et al. 2000; Lloyd and Williams 2000; Dwoskin and Crooks 2001; Dani et al.
2004; Hogg and Bertrand 2004). NIC and other nAChR agonists (e.g., epibatidine) are
not selective for α4β2* receptor subtypes, and produce significant side effects, making
these compounds less attractive as drug candidates. Consequently, previous studies have
generated quantitative structure-activity relationships (QSAR) in an attempt to
understand the interactions of these agonists with their recognition sites on nAChRs
(Barlow and McLeod 1969; Barlow and Johnson 1989; Dukat et al. 1996; Nielsen et al.
2000; Nicolotti et al. 2001).

To date, several of these QSAR studies have utilized linear regression analysis of ligandreceptor binding or function, in order to elucidate the nature of the ligand interactions
within several nAChR receptor subtypes (Barlow and McLeod 1969; Dukat et al. 1996;
Nielsen et al. 2000).

Of note, QSAR studies ha ve been used to investigate ligand

interactions at the α4β2* nAChR subtype (Dukat et al. 1996; Tonder and Olesen 2001;
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Tonder et al. 2001). Though generalities for the ligand interactions were drawn from the
SARs generated, insufficient model validation limited the ability of the previously used
models to recognize the training set of compounds. As such, generation of a nAChR
pharmacophore has proven difficult. In this respect the earlier pharmacophore model
generated by Sheridan et al. (1986), despite being based on crude pharmacological data,
still constitutes an approach worthy of further exploration (Sheridan et al. 1986; Schmitt
2000; Glennon et al. 2004).

Another model surmises that a water molecule may mediate binding of a ligand to the
receptor, perhaps through an interaction with the protonated nitrogen atom of the ligand
or the hydrogen bonding acceptor moiety in the ligand molecule (Glennon et al. 2004).
The crystallization of an acetylcholine binding protein (AChBP) from snail glia has also
provided insight into the binding domain of the nAChR.

Brejc et al. (2001) have

determined that the loop C (Changeux’s nomenclature) of the acetylcholine binding site
was crystallographically less well resolved than the rest of the binding site (Brejc et al.
2001), leading to the possibility that part of the binding site may take on different
conformations, depending on ligand shape and size. This represents a plausib le challenge
to the notion of a static pharmacophore. Due to the complexity of the nAChR molecular
recognition process and the difficulty in obtaining high-resolution (e.g. microscopic
kinetics) data for specific receptor subtypes, unambiguous models defining specific
nAChR subtype pharmacophores do not yet exist.
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It has been established previously that QSAR descriptor data has non-linear
characteristics (Zupan and Gasteiger 1993; Rogers and Hopfinger 1994; Kohonen 2001).
Therefore, alternative approaches such as self-organizing maps (SOMs) and the genetic
functional approximation (GFA) algorithm have been utilized to generate QSAR for
several biological systems (Gokhale and Kulkarni 2000; So et al. 2000; Yuan and Parrill
2002; Schneider and Nettekoven 2003; von Korff and Steger 2004), and may be better
suited for analysis of ligand interactions with α4β2* nAChRs. Regression analysis
typically employed in QSAR, such as Partial Least Squares (PLS) or Multiple Least
Squares (MLS) are limited to relating linear descriptor trends to a given activity or
property. Considering the complexity in the modeling of the mono- and bis-quaternary
ammonium salt interactions with nAChRs described in this study, we elected to use
SOMs and GFAs in the QSAR analysis described below as one valid modeling approach.

4.2.

4.2.1.

Experimental

Biological Data

Biological data were obtained from the [3 H]NIC binding assay using rat striatal
membranes, a well established assay reported to identify the α4β2* subtype (Xu et al.
2001; Ayers et al. 2002; Grinevich et al. 2003; Wilkins et al. 2003). The data set
consisted of ninety-three mono- and bis-substituted quaternary ammonium compounds
together with other related compounds developed in the Crooks laboratory, many of
which are described in earlier section of this dissertation. The chemical structures are
presented in Figure 1.

Activities (e.g. α4β2* receptor affinities) are expressed as

experimentally determined Ki values as explained in Chapter three.
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4.2.2.

Descriptor Generation

Descriptors were generated using the chemical modeling program Cerius2 (Accelrys, Inc.
San Diego CA) and QSARIS (MDL Information Systems Inc., San Liandro CA).
Descriptors

were

divided

into

one

of

several

physical

property

categories:

conformational, electronic, information, molecular shape analysis (MSA), quantum
mechanical, receptor, spatial, structural, thermodyna mic, and topological.

The

descriptors were used for the generation of both the SOMs and GFAs.

4.2.3.

Self-Organizing Maps with Descriptor Selection

In order to relate bioactivity and molecular features, a set of computational models were
developed using a custom-built stepwise descriptor selection algorithm coupled to a
supervised SOM (Bayram et al. 2004). The algorithm was developed using Matlab 6.1
with the SOM Toolbox 2.0 (http://www.cis.hut.fi/projects/somtoolbox/).
contains a description of the descriptors employed in the various models.
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Table 4.1

Table 4.1 Descriptors utilized in the generation of SOM and GFA models
Descriptors
Area
CIC
E-DIST-mag
Fh2o
Foct
IC
Jurs-FNSA-3
Jurs-PNSA-1
Jurs-RASA
Jurs-RPCS
Jurs-WNSA-2
Jurs-WNSA-3
Jurs-WPSA-1
LogP
Log Z
MW
PHI
S_aaCH
S_aasC
S_dCH2
S_dO
S_sCH3
S_ssCH2
S_sssNH
S_tCH
SC-3_P
SIC
Vm

Description
Molecular area
Complementary informational content
Entropy of the matrix
Desolvation free energy for water
Desolvation free energy for octanol
Informational content
Fractional negatively charged partial surface areas
Partial negative surface area
Relative hydrophobic surface area
Relative positive charge surface area
Surface weighted, partial negative charge
Partial weighting of the surface accessible portions of the molecule
Surface-weighted charged partial surface areas
Octanol/water partition coefficient
Logarithm of the Hosoya index
Molecular weight
Kier flexibility index
Energy states of aromatic CH bonds
Energy states of the C bonds
Energy states of all CH2 groups
Energy states of all carbonyl moieties
Energy states of all CH3
Energy states of the CH2 bonds
Energy states of all NH bonds
Energy states of total CH bonds
Molecular connectivity index of longer chain lengths
Structural informational content
Molecular volume

Datasets
Three data sets were created: (1) both mono- and bis-salts (92 molecules; the ‘ALL’ data
set); (2) mono-quaternary ammonium salts (69 molecules; the ‘MONO’ data set); and (3)
bis-quaternary ammonium salts (23 molecules; the ‘BIS’ data set). A binning scheme
was created to convert the numerical bioactivity into categorical data since our
implementation of SOMs works on categorical data. The scheme assigned roughly the
same number of molecules to each of three bins.
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Figure 4.1 N-Alkyl quaternary ammonium salts and their affinities (Ki) at α4β2*
nAChRs used in SOM and GFA studies

N-Alkylpyridinium Salts

N
I

53a
53b
53c
53d
53e
53f
53g
53h
53i
53j
53k
53l
53m
53n

NMPI
NEPI
NPrPI
NBuPI
NPePI
NHxPI
NHpPI
NOPI
NNPI
NDPI
NUPI
NDDPI
NPeDPI
NEcPI

R= Methyl
R= Ethyl
R= Propyl
R= Butyl
R= Pentyl
R= Hexyl
R= Heptyl
R= Octyl
R= Nonyl
R= Decyl
R= Undecyl
R= Dodecyl
R= Pentadecyl
R= Eicosonyl

R

Ki
20
28
42
9.7
8.7
9.1
15
20
19
17
17
120
49.7
>100

62a
62b
62c
62d
62e
62f
62g
62h
62i
62j
62k

NAPB
JTO
JCO
LO
MO
LN
JTN
JCN
LD
MU
NU

R= Allyl
R= trans-Oct-2-enyl
R= cis-Oct-2-enyl
R= Oct-2-ynyl
R= Oct-7-enyl
R= Non-2-ynyl
R= trans-Non-2-enyl
R= cis-Non-2-enyl
R= Dec-2-ynyl
R= Undec-10-enyl
R= Undec-10-ynyl

Ki
56.0
13.1
19.0
17.4
11.1
28.9
25.4
23.8
9.52
12.3
8.57

N-Alkylnicotinamide Salts
N-Alkylpicolinium Salts
O
CH3

I

54a NOPiI
54e NDDPiI

NH2

N
R
R= Octyl
R= Dodecyl

N
I
Ki
>100
>100

55a
55b
55c
55d
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NONAI
NNNAI
NDNAI
NUNAI

R
R= Octyl
R= Nonyl
R= Decyl
R= Undecyl

Ki
>100
>100
>100
>100

H
N

N-Alkylnicotinium Salts

CH3

N
I

56a
56b
56c
56d
56f
56g
56h
56i
56j
56l

NMNI
NENI
NPNI
NnBNI
NHxNI
NHpNI
NONI
NNNI
NDNI
NDDNI

R=
R=
R=
R=
R=
R=
R=
R=
R=
R=

Ki
3.5
1.0
22
10.9
0.53
2.1
20
0.84
0.093
0.14

Methyl
Ethyl
Propyl
Butyl
Hexyl
Heptyl
Octyl
Nonyl
Decyl
Dodecyl

R

63a
63b
63c
63d
63e
63f
63g
63h
63i
63j
63k
63l
63m
63n
63o
63p

NONB-7M
NCyNB-4
NCyNB-5
NCyNB-6
NBzNB
NANI
NONB-3c
NONB-3t
NONB-7e
NONB-3y
NONB-6e7M
NDNB-4c
NDNB-4t
NDNB-9e
NDNB-3y
NUNB-10e

R= 7-Methyloctyl
R= Octyl-cyclobutyl
R= Octyl-cyclopentyl
R= Octyl-cyclohexyl
R= Benzyl
R= Allyl
R= cis-Oct-3-enyl
R= trans-Oct-3-enyl
R= Oct-7-enyl
R= Oct-3-ynyl
R= 7-Methyl-oct-6-enyl
R= cis-Dec-4-enyl
R= trans-Dec-4-enyl
R= Dec-9-enyl
R= Dec-3-ynyl
R= Undec-10-enyl

Conformationally Restricted N-Alkylnicotinium Salts
H

H3C
H

N
H

H

N
I

25a
25b
25c
25d
25e

BCO
BCN
BCD
BCUD
BCDD

N
I

CH3

R= Octyl
R= Nonyl
R= Decyl
R= Undecyl
R= Dodecyl

Ki
>100
>100
>100
>100
>100

26a
26b
26c
26d
26e
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N
CH3

CH3

ACO R= Octyl
ACN R= Nonyl
ACD R= Decyl
ACUD R= Undecyl
ACDD R= Dodecyl

Ki
>100
>100
>100
>100
>100

Ki
0.44
4.56
5.54
7.20
2.67
2.1
0.075
3.97
0.45
0.20
0.45
7.39
0.32
0.049
0.49
0.54

bis-Quaternary Ammonium Salts

H 3C

CH 3
N

CH3
N CH
3
CH3

CH 3

H3C
H3C

CH3
N
CH3
CH3

N
CH3

45 HEX Ki = 31.9

63 DEC Ki = 4.27

bis-N,N'-Alkylpyridinium Salts

bis-N,N'-Alkylpicolinium Salts
CH3

N

N

2X

2X
n

n

N

N
H3C

56a
56c
56d
56e
56f
56g

n = 1; X = I
n = 4; X = I
n = 5; X = Br
n = 6; X = I
n = 7; X = Br
n = 8; X = Br

bPPeI
bPOI
bPNB
bPDI
bPUB
bPDDB

Ki
>100
33.9
24.1
18.6
14.4
9.14

57b
57c
57d
57e
57f

bPiOI
bPiNB
bPiDI
bPiUB
bPiDDB

Ki
>100
66.7
>100
82.0
33.0

n = 4; X = I
n = 5; X = Br
n = 6; X = I
n = 7; X = Br
n = 8; X = Br

bis-N,N'-Alkylnicotinium Salts
bis-N,N'-Alkylquinolinium Salts

H
N

N

CH3

N

2X

2X
n

n

N

N
H3C
N
H

58b
58c
58d
58e
58f

bQOI
bQNB
bQDI
bQUB
bQDDB

n = 4; X = I
n = 5; X = Br
n = 6; X = I
n = 7; X = Br
n = 8; X = Br

Ki
>100
20.1
>100
38.3
>100

60b
60c
60d
60e
60f
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bNOI
bNNB
bNDI
bNUB
bNDDB

n = 4; X = I
n = 5; X = Br
n = 6; X = I
n = 7; X = Br
n = 8; X = Br

Ki
1.50
4.31
0.28
0.37
1.43

In using the supervised SOM learning algorithm provided in the toolbox, this binning
scheme allowed for a more accurate clustering of the data sets and for extracting the
underlying commonalities of the molecules.
Bin 1: 0 < x = 5
Bin 2: 5 < x = 50
Bin 3: 50 < x = 100
The data set being modeled was partitioned into a set of test molecules (20%) and
training molecules (80%). Membership in the test or training set was random, with the
one requirement that the proportion of molecular population in each bin be identical in
both test and training sets. The descriptor blocks for each data set were normalized to
unit variance and mapped to a logistic function. Descriptors with zero variance were
removed, as were pairs with linear correlation above 0.90, retaining the most
representative of the pair.

The SOM-Stepwise Feature Reduction Algorithm
Finally, a SOM-oriented variation of a forward entry stepwise regression algorithm was
employed, to select a small number of independent variables from which the SOM model
was constructed. The algorithm used is identical to the forward entry stepwise method
with the following variations:
(1) the entry statistic was defined to be the percent of training set molecules
correctly classified by the model, any increase of which resulted in the inclusion
of the descriptors being tested;
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(2) the entry statistic was calculated by constructing a SOM using a supervised
learning algorithm; and,
(3) descriptors to be entered into the model were chosen in pairs, one from each of
two randomized lists of the full set of descriptors.

Algorithm training was conducted iteratively until some convergence criteria were met.

Experimental Design
For each of the three data sets, ten independent runs were conducted, each with distinct
training set/test set samplings. At the end of each training process, the test set molecules
were predicted with the trained SOM model, providing the benchmark statistic, e.g.,
‘percent age correctly classified’. Averaging these statistics over the ten runs produced an
estimate of the algorithm’s success in both learning the training data and generalizing to
the test data. Conducting multiple runs to some extent minimizes sampling bias, as well
as bias arising from the stochastic SOM initialization process. The best model for each of
the three data sets was further examined using custom visualization tools, as shown in the
Figures 4.2-4.4.

4.2.4.

Genetic Functional Activity Algorithms

Genetic functional algorithms (GFAs) as described by Rogers and Hopfinger (Rogers and
Hopfinger 1994) were implemented using Cerius2 (version 4.6) software (Accelrys Inc.,
San Diego, CA). GFAs were conducted using static 100 member populations; linear,
quadratic, and offset quadratic basis functions; the mutation probability for both additions
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and deletions was set at 0.2%. Lack of fit criterion was set at 1.0 and initial equation
length was set to three. Models were evolved over 50,000-80,000 generations using
standard convergence criterion.

4.3.

Results and Discussion

Self-Organizing Maps
U-matrix maps represent the descriptor-based relationships of the training set of
molecules by the SOM, and are constructed by projecting all selected descriptor’s
contributions to the mapping.

D-matrix maps indicate the classification mapping of the SOM, as learned from the
corresponding training sets. All three maps illustrate strong clustering.

The color level, in all the maps seen below (see Figures 4.2-4.4) describes the rela tive
clustering in the data; the darker areas indicate small distances, while the lighter areas
indicate larger distances.

The colored hexagons indicate the points on the map

corresponding to training molecules, and are colored by the affinity classification and
labeled with the corresponding training molecule names.

SOM models of the ALL data set
The ten models learned the training set with high classification accuracy (93% + 0.02)
and were able to correctly classify the test compounds with a percent accuracy of 68% +
0.08. The average number of descriptors chosen via the stepwise SOM was 11, which
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were selected from a total number of 47 descriptors. False negative values, where the
model placed the compound two bins removed from its actual value, were low,
accounting for less than 2% of the failures generated by the model. There were no false
positives reported for any of the models. Figure 4.2 is a graphical representation of the
best model of the ten models generated from the ALL data set. The descriptors selected
by the best model were, S_dO, S_aaCH, IC, S_sCH3, S_sssNH, S_tCH, and PHI.
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Figure 4.2 (A) D-matrix generated from the ALL data set, red numbers indicate the
classification mapping of each node; (B) U-matrix SOM generated from the ALL data
set. Key: red- class 1, green- class 2, blue- class 3. Inter-node distances are shown in
grey-scale coloring, the closer the distance the darker the shading.

A)

B)
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The D-matrix (Figure 4.2A) shows that there are three general clusters for the full
complement of compounds in the ALL data set.

The descriptor, IC (informational

content), is an information-theoretic topological index and may be identifying steric
qualities of the molecules.

The descriptors utilized, S_dO, S_aaCH, IC, S_sCH3,

S_sssNH, S_tCH, and PHI, by the model mostly correspond to the electrotopological (ETop) indices. S_dO describes the sum of the energies of carbonyl moieties in the set
from the N-n-alkylnicotinamide series. As the carbonyl-containing compounds of this
family are inactive, S_dO may be acting largely as a binary classifier. Additionally, the
best model used descriptors for the energy states of all CH3 , aromatic CH, total CH, and
NH bonds, e.g. S_sCH3 , S_aaCH, S_tCH, and S_sssNH, respectively. These descriptors
may differentiate the C3-functionality of the pyridine ring; the S_dO and S_sssNH
descriptors together likely map the SAR relative to the inclusion of the amide
functionality at the C3-position of the pyridine ring, leading to a decrease in affinity.
Another descriptor that may demonstrate the importance of the C3-position functionality
is the Kier flexibility index, PHI. The compounds in the N-n-alkylpicolinium series,
which contain a methyl group at the C3-position of the pyridine ring, were also inactive
and grouped with the N-n-alkylnicotinamide salts. The active N-n-alkylnicotinium salts,
with a 2-N-methylpyrrolidino functionality at the C3-position of the pyridine ring,
however, were separated from the inactive compounds. The rigidity of the methyl and
amide functionalities when compared to the more flexible pyrrolidine ring may also be
key to the observed affinity of these compounds at the a4ß2* nAChR.
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The U- matrix (Figure 4.2B) reflects chemically intuitive trends; the longer saturated N-nalkylnicotinium salts were clustered together.

Additionally, the unsaturated N-n-

alkylnicotinium compounds, NONB-3y, NDNB-4t, and NDNB-3y, were similar in
bioactivity and clustered near the saturated N-n-alkylnicotinium compound NNNI.
However, NONI, the less active eight-carbon analog, was clustered among the active
compounds, pointing to a limitation in the SOM or the descriptors. Shorter carbon chain
N-n-alkylnicotinium compounds and N-n-alkylpyridinium compounds were likewise
clustered together. Interestingly, rotationally restricted analogs were not found in the
freely rotating N-n-alkylnicotinium compound cluster. This reflects a bias toward their
different affinities, as the model does not recognize the two classes as structurally similar,
but actually classifies the restricted rotation analogs as being structurally similar to the
longer chain N-n-alkylpyridinium analogs (NEcPB and NDDPI).

A strong distinction is observed between the different structural classes of bis-substituted
quaternary ammonium compounds.

The active bis-quaternary ammonium salts are

closely associated with the N-n-alkylnicotinium compounds, as well as the classical
muscle nAChR antagonist, decamethonium bromide (DEC).
ammonium compounds

were

clustered

nearer

to

the

The bis-quaternary

mono-substituted N-n-

alkylpyridinium salts. This clustering may indicate that the bis-quaternary ammonium
compounds bind to the receptor in similar fashion as the N-n-alkylnicotinium compounds.
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SOM models of the MONO data set
The ten models learned the training set with high accuracy (95% ± 0.03) and were able to
predict test compound affinities with 72% ± 0.10 accuracy. The average number of
descriptors chosen via the stepwise SOM regression method was 7.8 descriptors, selected
from a total number of 42. A 7.2 percentile of the missed assignments by the model were
false positives. False negatives accounted for less than 1% of the failures generated by
the model. Figure 4.3 is a graphical demonstration of the best model generated from the
mono-substituted series of compounds. From the model generated, the descriptors used
to create the model were S_aaCH, Jurs-RASA, Jurs-PNSA-1, Foct, S_dCH2, Fh2o, and
LogP.
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Figure 4.3 (A) D-matrix generated from the MONO data set; (B) the U- matrix
representation.

A)

B)
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The mono-substituted quaternary ammonium salt model based on the MONO data set
also demonstrated three distinct areas of clustering (Figure 4.3A) and used different
descriptors, S_aaCH, Jurs-RASA, Jurs-PNSA-1, Foct, S_dCH2, Fh2o, and LogP, than
those used in the ALL compound set, with only one similar descriptor, e.g. S_aaCH. The
model did use a similar descriptor, S_dCH2, to describe the importance of the energy
states of all of the CH2 groups in the molecule. One of the new descriptors, Jurs-PNSA-1
describes the partial negative surface area (e.g. the sum of the solvent-accessible surface
areas of all negatively charged atoms). Also included in the model is the related JursRASA descriptor, which indicates the relative hydrophobic surface area, defined as the
total hydrophobic surface area divided by the total molecular solvent-accessible surface
area. The hydrophobic character of compounds in this series appears to be a major
determining factor for their affinity, and is supported by the three additional related
descriptors, e.g. Foct, Fh2o, and LogP. These descriptors are thermodynamic descriptors
that estimate the desolvation free energy for octanol, water, and the octanol/water
partition coefficient, respectively.

The long chain N-n-alkylnicotinium salts and the unsaturated N-n-alkenylnicotinium salts
were clustered together in the SOM model (Figure 4.3B). These compounds share
similar structures and similar a4ß2* nAChR affinities. The unsaturated and saturated Nalkylpyridinium salts were grouped together with the shorter chained N-nalkylnicotinium compounds, which indicates, according to the descriptors chosen, that
both the N-alkyl chain and the pyridine C3-position substituent are important for
determining a4ß2* nAChR affinity.

The longer chain N-n-alkylnicotinium salts
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exhibited the highest affinities, which correlate with a larger number of lipophilic group
(e.g. CH2 groups in the alkyl chains and in the N-methylpyrrolidine ring), whereas the
longer chain N-n-alkylpyridinium salts and the shorter chain N-n-alkylnicotinium salts
have fewer numbers of CH2 groups and therefore, lower affinities for the a4ß2* nAChR
receptor.

The third cluster contains two interesting compound families: N-n-alkylnicotinamide
salts, which were inactive in the [3 H]NIC binding assay, and the conformationally
restricted N-n-alkylnicotinium analogs, which were also inactive.

The N-n-

alkylnicotinamide salts possess a hydrophilic moiety at the 3-position of the pyridinium
ring. Similar to many nAChR ligands, affinity at the α4β2* nAChR subtype is positively
influenced by a hydrophobic interaction, whereas a hydrophilic moiety at the 3-position
of the pyridinium ring serves to decrease affinity. The low-affinity, conformationallyrestricted N-n-alkylnicotinium analogs have a high degree of hydrophobicity, and the
model was able to differentiate them from other nicotinium molecules. Although it is
unclear exactly which descriptor or descriptors may map this phenomenon, it is clear that
the SOMs can differentiate in a manner that takes into account both distributed
(hydropathy) and localized (functional groups) determinants of the observed SAR.

SOM models of the BIS data set
The ten models learned the training set with high accuracy (98% ± 0.03) and predicted
the test compounds with a percentage accuracy of 58% ± 0.15. The average number of
descriptors chosen via the stepwise SOM was 4.8 selected from a total number of 30
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descriptors. False positive and negative values were not observed in this model. Figure
4.4 is a graphical representation of the best model generated from the bis-substituted
series of compounds. From the model generated, the descriptors used to create the model
were S_ssCH2, CIC, S_aasC, Jurs-RPCS, and Jurs-WNSA-3.
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Figure 4.4 (A) D-matrix generated from the BIS dataset; (B) the U- matrix representation.

A)

B)
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The model developed for the bis-quaternary ammonium salts based on the BIS data set
also shows three distinct clustering areas (Figure 4.4A and 4.4B). This model contains
the descriptors S_ssCH2 (energy states of the CH2 bonds) and S_aasC (energy states of
the C bonds), again stressing the importance of the lipophilic nature of these compounds.
The model also contained the descriptor, CIC (complementary informational content),
which is an information-theoretic topological index similar to IC and may be identifying
steric interactions of the molecules. The bis-quaternary ammonium salt model utilized
the Jurs spatial descriptors to generate the model.

However, unlike the mono-N-n-

alkylated quaternary ammonium salt model, which uses a hydrophobic interaction
descriptor, the bis-quaternary ammonium salt SOM used a positive charge surface area
descriptor, Jurs-RPCS. This descriptor represents the most positively charged atom and
its relative accessible surface area. Since these bis- molecules possess two positive
charges, the selected descriptors may indicate an increased importance of charge
distribution within the series. The model also uses the Jurs-WNSA-3 descriptor, which is
similar to the Jurs-PNSA-1 descriptor used in the mono-N-n-alkylated quaternary
ammonium salt model, except that it represents only a partial weighting of the surface
accessible portions of the molecule. The highest affinity members of this data set, the
bis-quaternary ammonium salts, were clustered together. DEC was also clustered in the
high affinity bin, whereas the classical ganglionic nAChR antagonist, hexamethonium
bromide (HEX), was clustered with the lower affinity compounds, viz. the bisquinolinium and the bis-pyridinium salts. Additionally, the bis-picolinium compounds
were grouped with two of the bis-quinolinium salts in the weakest affinity set. Therefore,
the presence of the 2-N-methylpyrrolidine ring of the bis-nicotinium salts plays an
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important role in determining the affinities of this series of compounds for the a4ß2*
nAChR receptor. It was demonstrated that a pKa shift occurs in the pyrrolidino nitrogen
when the pyridino functionality in the NIC molecule is quaternized (Crooks et al. 1995).
Therefore, the importance of the 2-N-methylpyrrolidine may be due to increased
lipophilicity and/or to the possibility that the less basic nitrogen may act as a hydrogen
bond acceptor.

Genetic Functional Activity Algorithms
Genetic Functional Algorithm Models
N-Alkylpyridinium and N-Alkyl-3-substituted pyridinium salts
The resulting equation was derived using the GFA methods:
Ki = 161.582 + 0.004244 (Area)2 – 2.7e-5 (E-DIST- mag)2 – 5.12623 (Vm) + 36.4862
(SC-3_P) + 0.001581 (Jurs-WPSA-1)2

(1)

r2 : 0.835734
q2 : 0.720
The GFA methodology was applied to generate three equations for the prediction of the
quaternary ammonium compound’s affinity at the α4β2* nAChR subtype. Equation (1)
was generated to correlate the descriptors to the bioactivity of all of the N-nalkylpyridinium salts, N-n-alkylpicolinium salts and N-n-alkylnicotinamide salts (MONO
dataset). The equation reveals a positive correlation with increased molecular volume
(Vm) and area (Area), while the molecular connectivity index of longer chain lengths
(SC-3_P) has a negative correlation.

Interestingly, the compounds in the N-n-

alkylnicotinamide series, which have larger molecular volumes than their corresponding
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pyridinium cousins, possess less affinity toward this nAChR subtype. Additionally, the
affinities of the N-n-alkylnicotinamide salts were also decreased when compared to the
simpler N-n-alkylpyridinium salts. The GFA also had a negative correlation with the EDIST-mag descriptor, which describes the entropy of the matrix. The Jurs-WPSA-1
descriptor describes the surface-weighted charged partial surface areas; an indication that
the positive charge distribution plays a role in receptor recognition (note that the converse
descriptor, Jurs-PNSA-1 was used in the corresponding SOM model).

N-Alkylnicotinium salts
The resulting equation was derived using the GFA methods:
Ki = 43.5762 + 1.0e-6 (E-DIST- mag)2 – 3.03532 (Jurs-RPCS)2 – 6862.5 (Jurs-FNSA-3)2
+ 0.000602 (MW)2

(2)

r2 : 0.592152
q2 : 0.369
Equation (2) models the SAR of the N-n-alkylnicotinium salts only. As can be seen in
equation (1), the E-DIST- mag descriptor was utilized, however, a positive correlation
was found with this set of data. Jurs-RPCS, a measurement of the relative positive
surface charge, and Jur s-FNSA-3, fractional negatively charged partial surface areas,
positively correlate with affinity for the α4β2* nAChR binding site, with the latter
descriptor having the most weight.

Interestingly, molecular weight (MW) is also

negatively correlated. Since the highest affinity analogs NDDNI and NDNI (C 12 and the
C10 N-n-alkylnicotinium compounds, respectively) possess the highest molecular weight,
the spatial partial charge interactions described by the Jurs descriptors must be more
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heavily weighted in this case. Additionally, this data set did not include NONI, the C8 Nn-alkylnicotinium analog. The GFA was unable to generate a reliable model with NONI
included, indicating that the descriptor set was likely insufficient to fully describe the
SAR of this series.

bis-Quaternary Ammonium salts
The resulting equation was derived using the GFA methods:
Ki = -141.363 + 1449.55 (SIC)2 + 0.000602 (Jurs-WNSA-2)2 – 47.5526 (IC)2 + 2.43134
(Log Z)

(3)

r2 : 0.810622
q2 : 0.657
The affinity of the bis-quaternary ammonium compounds is modeled by equation (3).
Similar to the N-n-alkylnicotinium salts and the SOM maps, the bis-quaternary
ammonium salts utilized a surface weighted, partial charge descriptor.

Again, the

information-theoretic topological indices are found in the model equation. IC and SIC
(structural informational content) are present and may be identifying steric qualities of
the molecules and Log Z (logarithm of the Hosoya index), whic h deals with connectivity
of the molecule. It also appears that the Jurs descriptors are effective in describing the
SAR of the quaternary ammonium salts. The GFA selected a surface weighted, partial
negative charge descriptor, Jurs-WNSA, which is most likely related to a portion of the
molecule, possibly the aromatic pyridinium ring.
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It is important to note that although the SOM and GFA methodologies were provided the
same set of descriptors at the outset of training, not surprisingly, models resulting from
the two methods utilize different subsets of these descriptors. A combination of three
factors is thought to underlie this observation: 1) GFAs and SOMs model nonlineararity
in fundamentally different ways; 2) each method approaches descriptor selection in
fundamentally different ways and; 3) each have different susceptibilities to getting stuck
in local minima.

4.4.

Conclusion

Two different computational modeling methodologies were used to model the SAR of the
interaction of quaternary ammonium compounds with the α4β2* nAChR subtype. The
SOM methodology was effective in appropriately grouping compounds with diverse
structures and activities. GFAs were also able to predict compound activities from a set
of physical descriptions. Taken together, the charge distribution and the hydrophobic
free energies seem to be important indicators of bioactivity for this particular class of
molecules. However, both methodologies exhibited limitations when compounds with
similar physical properties, but vastly different biological activities were evaluated.
Nevertheless, the current work demonstrates that non- linear in silico methodologies can
be used to screen large series of compounds, and successful models can be generated to
aide in the selection of active compounds from larger compound libraries to be further
evaluated.
Copyright © Joshua Thomas Longen Ayers 2006
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Chapter 5: Enantioselective Synthesis of Nicotine Analogs as Precursors for the
Preparation of Novel Quaternary Ammonium Analogs

5.1.

Introduction

The principal tobacco alkaloid, NIC, is a potent agonist at nAChRs, and interacts with all
known nAChR subtypes. nAChR ligands modulate a number of functions within both
the peripheral and the central nervous systems, mediated by a diversity of nAChR
subtypes containing a2-a10 and ß2-ß4 subunits. Interestingly, leaves from Nicotiana
tobaccum contain a number of other minor alkaloids structurally related to nicotine, e.g.,
nornicotine, anabasine, and anatabine. S-(-)-Nicotine is biosynthesized in the tobacco
plant from nicotinic acid and L-ornithine or L-arginine. Nornicotine, the second most
abundant tobacco alkaloid, is biosynthesized via enzymatic N-demethylation of S-(-)nicotine; the minor alkaloid, anabasine, is generally believed to be biosynthesized from
nicotinic acid and lysine, via a similar pathway to that described above for nicotine (Bush
et al. 1999). Anatabine is derived biosynthetically solely from nicotinic acid, which is
decarboxylated to 1, 2-dihydropyridine and 2, 5-dihydropyridine followed by
condensation of these two molecules to form 3, 6-dihydroanatabine (Bush et al. 1999).
Aromatization of 3, 6-dihydroanatabine then affords anatabine.

While nicotine in tobacco is found almost exclusively in the S-(-)-enantiomeric form
(Crooks et al. 1992; Armstrong et al. 1999), the minor tobacco alkaloids are present as
mixtures of their respective optical isomers (Armstrong et al. 1999). In this respect,
unlike nicotine, nornicotine exists as a mixture of its S-(-)- and R-(+)-enantiomeric forms
in various ratios, depending on the species of Nicotiana from which it was isolated. Even
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different sources of tobacco, e.g. Burley, Turkish, or Virginia, contain different ratios of
nornicotine enantiomers (Armstrong et al. 1999). The presence of both enantiomeric
forms of nornicotine in the tobacco plant results from the enzymatic N-demethylation of
S-(-)-nicotine in the plant. Biosynthetic studies with 2’-[3 H]- nicotine have shown that the
2’-[3 H]-label is lost during formation of R-(+)- nornicotine, but is retained in the
formation of S-(-)-nornicotine (Bush et al. 1999).

These observations suggest the

formation of a planar intermediate in the formation of the R-(+)- isomer, and the likely
existence of two distinct N-demethylase enzymes.

The minor tobacco alkaloids are also known to possess nAChR agonist activity, and may
contribute to the neuropharmacological effects of smoking, although they are generally
relatively less pharmacologically active than S-(-)-nicotine (Crooks and Dwoskin 1997).
Pharmacological investigations and structure-activity studies with these minor tobacco
alkaloids have been somewhat limited, due to the lack of availability of their optically
pure forms.

Previous structure-activity studies have demonstrated that the optical

isomers of nornicotine show significant differences in their ability to bind to nicotinic
receptors in rat brain and generally are less potent compared with nicotine (Reavill et al.
1988; Copeland et al. 1991).

For example, S-(-)-nornicotine inhibits [3 H]- nicotine

binding to rat brain membranes with a 50- fold lower affinity (Ki= 47 nM) compared with
nicotine (Ki = 1.0 nM) (Xu et al. 2001). In contrast, S-(-)-nicotine and S-(-)-nornicotine
exhibit similar affinities for the [3 H]methyllycaconitine binding site (Ki = 770 nM and
1340 nM, respectively) in brain (Xu et al. 2001). These results indicate interaction of
nornicotine with both a4ß2* and a7* nAChR subtypes. Evidence has also accumulated
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demonstrating that nornicotine enantiomers differ in their neurochemical and behavioral
effects (Bardo et al. 1997; Crooks and Dwoskin 1997; Green et al. 2000; Green et al.
2001).

Similar to nicotine, both enantiomers of nornicotine evoke a concentration-

dependent, Ca2+-dependent and mecamylamine-sensitive increase in DA release from rat
striatal and nucleus accumbens slices (Dwoskin et al. 1993; Teng et al. 1997; Green et al.
2001), indicating that nornicotine acts as an agonist at nAChR subtypes modulating DA
release. Interestingly, R-(+)-nornicotine was more potent than the S-(-)-enantiomer in
evoking [3 H]dopamine overflow from rat nucleus accumbens slices, whereas both
isomers were equipotent in this respect in experiments with rat striatal slices, suggesting
the involvement of different nicotinic receptor subtypes in these brain regions. Whereas,
S-(-)-nicotine and S-(-)-nornicotine were equipotent in releasing DA from striatal slices,
nicotine was 43-fold more potent than nornicotine (EC 50 = 70 nM and 3.0 µM,
respectively) in releasing DA from nucleus accumbens slices (Green et al. 2001).
Interestingly, nornicotine has a longer half- life than nicotine in both rodent and nonhuman primate plasma and brain (Kyerematen et al. 1990; Crooks et al. 1997; Ghosheh
et al. 1999; Valette et al. 2003); and following chronic treatment with S-(-)-nicotine,
nornicotine

(of

unknown

chirality)

accumulates

in

rodent

brain

reaching

pharmacologically relevant concentrations (Ghosheh et al. 2001).

Behavioral studies using animal models also provide support for the use of nornicotine as
a tobacco use cessation agent.

Nornicotine produces nicotine- like discriminative

stimulus effects (Bardo et al. 1997), as well as nicotine- like effects on schedulecontrolled operant responding (Risner et al. 1988).
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Recent results indicate that

nornicotine functions as a positive reinforcer (Bardo et al. 1999); however, under similar
experimental conditions, nornicotine is associated with a lower rate of responding in
comparison with nicotine (Corrigall and Coen 1989; Bardo et al. 1999), suggesting that
nornicotine has a lower reinforcing efficacy. Moreover, nornicotine has been shown to
decrease nicotine self-administration in rats (Green et al. 2000). Furthermore, across
repeated nornicotine pretreatments, tolerance did not develop to nornicotine- induced
decrease in nicotine self-administration.

Importantly, nornicotine has been recently

found to inhibit dopamine transporter (DAT) function (Middleton et al. 2005), and thus,
acts similarly to bupropion, which is a currently available smoking cessation agent. In
summary, nornicotine increases DA release and inhibits DAT function, both mechanisms
being beneficial in the treatment of tobacco use. Thus, a simple structural change, e.g.,
removal of the N-methyl moiety from the pyrrolidine ring of nicotine, which affords
nornicotine, may be beneficial with respect to its pharmacological profile.

Taken

together, these current preclinical neurochemical and behavioral results suggest that
nornicotine could be a promising candidate for development as a tobacco cessation agent
(Middleton et al. 2005). In this respect, it should be noted that R-(+)- nornicotine is
currently being investigated as a potential smoking cessation agent (Crooks et al. 1998).

Dwoskin et al. (1995) have shown that S-(-)-anabasine increases fractional [3 H] release in
a concentration-dependent manner from rat striatal slices preloaded with [3 H]-dopamine
(EC50 = 19.3 ± 3.2 µM), but was less potent than S-(-)-nicotine (EC 50 = 3.0 ± 2.2 µM)
(Dwoskin et al. 1995). Similar results have been reported by Grady et al. (1992), who
demonstrated that (±)-anabasine stimulates [3 H]-dopamine release from mouse striatal

164

synaptosomes, and (±)-anabasine has been reported to inhibit high affinity binding of
[3 H]-S-(-)-nicotine to rat and mouse striatal membranes (Reavill et al. 1988; Grady et al.
1992). Thus far, direct comparisons of these pharmacological properties between the
enantiomers of anabasine and anatabine have not been determined due to difficulties in
obtaining the pure optical isomers of each compound.

Early efforts to develop synthetic routes to racemic minor tobacco alkaloids have utilized
a variety of methods (for a comprehensive review, see Crooks, 1999). However, few
examples of general preparative methods for these alkaloids have been reported. Deo and
Crooks (1996) have utilized a benzophenone imine intermediate for the general synthesis
of racemic nornicotine, anabasine, and anatabine, while a number of strategies have been
developed for the enantioselective synthesis of nornicotine, anabasine and anatabine
optical isomers (Deo and Crooks 1996; Crooks 1999; Loh et al. 1999; Yus et al. 2001),
few of these are of general utility. Recently, the S-(-)-isomers of nornicotine, anabasine
and anatabine have been synthesized via a 5-step enantioselective synthesis that utilizes a
ring-closing metathesis route (Felpin et al. 2001); also, Amat et al. (2002) have reported
a chiral synthesis of S-(-)-anabasine from a chiral lactam intermediate (Amat et al. 2002).
Additionally, S-(-)-anatabine has been synthesized by reacting an allylsulfone with an
azaaromatic chiral sulfinimine (Balasubramanian and Hassner 1998).

Aiqiao et al. (1991) have reported a rapid and convenient use of a 2-hydroxy-3-pinanone
intermediate for the enantioselective synthesis of 2-pyridyl methylamines; this method
was subsequently adapted by Swango et al. (1999) for the efficient synthesis of S-(-)- and
R-(+)-nornicotine isomers in three steps, with a reported ee of 91% and 81%, respectively
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(Aiqiao et al. 1991; Swango et al. 1999). This current study describes a general synthetic
procedure for the facile preparation of the optical isomers of nornicotine, anabasine, and
anatabine, utilizing modifications of the Swango et al. (1999) synthetic methodology
(Figure 5.1), and more importantly, establishes this synthetic route as a convenient
method for the preparation of the enantiomerically pure minor tobacco alkaloids.

5.2.

5.2.1.

Experimental

Materials

The chemicals utilized in the synthesis of the enantiomers of nornicotine, anabasine, and
anatabine were obtained from Aldrich Chemical Company (Milwaukee, WI), or from
Acros Organics (Somerville, NJ), and were used without further purification.

Flash

column chromatography was carried out using ICN SILITECH 32-63, 60Å silica gel.
Melting points were determined on a Fisher Scientific melting point apparatus and are
uncorrected. 1 H-NMR and 13 C-NMR spectra were recorded on a Varian 300 MHz NMR.
All Spectra were referenced, and chemical shifts were determined using tetramethylsilane
(TMS) as the internal standard.

Mass spectra were recorded on a JEOL JMS-700T

Mstation, or on a Bruker Autoflex MALDI-TOF mass spectrometer. Specific rotation
measurements were carried out on a Perkin-Elmer Model 241 Polarimeter.
Microanalyses were carried out by Atlantic Microlabs, Inc. (Atlanta, GE).
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5.2.2.

Synthetic Procedures

Enantioselective NIC Alkaloid Synthesis
(1R,2R,5R)- and (1S,2S,5S)- 2,6,6-Trimethyl-3-(pyridin-3-ylmethylimino)bicyclo[3.1.1]heptan-2-ol (67 and 67R)
Boron trifluoride diethyl etherate (0.3 mL) was added to a solution of 3-(aminomethyl)
pyridine (3.30 g, 30.6 mmol) and 1R, 2R, 5R-(+)-2-hydroxy-3-pinanone (5.00 g, 29.8
mmol).

The reaction mixture was refluxed for 2.5 h under N2 using a Dean-Stark

apparatus. After cooling, the solvent was evaporated under reduced pressure. The
residue

was

purified

by

flash

silica

gel

column

chromatography

us ing

CHCl3 :hexane:methanol, 12:2:1 as the elution solvent to afford the (+)-2-hydroxy-3pinanone ketimine 67 (6.24 g, 81%) as white crystals after removal of solvent: [a D] =
+3.8o (c = 1.0, methanol); 1 H NMR (300 MHz, CDCl3 ) δ 8.58 (1H, d, J = 2.4 Hz), 8.48
(1H, dd, J = 4.8, 1.8 Hz), 7.70 (1H, d, J = 7.8 Hz), 7.25 (1H, dd, J = 7.8, 4.8 Hz), 4.48
(2H, s), 2.80 (1H, br s), 2.58 (2H, m), 2.34 (1H, m), 2.06 (2H, m), 1.56 (1H, d, J = 10.8
Hz), 1.50 (3H, s), 1.31 (3H, s), 0.84 (3H, s) ppm.;

13

C NMR (75 MHz, CDCl3 ) δ 178.19,

149.33, 148.28, 135.81, 135.52, 123.60, 51.83, 50.46, 38.75, 38.50, 34.12, 28.56, 28.37,
27.51, 23.11 ppm. m/z 258 (M+, base peak).

The same procedure was utilized for the synthesis of 1S, 2S, 5S-(-)-2-hydroxy-3-pinanone
ketimine (6.58 g, 85%), which was obtained as white crystals from the reaction of 1S, 2S,
5S-(-)-2-hydroxy-3-pinanone with 3-(aminomethyl)pyridine; [a D] = -3.6o (c = 1.0,
methanol).
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Figure 5.1 Enantioselective Synthesis of S-(-)-Nornicotine, S-(-)-Anabasine, and S-(-)Anatabine
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(S)-(-)-Nornicotine and (R)-nornicotine (3 and 3R)
To a stirred solution of ketimine 67 (258 mg, 1.00 mmol) in THF (8 mL) was added
dropwise LDA (1.50 mL, 2.0 M solution in THF, 3.00 mmol) at 0°C. The purple
solution was stirred at 0°C for 15 min then cooled to –78°C. 1-Chloro-3-iodopropane
(0.32 mL, 3.00 mmol) in THF (2 mL) was then added dropwise. The reaction mixture
was stirred for an additional 30 min at –78°C, and then quenched with saturated aqueous
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NH4 Cl solution.

The solution was extracted with diethyl ether (3x10 mL).

The

combined organic layers were washed with brine, dried over anhydrous magnesium
sulfate, filtered, and the solvent evaporated. The residue was passed through a short
silica gel column, eluting with hexane, followed by CHCl3 :MeOH (20:1) to give the Calkylated intermediate as a yellow oil.

The crude product was not purified, but

immediately added to a mixture of 95% EtOH (6 mL), hydrazine monohydrate (4 mL)
and acetic acid (2 mL). The mixture was stirred overnight at room temperature and 10%
aqueous NaOH solution (10 mL) was added.

The solution was then extracted with

CHCl3 (3x20 mL), the combined organic liquors were dried over anhydrous magnesium
sulfate, filtered, and the solvent evaporated. The residue was purified by flash column
chromatography on silica gel, eluting with CHCl3 :MeOH:Et3 N (100:10:1) to afford S-(-)nornicotine (3) (118 mg, 79% overall) as a pale yellow oil; [aD] = -32.6o (c = 1.0,
methanol); 1 H NMR (300 MHz, CDCl3 ) δ 8.60 (1H, d, J = 1.8 Hz), 8.45 (1H, dd, J = 4.8,
1,7 Hz), 7.74 (1H, “dt”, J = 7.8, 1.9 Hz), 7.25 (1H, dd, J = 7.8, 4.8 Hz), 4.14 (1H, dd,
J=7.3, 2.1 Hz), 3.11 (2H, m), 2.20 (1H, m), 2.11 (1H, m), 1.91 (2H, m), 1.66 (1H, m)
ppm.;

13

C NMR (75 MHz, CDCl3 ) δ 148.3, 148.0, 140.1, 134.2, 123.2, 59.7, 46.7, 34.0,

25.2 ppm; m/z 148 (M+).

The same procedure was utilized for the synthesis of R-(+)-nornicotine (110 mg, 76%
overall) from 1S, 2S, 5S-(-)-2-hydroxy-3-pinanone ketimine and 1-chloro-3-iodopropane,
and the product was obtained as a pale yellow oil; [a D] = +32.8o (c = 1.0, methanol).

169

(S)-(-)-Anabasine and (R)-(+)-anabasine (5 and 5R)
A similar procedure used to synthesize 3 was also utilized for the synthesis of S-(-)anabasine (5), which was obtained in 72% yield from 1R, 2R, 5R-(-)-2-hydroxy-3pinanone ketimine (67) using 1-chloro-4- iodobutane as the alkylating agent instead of 1chloro-3-iodopropane. The product was obtained as a light-yellow oil; [a D] = -79.8o (c =
0.9, methanol); 1 H NMR (300 MHz, CDCl3 ) δ 8.60 (1H, s), 8.50 (1H, dt, J = 4.8, 1,7
Hz), 7.74 (1H, dm, J = 7.8, 1.8 Hz), 7.25 (1H, dd, J = 7.8, 4.8 Hz), 3.65 (2H, dd, J=11,
2.2 Hz), 3.22 (1H, dm, J= 11 Hz), 2.75-2.85 (1H, m), 2.00 (1H, s), 1.46-1.95 (6H, m)
ppm.;

13

C NMR (75 MHz, CDCl3 ) δ 148.0, 148.2, 139.9 133.7, 122.8, 59.2, 47.0, 34.00,

24.9, 24.6 ppm. m/z 163 (M+).

Additionally, R-(+)-anabasine was synthesized in a similar manner, utilizing 1S, 2S, 5S(-)-2-hydroxy-3-pinanone ketimine as the chiral intermediate, and was obtained as a pale
yellow oil (75% yield); [aD] = +80.2 o (c = 1.0, methanol).

S-(-)-Anatabine and R-(+)-anatabine
cis-2-(4-Bromobut-2-enyloxy)tetrahydropyran (68)
p-Toluenesulfonic acid monohydrate (0.13 g) was added to a stirred solution of cis-but-2ene-1,4-diol (2.64 g, 30.0 mmol) and THP (2.53 g, 30.0 mmol) in CH2 Cl2 (10 mL) and
THF (25 mL) at 0°C. After stirring at 0 °C for 2 h, the reaction mixture was stirred at
room temperature for a further 20 min. Water was added, and the aqueous phase was
extracted with diethyl ether (3x20 mL). The combined organic layers were dried over
anhydrous magnesium sulfate, filtered, and the solvent evaporated. The residue was
purified by flash column chromatography on silica gel, eluting with hexane:EtOAc, (2:1)
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to give cis-4-(tetrahydropyran-2-yloxy)but-2-en-1-ol (2.66 g, 52%) as a colorless oil: 1 H
NMR (300 MHz, CDCl3 ) δ 5.81 (1H, m), 5.67 (1H, m), 4.64 (1H, m), 4.15 (4H, m), 3.82
(1H, m), 3.49 (1H, m), 1.42-1.84 (6H, m) ppm;

13

C NMR (75 MHz, CDCl3 ) δ 132.54,

128.11, 97.68, 62.63, 62.31, 58.50, 30.71, 25.59, 19.49 ppm.

To a solution of cis-4-(tetrahydropyran-2-yloxy)but-2-en-1-ol (2.44 g, 14.2 mmol) in
DMF (40 mL) was added triphenylphosphine (4.17 g, 15.9 mmol). The solution was
cooled to 0°C and NBS (2.73 g, 15.5 mmol) was added in portions. After stirring for 30
min at room temperature, the reaction was quenched with methanol (2 mL). The solution
was diluted with diethyl ether (200 mL), and washed with water, saturated aqueous
NaHCO3, and brine, successively.

The organic layer was dried over anhydrous

magnesium sulfate, filtered, and concentrated.

The residue was purified by flash

chromatography on silica gel, eluting with hexane to afford the bromide 68 (2.24 g, 67%)
as a colorless oil: 1 H NMR (300 MHz, CDCl3 ) δ 5.86 (1H, m), 5.69 (1H, m), 4.61 (1H,
dd, J = 4.2, 3.0 Hz), 4.31 (1H, m), 4.14 (1H, m), 4.01 (2H, d, J = 7.8 Hz), 3.84 (1H, m),
3.51 (1H, m), 1.40-1.90 (6H, m) ppm;

13

C NMR (75 MHz, CDCl3 ) δ 130.95, 128.41,

98.15, 62.49, 62.08, 30.80, 26.84, 25.65, 19.67 ppm. m/z: 155 (M+-81), 133/135, 85, 53.

1R, 1’S, 2R, 5R-2,6,6-Trimethyl-3-[1’-pyridin-3’’- yl-5’-(tetrahydro-pyran-2’’yloxy)pent-3’-enylimino]bicyclo[3.1.1]heptan-2-ol (69)
To a stirred solution of ketimine 67 (1.94 g, 7.50 mmol) in THF (60 mL) was added
dropwise LDA (11.3 mL, 2.0 M solution in THF, 22.6 mmol) at 0°C. The purple
solution was stirred at 0°C for 15 min then cooled to –78°C. The bromide 68 (2.12 g,
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9.00 mmol) in THF (8 mL) was added dropwise. The reaction mixture was stirred for an
additional 30 min at –78°C, and then quenched with saturated aqueous NH4 Cl solution.
The aqueous phase was extracted with diethyl ether (3x20 mL). The combined organic
layers were washed with brine, dried over anhydrous magnesium sulfate, filtered, and
evaporated.

The residue was flash chromatographed on silica gel, eluting with

CHCl3 :hexane:MeOH (100:20:2) to give 69 (2.80 g, 91%) as a colorless oil: 1 H NMR
(300 MHz, CDCl3 ) δ 8.56 (1H, d, J = 2.1 Hz), 8.48 (1H, dd, J = 5.1, 1.8 Hz), 7.72 (1H, d,
J = 7.5 Hz), 7.25 (1H, dd, J = 7.5, 4.8 Hz), 5.61 (1H, m), 5.50 (1H, m), 4.59 (2H, m), 4.19
(1H, m), 4.01 (1H, m), 3.84 (1H, m), 3.49 (1H, m), 2.63 (3H, m), 2.44 (1H, m), 2.26
(1H, m), 2.06 (1H, t, J = 6.3 Hz), 1.99 (1H, m), 1.62-1.88 (2H, m), 1.52 (3H, s), 1.44-1.60
(4H, m), 1.39 (1H, d, J = 10.5 Hz), 1.31 (3H, s), 0.90 (3H, s) ppm;

13

C NMR (75 MHz,

CDCl3 ) shows signals for two diastereomers δ 176.13, 148.77, 148.53, 138.73 (138.70),
134.69, 129.13 (128.98), 128.80 (128.74), 123.70, 98.17 (97.99), 62.94 (62.85), 62.46,
61.10 (61.06), 50.26, 38.63, 37.08, 33.91, 30.90, 28.79, 28.26, 27.60, 25.71, 23.32, 19.77
ppm. m/z: 412 (M+), 327, 311, 257, 162, 144, 85; Anal. Calcd for C25 H36 N2 O3 ⋅H2 O: C,
69.74; H, 8.90; N, 6.51. Found: C, 69.80; H, 8.58; N, 6.33.

1R, 1’S, 2R, 5R-3-(5’-Hydroxy-1’-pyridin-3’’-yl-pent-3’-enylimino)-2,6,6-trimethylbicyclo[3.1.1]heptan-2-ol (70)
To a solution of THP ether 69 (1.45 g, 3.52 mmol) in MeOH (90 mL) was added ptoluenesulfonic acid (1.37 g, 7.04 mmol). The mixture was stirred at room temperature
for 3 h and then concentrated. Saturated aqueous NaHCO3 solution (20 mL) was added,
and the aqueous phase was extracted with diethyl ether (3x20 mL). The combined
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organic layers were washed with brine, dried over anhydrous magnesium sulfate, and
evaporated.

The residue was flash chromatographed on silica gel, eluting with

CHCl3 :MeOH (25:1) to give 70 (1.05 g, 90%) as a colorless oil: [aD] = –33.1° (c = 1.0,
MeOH); 1 H NMR (200 MHz, CDCl3 ) δ 8.51 (1H, br s), 8.44 (1H, d, J = 4.0 Hz), 7.66
(1H, dt, J = 8.0, 2.0 Hz), 7.22 (1H, dd, J = 8.0, 5.0 Hz), 5.71 (1H, m), 5.42 (1H, m), 4.55
(1H, dd, J = 8.4, 4.8 Hz), 4.08 (2H, m), 2.42-2.84 (4H, m), 2.16-2.38 (2H, m), 20.1 (1H,
t, J = 6.0 Hz), 1.94 (1H, m), 1.50 (3H, s), 1.33 (1H, d, J = 11.4 Hz), 1.27 (3H, s), 0.85
(3H, s) ppm;

13

C NMR (75 MHz, CDCl3 ) δ 177.81, 148.78, 148.69, 138.69, 134.68,

131.98, 128.25, 123.85, 76.79, 60.45, 58.64, 50.55, 38.52, 38.46, 37.23, 34.15, 28.52,
28.13, 27.41, 23.13 ppm. m/z: 329 (M++1); Anal. Calcd for C20 H28 N2 O2 ⋅0.3CHCl3 : C,
66.93; H, 7.83; N, 7.69. Found: C, 67.16; H, 7.94; N, 7.77.

S-5-Amino-5-pyridin-3-yl-pent-2-en-1-ol (71)
To a solution of 70 (0.86 g, 2.6 mmol) in MeOH (40 mL) was added hydroxylamine
hydrochloride (1.39 g, 20.0 mmol). The mixture was stirred at room temperature for
18 h. Ammonia gas was bubbled into the solution to adjust the pH to 9. The MeOH was
then evaporated and CHCl3 (15 mL) was added to the residue. The resulting mixture was
filtered and the filtrate was concentrated.

The resulting residue was flash

chromatographed on silica gel, eluting with CHCl3 :MeOH:Et3 N (100:10:1) to give 71
(0.34 g, 74%) as a colorless oil: [a D] = –44.3° (c = 1.0, MeOH); 1 H NMR (200 MHz,
CDCl3 ) δ 8.53 (1H, d, J = 2.4 Hz), 8.46 (1H, dd, J = 4.8, 1.6 Hz), 7.68 (1H, dt, J = 7.6,
1.8 Hz), 7.24 (1H, dd, J = 7.4, 5.0 Hz), 5.85 (1H, m), 5.47 (1H, m), 3.90-4.20 (3H, m),
2.30-2.60 (5H, m) ppm;

13

C NMR (50 MHz, CDCl3 ) δ 149.00, 148.65, 140.70, 134.10,
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133.01, 128.43, 123.80, 57.84, 52.73, 37.42 ppm. m/z: 179 (M++1); Anal. Calcd for
C10 H14N2 O⋅0.2H2 O: C, 66.05; H, 7.98; N, 15.41. Found: C, 66.23; H, 7.91; N, 15.37.

S-(-)-Anatabine and R-(+)-anatabine (6 and 6R)
Diethyl azodicarboxylate (DEAD, 0.23 mL, 1.40 mmol) was added dropwise to a stirred
solution of triphenyl phosphine (365 mg, 1.40 mmol) in THF (6 mL) at 0°C under N2 .
The reaction mixture was stirred at 0°C for 20 min. A solution of 71 (178 mg, 1.00
mmol) in THF (3 mL) was then added dropwise. The mixture was stirred at 0°C for 30
min, and then at room temperature for 2 h. Evaporation of the solvent followed by
purification of the residue by flash column chromatography on silica gel (CHCl3 :MeOH,
20:1) gave S-(-)-anatabine (6) (124 mg, 77%) as a colorless oil: [a D] = -180o (c = 1.0,
methanol); 1 H NMR (300 MHz, CDCl3 ) δ 8.56 (1H, d, J = 1.6 Hz), 8.46 (1H, dd, J = 4.8,
1.6 Hz), 7.68 (1H, dt, J = 8.0, 1.8 Hz), 7.23 (1H, dd, J = 4.0, 2.8 Hz), 5.79 (2H, m), 3.84
(1H, t, J = 7.0 Hz), 3.33-3.65 (2H, m), 2.21 (2H, m), 2.00 (1H, br s) ppm;

13

C NMR (75

MHz, CDCl3 ) δ 148.93, 148.82, 140.05, 134.29, 126.46, 125.26, 123.71, 55.44, 46.12,
34.01 ppm. m/z: 160 (M+, base peak), 159, 145, 131, 118, 105, 80, 54.

The same procedure was utilized for the synthesis of R-(+)-anatabine from 1S, 2S, 5S-(-)2-hydroxy-3-pinanone

ketimine

and

cis-2-(4-bromobut-2-enyloxy)tetrahydropyran,

which was obtained as a pale yellow oil (70% yield); [a D] = +177o (c = 1.0, methanol).
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5.3.

Results and Discussion

The R- and S-enantiomers of nornicotine, anabasine, and anatabine were successfully
synthesized in good to moderate yields, and in good enantiomeric purity. The stereocontrolled C-alkylation of the 2-hydroxy-3-pinanone-3-(aminomethyl)pyridine ketimine
intermediate is the key step in the reaction sequence. Experimental evidence from the
crystal structure of the ketimine (Ayers et al., 2005) formed during the C-alkylation step
supports the findings that the (+)-ketimine is C-alkylated from the re face of the (-)ketimine- lithium complex. This alkylation affords the S- isomer exclusively, while the Calkylated product with the R-configuration is generated from the (- )-ketimine-lithium
complex.

LDA was chosen from a number of possible catalytic bases, including

KtBuOH, due to the higher yields obtained, and because of the improvement in purity of
the isolated products when using this base. As determined by Aiqiao et al., the base
(LDA) forms a stable complex with the ketimine, effectively blocking the si face of the
molecule and opening the re face of the molecule to addition of an alkyl halide (Figure
5.2) (Aiqiao et al. 1991).

Figure 5.2 Stable carbanion (+)-ketimine intermediate.
re

O

N
Li
N
si
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An advantage in the above procedure over previously reported literature syntheses of R(+)- and S-(-)-nornicotine, and R-(+)- and S-(-)-anabasine isomers is the small number of
overall steps to achieve the formation of the desired alkaloids. In an earlier approach to
that outlined above, Swango et al. (1999) utilized the 2-hydroxy-3-pinanone-3(aminomethyl)pyridine ketimine reagent in the synthesis of nornicotine isomers, but Calkylation was carried out with a halogenoalcohol, to afford an intermediate

N-

alkylhydroxy analog, which had to be isolated and converted to the corresponding Nalkylbromo analog, prior to cyclization to afford the final product. The current synthesis
outlined in this paper constitutes a two-step, general procedure for the synthesis of the
optical isomers of both nornicotine and anabasine, by utilizing a 1, 4-dihalogeno alkane
instead of a halogenoalcohol in the C-alkylation of the ketimine. This change reduces the
number of steps in the reaction sequence from three to two, and significantly simplifies
the work-up procedure for obtaining the final chiral product.

Attempts at utilizing

diiodopropane or diiodobutane in the reaction resulted in lower yields of reaction
products. The use of a chloroiodoalkane reactant affords rapid and more efficient Calkylation of the ketimine, but slow solvolytic degradation at the chloro-terminus. This
allows for flash silica gel column purification to be performed, thereby obtaining a stable
intermediate for the final cyclization event of the reaction sequence in the presence of
hydrazine and water.

In addition to Swango et al., other groups have successfully synthesized nornicotine and
anabasine enantiomerically pure (Felpin et al. 2001; Amat et al. 2002). However, both
these syntheses are five steps and result in lower overall yields. Felpin et al., utilize a
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novel approach, employing ring closuring metathesis. Though this synthesis resulted in
high enantioselective yields the metal used in the final cyclization step is expensive and
the final step is significantly longer than the ketimine synthesis.

The above procedure can also be utilized for the synthesis of anatabine enantiomers.
However, three steps are required to introduce the C-hydroxy-cis-alkene substituent at the
α-carbon of the 2-hydroxy-3-pinanone-3-(aminomethyl)pyridine ketimine, followed by a
final cyclization step using a Mitsunobu reaction. Nevertheless, this synthetic route is
very favorably comparable to previously reported enantioselective syntheses of anatabine
described by Balasubramanian and Hassner (1998), and by Mehmandoust et al. (1989),
both of which involve five steps overall (Mehmandoust et al. 1989; Balasubramanian and
Hassner 1998). The methodology outlined by Balasubramanian and Hassner could not
definitively rule out the presence of an enantiomer in the final steps. The resulting
enantiomeric yields were only 70% and the overall yield was 60%.
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5.4.

Conclusions

Successful adaptation and improvement of an existing methodology has allowed for a
streamlined approach in the stereoselective synthesis of the enantiomers of the nicotinic
analogs, nornicotine, anabasine, and anatabine. A two-step synthetic procedure for the
enantioselective synthesis of the optical isomers of nornicotine and anabasine, and a
modified procedure for the synthesis of anatabine enantiomers have been successfully
developed, and all compounds were synthesized in good yields and high enantiomeric
purity. Due to this purity, these compounds are ideal to use as precursors for another
generation of quaternary ammonium analogs.

Copyright © Joshua Thomas Longen Ayers 2006
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Chapter 6: Summary and Future Directions

6.1.

Summary

This research project successfully utilized the introductory phases of the drug discovery
process in order to explore neuronal nAChR subtypes. Previous research indicated that
NONI and NDNI were selective and potent antagonists for the nAChRs that mediate DA
release and for α4β2* nAChR subtypes, respectively. Synthetic analogs of NONI and
NDNI were synthesized and evaluated at a4ß2*, a7* and nAChRs that mediate DA
release to create a structure activity relationship and afforded potent and selective
antagonists. The [3 H]NIC binding data were also used to create predictive models for the
binding of these series of compounds to a4ß2* receptor subtypes. Additionally, new
enantioselective synthetic routes were developed to afford optically pure NIC analogs.

6.1.1.

Quaternary Ammonium Analogs

In order to begin the drug discovery process, a series of compounds were designed based
on initial work on NONI and NDNI and synthesized. Many of the compounds were
isolated in high yields, and all were obtained in high purity and fully characterized. In
the N-n-alkylnicotinium series, in order to selectively N-alkylate the pyridyl N-atom of
S-(-)-nicotine, a protonation of the pyrrolidine N-atom, using an adaptation on the
Menshutkin reaction using acetic acid, was necessary.

Purification of the resulting

compounds was especially important, due to the need to eliminate nicotine completely
from the product, as it would interfere with pharmacological evaluation in the binding
and release assays. Additionally, the N-N-bis-compounds, although similar in structure,
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proved difficult to isolate and purify, and several different work- up techniques had to be
developed.

The mono-quaternary ammonium compounds evaluated had a variety of nAChR
antagonist activities, depending on the length of the chain, as well as the nature of the 3pyridyl substituent.

N-n-Alkylnicotinium salts exhibited antagonist activity at both

α4β2* receptor subtypes and nAChR subtypes that mediate DA release depending on
alkyl chain length, while having little to no affinity for the α7* receptor subtype. From
these studies, NDDNI has emerged as a potential tool for antagonism of the α4β2*
receptor subtype. The activities of the N-n-alkylpyridinium, N-n-alkylpicolinium, and Nn-alkylnicotinamide salts have also led to a better understanding of how the N-nnicotinium series of compounds may be interacting with the α4β2* binding site, and has
highlighted the importance of the pyrrolidine ring as a necessary component to obtain
antagonist activity.

The length of the N-n-alkyl substituent is also an important

determinant of the antagonist activity of these molecules, as evidenced by the increased
activities when the chain length increased for the N-n-alkylpicolinium and N-nalkylnicotinium salts.

In contrast to the α4β2* receptor subtype, the pyrrolidine ring of the NONI molecule was
found not to be critical for binding to and inactivation of nAChR subtypes that mediate
DA release. However, the presence of the pyrrolidine ring did afford the most potent
antagonist, NDDNI. In addition to the N-n-alkylnicotinium compounds, the N-n-alkyl
pyridinium and N-n-alkylpicolinium compounds were generally active in inhibiting NIC-
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evoked DA release from rat striatal slices, and had relatively lower affinity for α4β2* and
α7* nAChR subtypes.

Thus, removal of the pyrrolidine ring from the N-n-

alkylnicotinium series afforded a series of compounds which exhibited an increase in
antagonist potency for the nAChR subtypes that mediate DA release, while having little
or no activity in α4β2* and α7* nAChR subtypes. This supports the idea that there is a
difference in the binding domains of α4β2* nAChR subtypes, α7* nAChR subtypes, and
certain nAChRs that mediate DA release.

The bis-quaternary ammonium compounds also demonstrated activity at the various
nAChR subtypes.

N,N-bis-alkylnicotinium compounds were found to be selective

antagonists at a4ß2* receptor subtypes, similar to the N-n-alkylnicotinium series.
However, unlike the N-n-alkylnicotinium series, the N,N-bis-alkylnicotinium compounds
were not the most potent antagonists at the receptors that mediate NIC-evoked DA
release. N,N-bis-Dodecylpicolinium (bPiDDB) proved to be the most potent antagonist
at the receptors that mediate NIC-evoked DA release. That, coupled with it inactivity at
a4ß2* and a7* receptor subtypes, make this compound the most potent and selective
compound in the all the series tested. Furthermore, the lack of a4ß2* activity and the
partial antagonist effect of bPiDDB in the NIC-evoked DA overflow assay, allows for a
putative assignment of the antagonist activity occurring at α6β2β3 and α6α4β2β3
nAChR subtypes. bPiDDB is an excellent lead candidate for exploring the these nAChR
subtypes due to it pharmacological profile. In addition to its laboratory utility, acute
dosing of bPiDDB has recently been shown to decrease nicotine self-administration in
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rats and may be used as a lead compound for clinical development (Neugebauer et al.
2006).

The only compounds that were found to be active in the α7* MLA binding assay were
the heteroaromatic analogs (i.e. N,N-bis-isoquinolinium and N,N-bis-quinolinium salts).
Within these series of compounds, the most potent analog was bQDDB, the twelvecarbon quinoline analog, suggesting that the position of the extended aromatic ring is an
important aspect to the binding of these compounds.

6.1.2.

Modeling

Using several different classes of quaternary ammonium salts, two different established
molecular modeling techniques were applied to create a novel approach to SAR studies.
Three self-organizing map (SOMs) models were generated from three different sets of
compounds.

The groups consisted of the mono-substituted compounds, the bis-

substituted compounds, and both sets combined. The models were able to successfully
"bin" the test set of compounds after developing a model from a similar set of training
compounds.

Additionally, using genetic functional activity (GFA) algorithms an

evolutionary approach to generating predictive model equations was applied to the
compounds.

Three separate equations were generated in order to form a predictive

method for evaluating affinities at the α4β2* receptor subtype.
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6.1.3.

Synthesis of Enantiomerically Pure Nicotinic Analogs

In addition to the modeling and SAR work of the quaternary ammonium compounds,
novel synthetic methods were also employed to develop enantiomerically pure nicotine
analogs. Efficient enantioselective syntheses of (S)- and R-(+)-nornicotine, (S)-and R(+)-anabasine, and (S)-and R-(+)-anatabine have been developed, affording isomers in
high enantiomeric excess.

6.2.

Future Directions

The three areas of focus of this project can all be expanded. Evaluation of the quaternary
ammonium pyridinium analogs in the functional [3 H]DA release assay, as well as in the
86

Rb+ efflux assay, is necessary for a complete functional profile to be obtained on each

compound in each of these series. Additionally, those compounds that had affinity for
the α7* nAChR subtype should be tested for their functional activities.

Once the

functional profile was complete for these compounds, further study of their mode of
action would be important. Of considerable interest would also be the functional activity
of the nicotinamide analogs at nAChRs that mediate DA release.

The compounds

provide a different functional 3-position substituent with different electronic properties.
This would allow probing the H-bonding binding area of the nAChRs that mediate DA
release.

In addition to further testing, novel pyridinium compounds could also be preformed on
those compounds that were synthesized in Chapter 5. S-(-)- and R-(+)-Nornicotine (3
and 3R), S-(-)- and R-(+)-anabasine (5 and 5R), S-(-)- and R-(+)-anatabine (6 and 6R), as
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well as their N-methylated derivatives, could be quaternized with various chain lengths,
(Figure 6.1).

Figure 6.1 N-Alkylated quaternary ammonium salts of S-(-)- and R-(+)-Nornicotine (72
and 73), S-(-)- and R-(+)-anabasine (74 and 75), S-(-)- and R-(+)- anatabine (76 and 77),
and their methylated derivatives (78, 79, 80, 81, and 82).
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Novel synthetic compounds may also be synthesized using the techniques outlined in
Chapter 5. Although the racemic forms of azetidine and azepine NIC analogs have been
synthesized, no enantioselective syntheses of these compounds have so far been reported.
Using the enantioselective synthetic route developed for nornicotine, anabasine, and
anatabine, synthesis of enantiomerically pure forms of these compounds may be possible.
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To better direct the next generation of compounds in these series, the computational
models developed from the initial SAR study of the α4β2* may be used predictively to
determine active compounds in silico.

Additionally, predictive models could be

developed for nAChR subtypes that mediate DA release and α7* nAChR subtypes, as
more data become available.

One of the advantages of the peripheral antagonists, DEC and HEX, is that their
quaternary ammonium cationic nature does not allow for their passage into the central
nervous system (CNS), therefore isolating their antagonist activity to nAChRs in the
periphery. Although several of these compounds have excellent chloroform solubility
and could theoretically pass into the CNS, it is not certain if a quaternary ammonium
molecule can passively enter the blood-brain barrier (BBB). Active transport into the
CNS, via the choline transporter may allow the passage of such quaternary ammonium
molecules. Allen et al. (2003) have investigated NONI, NDNI, NOPI, binding to the
BBB choline transporter and found that these salts do have affinity (27 – 49 µM) for the
transporter binding site. Research on the bis-azaaromatic quaternary ammonium analogs,
revealed that bPiDDB also had affinity for the BBB choline transporter (1.57 µM).
Furthermore, it was determined that radiolabeled NONI and bPiDDB are both transported
via the BBB choline transporter into the CNS (Allen et al. 2003; Geldenhuys et al. 2005).
Another possible strategy for delivery of these pyridinium compounds across the BBB
into the CNS involves the synthesis of a pyridinium head group designed to be a
bioprecursor of these compounds. Bodor et al. (1990) have designed uncharged stable
dihydropyridine analogs that do not rearomatize due to the presence of a C3 or C5
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electron withdrawing substitution. Once the reduced product passes the BBB, the CNS
enzyme monoamine oxidase-B (MAO-B) oxidizes the dihydropyridine analog to the
quaternary ammonium compound that is active at neuronal nAChRs. This could be
important in establishing a delivery method for this class of compounds, and would
further the potential use of these compounds in nAChR related pathologies.

6.3.

Conclusion

There is much to explore regarding the pharmacology of the neuronal nAChRs and the
interaction of potential drug molecules with these receptors. The studies described herein
have provided initial useful information that may be helpful in determining the functional
properties of the individual nAChR subtypes, as well as in developing new synthetic
methods for the preparation of novel compounds to add to the library of ligands available
for probing the function of the various nAChR subtypes. Additionally, using established
modeling techniques, new predictive models could be developed and utilized to increase
the probability of success in the discovery of biologically active compounds with clinical
potential. Using these methodologies allows for the successful identification of potent
and selective nAChR ligands, of utility in unraveling the complexities of neuronal
nAChRs, as well as having potential therapeutic uses in the clinic.

Copyright © Joshua Thomas Longen Ayers 2006
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List of Abbreviations
α-Btx
α-CBT
α-ctx
5-HT
ACh
AChBP
AD
ADME
AMPA
ANOVA
Atx
BBB
CHCl3
CNS
CoMFA
Cyt
DA
DAT
DCEH
DEAD
DEC
DHβE
DMF
d-TC
Epi
Et3 N
EtOAc
EtOH
ETX-a
ETX-b
FDA
GABAA
GFA
HEK
HEPES
HEX
IND
KtBuOH
LDA
L-DOPA
LOB
LTX
MAO-B
MEC

α-Bungarotoxin
α-Cobratoxin
α-Conotoxins
Serotonin
Acetylcholine
Acetylcholine binding protein
Alzheimer’s disease
Absorption, distribution, metabolism, and elimination
α-amino-3-hydroxy-5- methyl-4- isoxazolepropionate
One-way repeated- measure analysis of variance
(+)-Anatoxin-a
Blood-brain barrier
Chloroform
Central nervous system
Comparative molecular field analysis
Cytisine
Dopamine
Dopamine transporter
(R)-descholoroepibatidine
Diethyl azodicarboxylate
Decamethonium
Dihydro-β-erythroidine
N,N-Dimethylformamide
d-Tubocurarine
Epibatidine
Triethylamine
Ethyl acetate
Ethanol
Erabutoxin-a
Erabutoxin-b
Food and Drug Administration
Gamma-aminobutyric acid
Genetic functional approximation algorithm
Human embryonic kidney
N-[2-Hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid]
Hexamethonium
Investigational new drug application
Potassium tert- butoxide
Lithium diisopropylamide
L-Dihydroxyphenylanine
Lobeline
Lophotoxin
Monoamine oxidase-B
Mecamylamine
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MeOH
Methanol
MLA
Methyllycaconitine
MLS
Multiple least squares
MSA
Molecular shape analysis
nAChR
Nicotinic acetylcholine receptor
NaHCO3
Sodium bicarbonate
NBS
N-bromosuccinimide
n-Btx
Neuronal bungarotoxin
NDA
New drug application
NIC
Nicotine
NMDA
N-Methyl-D-aspartate
NSAID
Nonsteroidal anti- inflammatory drug
NSTX
Neosurugatoxin
NT
Neurotransmitter
OCB
Open channel blockers
PD
Parkinson’s disease
PEI
Polyethylenimine
PLS Partial least squares
QSAR Quantitative structure-activity relationship
R-NIC R-(+)-Nicotine
SAR
Structure-activity relationship
SOM
Self-organizing map
THF
Tetrahydrofuran
THP
Tetrahydropyran
Trizma HCl Tris[hydroxymethyl]-aminomethane hydrochloride
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